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  This	   thesis	   details	   two	   projects	   at	   the	   interface	   of	   chemistry	   and	  neuroscience.	  	  Part	  I	  (consisting	  of	  chapters	  1	  –	  5)	  focuses	  on	  the	  development	  and	  characterization	  of	  fluorescent	  optical	  tracers	  of	  monoamine	  neurotransmitters	  for	  use	   in	   the	   study	   of	   monoamine	   transporter	   activity	   and	   distribution,	   as	   well	   as	  synaptic	   transmission	   in	   the	   brain.	   	   The	   second	   section	   details	   early	   studies	  concerning	  experimental	  therapeutics	  recently	  identified	  by	  our	  group	  to	  induce	  the	  synthesis	   and	   release	   of	   glial	   cell	   line-­‐derived	   neurotrophic	   factor	   (GDNF)	   from	   a	  model	  astroglial	  cell	  line.	  In	   Part	   I	   of	   this	   thesis,	   Chapter	   1	   provides	   a	   brief	   introduction	   to	   the	  relationship	  between	  chemistry	  and	  neuroscience,	  while	  explaining	  the	  motivation	  and	   background	   behind	   the	   development	   and	   study	   of	   Fluorescent	   False	  Neurotransmitters	   (FFNs).	   	   Chapter	   2	   discusses	   the	   characterization	   of	   new	  fluorescent	   substrates	   for	   the	   Vesicular	   Monoamine	   Transporter	   2	   (VMAT2)	   for	  applications	  in	  high	  throughput	  screening	  of	  VMAT	  activity	  and	  inhibition,	  as	  well	  as	  for	  imaging	  aminergic	  synaptic	  transmission	  in	  brain	  tissue.	  Chapter	  3	  describes	  the	  discovery	   of	   fluorescent	   probes	   FFN201	   and	   AGH093	   as	   dual	   substrates	   for	   the	  norepinephrine	   transporter	   (NET)	   and	   VMAT,	   with	   potential	   applications	   in	   the	  
imaging	   of	   noradrenergic	  modulation	   of	   cortical	   signaling	   networks.	   NG54,	   a	   FFN	  with	  substrate	  activity	  at	  each	  of	   the	  monoamine	   transporters	  was	  also	   identified,	  and	   represents	   a	   new	   structural	   class	   of	   FFNs.	   	   In	   Chapter	   4,	   APP+,	   a	   known	  fluorescent	   substrate	   for	   the	  monoamine	   transporters,	   is	   evaluated	   as	   a	   potential	  tracer	  of	  monoamines	  in	  the	  brain.	  	  It	  has	  been	  determined	  that	  while	  this	  molecule	  may	   have	   utility	   as	   a	   marker	   for	   monoaminergic	   neurons,	   APP+	   is	   not	   an	  appropriate	   FFN	   due	   to	   high	   background	   labeling	   of	   mitochondria	   and	   other	  intracellular	  structures.	  	  Chapter	  5	  discusses	  the	  discovery	  of	  fluorescent	  substrates	  of	   the	   Organic	   Cation	   Transporter	   3	   (OCT3)	   and	   Plasma	   Membrane	   Monoamine	  Transporter	   (PMAT).	   Mounting	   evidence	   suggests	   that	   these	   transporters	   play	   a	  significant	   role	   in	   clearing	   extracellular	   space	   of	   monoamines	   and	   are	   likely	  involved	  in	  neurological	  disease.	   	  As	  such,	  fluorescent	  substrates	  of	  OCT3	  or	  PMAT	  would	  be	  useful	   as	   imaging	  agents	   in	   the	  brain,	   as	  well	   as	   for	   the	  development	  of	  fluorescence-­‐based	  quantitative	  inhibition	  assays.	  	  	  Part	   II	   of	   this	   thesis	   (Chapter	   6)	   discusses	  N-­‐arylethyl	   isoquinuclidines	   as	  releasers	  of	  glial	  cell	  line-­‐derived	  neurotrophic	  factor	  (GDNF)	  from	  a	  model	  glial	  cell	  line.	   	   Initial	   characterization	   of	   GDNF	   release	   and	   its	   dependence	   on	   protein	  synthesis	  and	  MAPK/ERK	  signaling	   is	  described.	   	  Preliminary	  studies	   indicate	  that	  at	  least	  two	  experimental	  compounds	  described	  herein	  modulate	  fibroblast	  growth	  factor	  receptor	  (FGFR)	  signaling.	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“In	  the	  same	  way	  that	  chemistry	  grew	  from	  the	  ashes	  of	  alchemy,	  neuroscience,	  
a	  field	  still	  in	  its	  infancy,	  may	  one	  day	  subsume	  psychology.”	  
	  
-­‐Neil	  deGrasse	  Tyson	  
	  
 
I:	  Introduction	  	   Mother	   nature	   has	   hidden	   some	   truly	   wondrous	   complexities	   within	   the	  brain,	  and	  humankind	  is	  currently	  on	  the	  threshold	  of	  a	  new	  understanding	  of	   the	  physical	   basis	   of	   our	   rich	   human	   experience.	   It	   is	   the	   biochemical	   control	   of	  information	  that	  constitutes	  our	  entire	  experience	  of	   the	  universe:	  our	  perception,	  our	  emotions,	  our	  ability	   to	   learn	  and	  communicate,	  and	   the	  autonomic	  control	  of	  our	  physical	  bodies.	  	  Indeed,	  biochemical	  processes	  underlie	  the	  function,	  structure,	  plasticity,	   and	   disease	   etiologies	   of	   the	   brain.	   	   Because	   of	   this	   truth,	   infinitesimal	  biochemical	   deficiencies	   or	   divergences	   within	   the	   brain	   can	   have	   tremendous	  influence	   over	   our	   personalities,	   physical	   health,	   and	   overall	   interaction	  with	   the	  world.	   	   Humankind	   is	   beginning	   to	   understand	   the	   complex	   intracellular	   and	  extracellular	  signaling	  networks	  involved	  in	  the	  control	  of	  information	  in	  the	  brain,	  and	   we	   are	   using	   this	   new	   knowledge	   to	   describe	   the	   brain	   with	   the	   rigorous,	  empirical	   language	  of	   science.	  Neuroscience	   is	   approaching	   a	   leap	  of	   similar	   scale	  and	  impact	  as	  when	  chemistry	  arose	  to	  describe	  the	  physical	  world.	  We	   can	   imagine	   a	   future	   where	   medicine	   has	   the	   ability	   to	   rapidly	   and	  accurately	   diagnose	   every	   disease	   or	   disorder	   of	   the	   central	   nervous	   system	  with	  minimally	   invasive	   techniques.	  We	   can	   also	   envision	   a	   day	  when	  we	   have	   at	   our	  disposal	  targeted	  therapies	  that	  overcome	  the	  genotypic	  or	  phenotypic	  deficiencies	  characteristic	   of	   and	   causal	   of	   many	   of	   these	   disorders.	   	   In	   order	   for	   the	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development	   of	   these	   technologies	   to	   be	   realized,	   both	   diagnostic	   imaging	   and	  therapeutics,	  we	  have	  much	  to	  learn	  about	  the	  structure	  and	  function	  of	  the	  brain.	  	  It	  was	  only	  recently	  in	  human	  history	  when	  Ramón	  y	  Cajal,	  employing	  the	  Golgi	  stain	  and	   a	   light	  microscope,	   visualized	   the	   discrete	   nature	   of	   neurons	   in	   brain	   tissue,	  leading	   ultimately	   to	   the	   understanding	   of	   the	   neuron	   as	   the	   principal	   signaling	  element	   of	   the	   brain,	   with	   functional	   connections	   through	   synapses.(1)	   	   Cajal’s	  example	  is	  an	  excellent	  and	  fundamentally	  simple	  one:	  he	  employed	  new	  techniques	  at	  the	  interface	  of	  chemistry,	  brain	  science,	  and	  microscopy	  in	  order	  to	  see	  what	  had	  yet	   been	   elusive.	   	   The	   development	   and	   application	   of	   new	   methods	   generates	  knowledge.	  	  	  	  
Chemistry	  and	  Neuroscience	  The	  field	  of	  chemistry	  is	  uniquely	  positioned	  to	  create	  new	  methods	  for	  the	  study	  of	   the	  brain.	   	   Fluorescent	   small	  molecules	  have	  been	  developed	  as	   selective	  labels	   for	   distinct	   cells,	   organelles,	   proteins,	   and	   other	   structures.	   Additionally,	  functional	   fluorescent	  probes	  have	  been	  developed	  for	  the	  purpose	  of	   imaging	  key	  cellular	   parameters	   including	   membrane	   potential	   and	   intracellular	   calcium	  concentrations,	  both	  of	  which	  are	  used	  in	  the	  study	  of	  the	  brain.(2,	  3)	  	  	  Nanoparticles	  and	   functional	  materials	   are	   also	   being	   developed	   using	   the	   tools	   of	   chemistry	   in	  order	   to	   sensitively	   detect	   structures	   and	   processes	   in	   the	   brain,(4,	   5)	   and	   drugs	  which	   target	   specific	   tissues	  or	   cells	  have	  been	  developed	   into	   imaging	  agents	   for	  positron	   emission	   tomography	   (PET)	   and	   single	   photon	   emission	   computed	  tomography	  (SPECT)	  imaging.(6,	  7)	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The	  development	  of	  imaging	  agents	  is	  not	  the	  only	  role	  that	  chemistry	  plays	  in	   neuroscience.	   In	   the	   context	   of	   neuropharmacology,	   chemistry	   continues	   to	  expand	   our	   understanding	   of	   the	   function	   of	   the	   brain.	   	   A	   classic	   example	   is	   the	  serendipitous	  discovery	  of	  thorazine	  as	  a	  first	  generation	  antipsychotic	  drug,	  which	  made	   the	   draconian	   surgical	   transorbital	   lobotomy	   procedure	   obsolete	   while	  simultaneously	   igniting	   a	   curiosity	   about	   chemical	   neurotransmitters	   and	   their	  centrality	  in	  signaling.(8)	  	  Thorazine	  (chlorpromazine)	  and	  other	  early	  antipsychotic	  drugs	  interact	  with	  a	  number	  of	  receptors	  in	  the	  central	  nervous	  system	  (CNS)	  and	  cause	   myriad	   side	   effects,	   and	   the	   early	   and	   widely-­‐prescribed	   antipsychotic	  haloperidol	   is	   in	   fact	  metabolized	   to	   toxic	  pyridinium	  species	   (See	  Chapter	  4	   for	  a	  discussion	   of	   pyridiniums	   and	   neurotoxicity).	   	   The	   neuropsychopharmacological	  examination	  of	  small	  molecules	  with	  well-­‐characterized	  pharmacological	  profiles	  is	  emerging	   as	   a	   means	   of	   understanding	   the	   complex	   interplay	   between	   receptor	  agonism/antagonism	  and	  behavior.	  	  	  Furthermore,	   once	   the	   brain	   is	   sufficiently	   understood	   such	   that	   the	  pathophysiologies	   of	   disease	   states	   are	   well	   characterized,	   chemistry	   will	   likely	  continue	   to	   play	   an	   important	   role	   in	   the	   development	   of	   small	   molecules	  specifically	  targeted	  to	  compensate	  for	  phenotypic	  and	  genotypic	  deficiencies	  which	  underlie	   disease.	   	   These	   future	   therapies	   would	   not	   rely	   on	   the	   serendipitous	  discovery	   of	   efficacious	   drugs	   working	   through	   unknown	   and	   uncharacterized	  mechanisms	  with	  potentially	  devastating	  side	  effects.	  	  	  It	   is	   evident	   that	   we	   need	   a	   more	   clear	   and	   sound	   understanding	   of	   the	  function	  and	  structure	  of	  the	  human	  brain	  and	  its	  disease	  states	  in	  order	  to	  create	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more	  selective,	  cleaner,	  more	  advanced,	  and	  more	  efficacious	  therapies.	  	  The	  specific	  example	  of	  thorazine’s	  accidental	  launch	  of	  neuropharmacology,	  while	  an	  early	  step	  in	  the	  progression	  of	  our	  understanding	  of	  the	  brain,	  proves	  the	  principle	  that	  such	  steps	   lead	   to	  meaningful	   improvement	   in	   treatment	  of	  neuropsychiatric	  disorders.	  	  Moreover,	   thorazine	   and	   other	   later	   pharmaceuticals	   serve	   as	   probes	   of	   the	  relationship	  between	  receptor	  activity/expression	  and	  physiology/behavior.	  It	  is	  up	  to	   interdisciplinary	   neuroscientific	   research,	   for	   which	   chemistry	   and	   chemical	  neuroscience	   plays	   a	   central	   role,	   to	   engage	   in	   the	   methodological	   research	   to	  develop	  a	  modern	  toolbox	  of	  approaches	  to	  better	  study	  the	  brain.	  	  
Signaling	   Networks	   in	   the	   Brain:	   	   Functional	   Connectomics	   and	   Optical	  
Imaging	  Methods	  for	  the	  Study	  of	  Neural	  Circuits	  
	   In	   order	   to	   completely	   understand	   the	   brain,	   its	   disease	   states,	   and	   its	  remarkable	  plasticity,	  we	  must	  understand	  the	  interconnected	  networks	  of	  billions	  of	   neurons	   that	   constitute	   its	   structure	   and	  underlie	   its	   function.	   	   In	   an	   emerging	  area	  of	  research	  termed	  connectomics,	   some	  groups	  are	  employing	  methods	  at	   the	  interface	   of	   neuroscience,	   imaging,	   and	   computer	   engineering	   to	   gather	   detailed	  information	   on	   the	   structure,	   function,	   and	   connections	   of	   neurons,	   with	   the	  ultimate	  goal	  of	  understanding	  how	  every	  neuron	  in	  the	  human	  brain	  is	  connected	  to	   every	   other	   neuron.(9-­‐11)	   This	   presents	   an	   enormous	   challenge	   to	   science	  reminiscent	   of	   the	   Human	   Genome	   Project	   in	   its	   bold	   aspirations,	   as	   the	  technologies	   and	   paradigms	   for	   data	   acquisition,	   storage,	   and	   analysis	   have	   not	  clearly	  emerged.	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The	  general	  motivation	  behind	   connectomics	   relies	  on	   the	  assumption	   that	  invaluable	   information	  will	  be	   learned	  about	   the	   function	  of	   the	  brain	  through	  the	  mapping	   of	   its	   physical	   connections.	   There	   is	   debate	   as	   to	   whether	   a	   solved	  connectome	  will	  serve	  as	  a	  useful	  tool	  for	  understanding	  the	  function	  of	  the	  brain,	  as	  a	   connectome	   tells	   us	   little	   about	   the	   strength	   of	   these	   connections,	   and	   its	  definition	   of	   these	   connections	  may	   not	   be	   the	  most	   clear	   and	   precise	   (based	   on	  morphology	  and	  distance	  rather	  than	  the	  strength	  and	  nature	  of	  signals	  conveyed).	  	  What	   is	   necessary	   beyond	   a	   solved	   connectome	   is	   detailed	   information	   about	   the	  functionality	  of	   the	  connections	  and	   the	  networks	  discovered,	  how	  and	  why	   those	  networks	  signal,	  and	  how	  those	  signals	  change	  in	  response	  to	  stimulus	  or	  disease.(12)	  Recently,	   an	   advanced,	   collaborative	   superproject	   termed	   the	   Brain	   Activity	   Map	  (BAM)	  was	  proposed,(13)	  and	  has	  been	  supported	  by	  the	  White	  House	  and	  funded	  by	  Congress	   as	   a	   project	   called	   the	   Brain	   Research	   through	   Advancing	   Innovative	  Neurotechnologies	   (BRAIN)	   Initiative.	   	   This	   project	   envisions	   an	   international,	  interdisciplinary	   program	   to	  map	   the	   functional	   connectome	   of	   the	   human	   brain,	  and	   must	   in	   the	   process	   develop	   and	   cultivate	   the	   methods	   for	   collection	   and	  analysis	  of	  data	  on	  an	  unprecedented	  scale.	  	  	  Much	   of	   the	   technology	   used	   in	   early	   pursuits	   toward	   the	   BAM	   has	   been	  developed	   from	   fluorescent	   reporters	   of	   cellular	   conditions,	   namely	   calcium	  concentrations	   and	   membrane	   potential.(2,	   3)	   Small	   molecule	   fluorescent	   calcium	  reporters	  have	  been	  found	  to	  be	  sufficiently	  sensitive	  to	  the	  changes	  in	  intracellular	  calcium	  that	  result	  from	  action	  potentials	  to	  enable	  imaging	  of	  individual	  cell	  bodies	  propagating	   single	   action	  potentials.	   	   Similar	   small	  molecule-­‐based	   environmental	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sensors	  with	  electrochemically-­‐sensitive	  fluorescence	  properties	  have	  proven	  useful	  in	   detecting	   action	   potentials.	   	   Both	   of	   these	   technologies	   are	   employed	   today	   in	  mapping	   functional	   networks	   of	   neurons	   in	   living	   brain	   tissue	   by	   allowing	  observation	  and	  characterization	  of	  arrangements	  of	  neurons	  signaling	  together	  in	  concert,	   in	  patterns	   thought	   to	  represent	   local	  signaling	  networks.(3,	  14)	   	  As	  such,	   it	  has	  been	  shown	  that	  imaging	  technologies	  with	  the	  spatial	  resolution	  of	  single	  cells,	  and	  temporal	  resolution	  sufficient	  to	  detect	  individual	  action	  potentials,	  will	  play	  a	  key	  role	  in	  the	  discovery	  of	  the	  functional	  organization	  of	  signaling	  networks	  in	  the	  brain.	   While	  it	  is	  important	  to	  observe	  how	  clusters	  of	  neurons	  signal	  in	  concert,	  as	  well	  as	  how	  these	  patterns	  of	  collections	  of	  signaling	  neurons	  change	  with	  response	  to	   stimulus,	   there	   is	   an	   additional	   need	   to	   resolve	   activity	   of	   individual	   synapses	  within	   the	   functional	   network.	   	   	   It	   is	   well	   understood	   that	   synaptic	   hypertrophy,	  dystrophy,	  or	  general	  dysfunction	  are	  characteristic	  of	  the	  pathophysiology	  of	  most	  neurological	   diseases.	   Imaging	   synaptic	   events	   in	   neuronal	   signaling	   will	   prove	  useful	   for	   the	   characterization	   of	   signaling	   networks	   in	   the	   brain,	   both	   to	   fully	  characterize	   the	   synaptic	  nature	  of	   observed	   signaling	   events	  within	   the	  network,	  and	  to	  image	  direct	  communication	  between	  neurons	  where	  the	  cell	  bodies	  in	  direct	  communication	  are	  not	  located	  in	  the	  imaging	  frame.	  	  A	  hypothetical	  example	  would	  be	   the	   study	  of	  monoaminergic	   signaling	  on	   the	  dendritic	   trees	   and	   cell	   bodies	   of	  cortical	   neurons.	   	   Using	   fluorogenic	   calcium	   sensors,	   it	   is	   currently	   possible	   to	  resolve	   patterns	   of	   neurons	   signaling	   in	   the	   cortex.	   	   It	   is	   also	   known	   that	  monoamines	   such	   as	   dopamine	   and	   norepinephrine	   modulate	   these	   signaling	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networks,	  resulting	  in	  observable	  differences	  in	  cortical	  signaling	  upon	  stimulation	  by	   aminergic	   signaling	   or	   direct	   application	   of	   neurotransmitter	   to	   the	   brain.	  	  Because	  the	  cell	  bodies	  of	  the	  modulatory	  aminergic	  neurons	  are	  spatially	  separated	  from	   the	   cortical	   neurons	   that	   they	   modulate,	   it	   is	   not	   possible	   with	   current	  methods	   to	   observe	   with	   one	   microscope	   how	   these	   aminergic	   neurons	   directly	  affect	   cortical	   signaling	   networks.	   	   As	   such,	   a	   tracer	   of	   monoaminergic	   synaptic	  activity	   could	   prove	   useful	   in	   this	   hypothetical	   example	   and	   in	   the	   pursuit	   of	  functional	  connectomics	  in	  general.	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II	  –	  Imaging	  Neurotransmitter	  Release	  in	  the	  Brain	  
Detecting	  Neurotransmitters	  	  As	   neurotransmitters	   are	   the	   fundamental	   signaling	   components	   of	   the	  chemical	   synapse,	   the	   ability	   to	   sensitively	   detect	   neurotransmitter	   release,	  concentration,	   and	   distribution	   in	   the	   brain	   has	   become	   centrally	   important	   to	  neuroscience.	   	   Microdialysis	   and	   electrochemical	   methods	   including	   cyclic	  voltammetry	  are	  widely-­‐used	  methods	  used	  to	  study	  neurotransmitter	  release.(15,	  16)	  Although	   these	   methods,	   particularly	   voltammetry,	   are	   quite	   sensitive	   and	   are	  capable	   of	   detecting	   neurotransmitter	   concentrations	   with	   excellent	   temporal	  resolution,	   their	   poor	   spatial	   resolution	   —	   limited	   in	   large	   part	   by	   the	   physical	  dimensions	  of	  the	  probes	  —	  leads	  to	  the	  collection	  of	  information	  from	  a	  number	  of	  synaptic	   inputs	   from	   numerous	   different	   cells.	   	   We	   have	   estimated	   that	   for	  voltammetric	  measurements	  of	  dopamine	  in	  the	  striatum,	  hundreds	  of	  synapses	  are	  measured	  at	  once,	  based	  on	  the	  density	  of	  dopamine	  synapses	  and	  the	  dimensions	  of	  the	  microelectrode	  probes	  commonly	  used	  (Figure	  1).(17)	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Figure	   1.	   While	   voltammetric	   measurement	   of	   neurotransmitter	   (NT)	   release	  provides	   excellent	   temporal	   resolution	   and	   kinetic	   data,	   this	   method	   is	   limited	  spatially	   as	   a	   function	   of	   the	   size	   of	   the	   probe,	   as	   illustrated	   in	   the	   left	   panel,	  representing	  a	  microelectrode	  in	  1	  mm3	  of	  brain	  tissue.	  The	  central	  panel	  represents	  the	   area	   from	  which	   the	   voltammetric	   probe	   records,	   and	   is	   represented	   by	   a	   3D	  projection	   of	   a	   fluorescent	   false	   neurotransmitter,	   FFN102,	   in	   the	   dorsal	   striatum	  with	   an	   accompanying	   illustration	   of	   a	  microelectrode	  measuring	   an	   ensemble	   of	  hundreds	   of	   terminals	   (microelectrode	   is	   represented	   by	   the	   cylinder	   of	   the	  indicated	  dimensions,	   scale	   bars	   represent	  µm,	  FFN102	   image	   is	   courtesy	   of	  Matt	  Dunn).	   The	   right	   panel	   is	   a	   representation	   of	   a	   striatal	   dopaminergic	   presynaptic	  release	  site,	  which	  is	  known	  to	  modulate	  excitatory	  (glutamatergic)	  synaptic	  inputs	  to	   dendritic	   spines	   of	   medium	   spiny	   neurons	   (MSN).	   The	   small	   black	   circles	  represent	  dopaminergic	  synaptic	  vesicles.	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Because	   of	   its	   centrality	   to	   brain	   function,	   glutamate	   has	   become	   an	   early	  target	  of	  optical	  methods.	  	  An	  early	  fluorescence-­‐based	  approach	  to	  the	  detection	  of	  the	   glutamate	  was	   an	   indirect	   one.	   	   The	   experimental	   system	  was	   treated	  with	  L-­‐glutamate	  dehydrogenase	  and	  NAD(+),	  which	  was	  reduced	  to	  the	  fluorescent	  NADH	  in	   the	   presence	   of	   glutamate.	   	   	   This	   allowed	   for	   indirect	   fluorescence	   imaging	   of	  “waves”	   of	   glutamate	   release.(18)	   	   Later,	   glutamate	   optical	   sensors	   (EOS)	   were	  engineered	  from	  scaffolds	  of	  glutamate	  receptors.(19-­‐21)	  	  These	  EOSs	  are	  designed	  to,	  upon	   binding	   of	   glutamate,	   induce	   detectable	   photophysical	   changes	   in	   a	   bound,	  environmentally	  sensitive	  fluorophore	  (Figure	  2).	  The	  binding	  of	  glutamate	  induces	  allosteric	   changes	   of	   the	   receptor-­‐sensor,	   to	  which	   the	   environmentally	   sensitive,	  bound	   fluorophore	   dye	   responds	   in	   a	  measurable	  manner.	   	   The	   EOS	   technique	   is	  only	   capable	   of	   labeling	   tissues	   via	   a	   chemical	   or	   biochemical	   linker,	   such	   as	   a	  biotin-­‐streptavidin	   bridge.	   	   This	   requires	   the	   biotinylation	   of	   local	   tissue	   being	  studied,	  and	  could	  significantly	  alter	   the	  behavior	  of	  systems,	  although	   it	  provides	  an	  excellent	  readout	  of	  extrasynaptic	  glutamate,	  and	  by	  association,	  local	  glutamate	  release.	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be	   applied	   via	   biotin-­‐streptavidin	   linkage	   to	   nonspecifically-­‐biotinylated	  extracellular	   structures,	   or	   can	   be	   genetically	   encoded	   via	   transgenic	   approaches.	  	  To	   date,	   glutamate	   is	   the	   only	   neurotransmitter	   capable	   of	   detection	   by	   these	  means,	   although	   one	   can	   envision	   sensors	   for	   other	   neurotransmitters	   acting	  similarly,	  or	  these	  sensors	  acting	  in	  concert	  with	  FFNs	  (introduced	  below).	  	  	   Genetically	   encoded	   glutamate	   sensors	   have	   also	   been	   used	   to	   detect	  glutamate	  release,(22)	  and	  these	  sensors	  function	  in	  a	  conceptually	  similar	  manner	  to	  EOS	  (Figure	  2),	  with	  some	  notable	  advantages	  in	  comparison.	  	  These	  sensors	  utilize	  fluorescence	  resonance	  energy	  transfer	  (FRET)	  to	  detect	  neurotransmitter	  release.	  	  A	  bacterial	  glutamate	  binding	  protein	  was	  engineered	  with	   fluorescence	  reporters	  capable	   of	   FRET	   on	   two	   regions	   of	   the	   protein,	   which	   undergoes	   a	   large	  conformational	   change	   upon	   glutamate	   binding,	   leading	   to	   a	   detectable	   FRET	  response.	  	  Recently,	  an	  advanced	  sensor	  called	  an	  intensity-­‐based	  glutamate-­‐sensing	  fluorescent	   reporter	   (iGluSnFR)	  was	  reported.(23)	  As	   this	   sensor	  can	  be	  genetically	  encoded	   and	   directed	   to	   specific	   cell	   populations,	   the	   problematic	   need	   for	  functionalization	  of	  tissue	  and	  physical	  application	  of	  the	  sensor	  to	  the	  brain	  region	  of	  interest	  is	  eliminated,	  allowing	  for	  facile	  in	  vivo	   imaging.	   	  This	  sensor	  was	  found	  to	  have	  a	  sufficient	  signal	  to	  background	  ratio	  to	  detect	  glutamate	  signaling	  events	  in	  the	  brain,	  and	  allowed	  synaptic	  resolution	  of	  task-­‐dependent	  signaling	  events	  in	  behaving	  mice.	  The	   iGluSnFR	  has	  also	  been	  used	  to	  study	  glutamate	  release	  at	   the	  synaptic	  level	  with	  physiologically	  relevant	  (1-­‐5)	  pulses	  of	  electrical	  stimulation.	  	  	  	   A	  third	  approach	  developed	  recently	  has	  been	  the	  use	  of	  specially	  engineered	  cells	  that	  respond	  fluorogenically	  to	  extracellular	  acetylcholine	  (ACh).(24)	  	  Termed	  cell-­‐based	  neurotransmitter	  fluorescent	  engineered	  reporters	  (CNiFERs),	  these	  cells	  express	  the	  M1	  muscarinic	  receptor	  as	  well	  as	  a	  genetically	  encoded	  fluorescent	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calcium	  sensor,	  which	  responds	  to	  changes	  in	  intracellular	  calcium	  concentrations	  as	  a	  function	  of	  receptor	  activation	  (Figure	  3).	  	  	  Drawbacks	  include	  the	  invasiveness	  of	  this	  method	  and	  the	  indirect	  nature	  of	  the	  detection.	  	  While	  it	  is	  conceivable	  that	  CNiFERs	  could	  be	  developed	  for	  the	  detection	  of	  any	  number	  of	  neurotransmitters	  simply	  by	  overexpressing	  different	  neurotransmitter	  receptors,	  the	  reported	  application	  has	  been	  limited	  to	  acetylcholine. 	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have	  not	  been	  reported	  in	  brain	  tissue	  or	  primary	  neuronal	  culture.	  	  These	  sensors	  represent	   an	   advance	   over	   classical	   histochemical	   techniques	   for	   detection	   of	  catecholamines	  in	  cultured	  cells,	  as	  fixation	  is	  not	  required.	  
	  	  
Figure	  4:	   	  Fluorogenic/fluoromorphic	  chemosensors	  have	  been	  developed	  to	  react	  with	  and	  detect	  monoamine	  neurotransmitters.	  	  	  
Endocytic	  Dyes	  and	  SynaptopHluorins	  Enable	  the	  Study	  of	  Individual	  Synapses	  
but	  not	  Neurotransmitters	  	   Two	   related	   optical	  methods	   have	   been	   developed	   recently	   for	   imaging	   of	  synaptic	  vesicle	  fusion,	  but	  not	  neurotransmitter	  release.	  	  These	  are	  the	  fluorescent	  endocytic	  dyes	  and	  the	  synaptopHluorins.	  Fluorescent	   endocytic	   dyes	   enable	   visualization	   of	   synaptic	   activity	   with	  sufficient	  spatial	  and	  temporal	  resolution	  to	  monitor	  vesicular	  fusion	  at	  the	  synaptic	  level.	  	  One	  of	  the	  most	  well	  known	  of	  these	  endocytic	  dyes	  is	  FM1-­‐43	  (Figure	  5).	  (27,	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which	  may	  affect	   the	  system	  being	  studied,	  as	  well	  as	   the	   lack	  of	   specificity	  of	   the	  label	  among	  the	  heterogeneous	  population	  of	  active	  synapses.	  	  
	  	  
Figure	  5:	   	  Structure	  of	  FM1-­‐43.	  	  This	  and	  related	  amphipathic	  endocytic	  dyes	  bind	  to	   the	   plasma	   membrane	   of	   all	   cells	   without	   crossing	   the	   membrane	   (by	   the	  dicationic	   nature	   of	   the	   polar	   head).	   	   FM1-­‐43	   can	   be	   endocytosed	   via	   electrical	  stimulation	   to	   label	  active	  synaptic	  zones,	  and	  the	  remainder	  of	  extracellular	   label	  can	  then	  be	  removed	  by	  washing	  with	  cyclodextrins.	  	   	  	   A	   genetically-­‐encoded	   pH-­‐sensitive	   variant	   of	   green	   fluorescent	   protein	  (GFP),	  known	  as	  pHluorin,	  has	  been	  developed	  to	   image	  synaptic	  vesicle	   fusion.(30,	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III	   –	   Fluorescent	   False	   Neurotransmitters	   as	   Optical	  
Tracers	  of	  Monoamine	  Neurotransmitters	  	  	  
Monoamine	  Neurotransmitters:	  	  Life	  Cycle	  	  The	   monoamine	   neurotransmitters	   associated	   with	   CNS	   signaling	   include	  dopamine	   (DA),	   serotonin	   (5HT),	   and	   norepinephrine	   (NE).	   These	  neurotransmitters	  are	  responsible	  for	  modulating	  both	  excitatory	  glutamatergic	  and	  inhibitory	  GABAergic	   synapses,(29,	  32,	  33)	   and	  are	  associated	  with	  mood,	   reward	  and	  learning,	   cognition,	  motor	   function,	   sleep	   and	  wakefulness,	   and	   homeostasis.(33-­‐35)	  Histamine	   has	   also	   shown	   to	   have	   similar	   modulatory	   effects	   in	   the	   CNS.(36)	  Dysfunction	  of	  monoaminergic	  signaling	  has	  been	   implicated	   in	  or	  associated	  with	  numerous	   diseases.	   	   Because	   of	   their	   involvement	   in	   behavior	   and	   disease,	  monoaminergic	  neurons	  and	  monoamine	  neurotransmitters	  are	  of	  interest.	  	  The	  life	  cycle	  of	  monoamine	  neurotransmitters	  has	  been	  studied	  in	  significant	  detail,	  and	  is	  introduced	   below	   with	   respect	   to	   the	   role	   of	   these	   signaling	   molecules	   in	  neurotransmission.	  Monoamine	  neurotransmitters	  are	  principally	  synthesized	  in	  the	  cell	  bodies	  and	   axons	   of	   their	   cognate	   neurons.	   	   Cell	   bodies	   of	   dopaminergic	   neurons	   are	  located	  in	  the	  zona	  compacta	  of	  the	  substantia	  nigra	  (SN),	  as	  well	  as	   in	  the	  nearby	  ventral	   tegmental	  area	   (VTA),	  and	  project	  primarily	   to	   the	  striatum	  and	  cortex.(37)	  	  Serotonergic	  cell	  bodies	  reside	  in	  the	  dorsal	  and	  median	  raphe	  nuclei	  (DR	  and	  MR),	  and	  project	  to	  the	  CA1	  and	  CA3	  regions	  of	  the	  hippocampus,	  as	  well	  as	  the	  cerebral	  cortex.	  	  Noradrenergic	  cells	  originate	  from	  the	  locus	  coeruleus	  (LC)	  and	  other	  areas	  of	  the	  brainstem,	  and	  also	  project	  to	  the	  hippocampus	  and	  cortex.	  	  




Figure	   6:	   	   A)	   Biosynthesis	   of	   dopamine	   and	   norepinephrine.	   	   B)	   Biosynthesis	   of	  serotonin.	  	  TH	  =	  tyrosine	  hydroxylase,	  AAAD	  =	  aromatic	  amino	  acid	  decarboxylase,	  DBH	  =	  dopamine	  β-­‐hydroxylase.	  	  HTP	  =	  tryptophan	  hydroxylase.	  	  	  Dopamine	   and	   norepinephrine	   are	   derived	   from	   the	   aromatic	   amino	   acid	  tyrosine	   (Figure	   6A),	   which	   is	   transported	   into	   the	   brain	   across	   the	   blood	   brain	  barrier	   via	   amino	   acid	   transporters.	   	   The	   enzyme	   Tyrosine	   Hydroxylase	   (TH)	   is	  principally	   responsible	   for	   the	   o-­‐hydroxylation	   of	   tyrosine	   to	   form	   the	   catechol	  amino	   acid	   DOPA.	   	   DOPA	   is	   decarboxylated	   by	   the	   enzyme	   aromatic	   amino	   acid	  decarboxylase	   (AAAD)	   to	   form	   dopamine.	   	   In	   noradrenergic	   neurons,	   dopamine	  further	   undergoes	   β-­‐hydroxylation	   by	   dopamine	   β-­‐hydroxylase	   in	   the	   synaptic	  vesicles	  to	  form	  norepinephrine.	  	  Serotonin	  is	  metabolized	  from	  tryptophan	  (Figure	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neurotransmitter)	   is	   sequestered	   at	   high	   concentration	   into	   synaptic	   vesicles	   by	  action	   of	   the	   neuronal	   vesicular	  monoamine	   transporter	   (VMAT2,	  Figure	   7B,	   see	  Chapter	  2	  for	  a	  full	  discussion	  of	  VMAT).(38)	  	  Once	  an	  action	  potential	  arrives	  at	  the	  synapse,	   a	   complex	   series	   of	   signaling	   events	   occurs,	   leading	   to	   fusion	   of	   the	  vesicular	   membrane	   with	   the	   plasma	   membrane	   and	   subsequent	   release	   of	   the	  packaged	   monoamine	   into	   the	   synaptic	   cleft	   (Figure	   7C).	   	   The	   monoamine	  neurotransmitter	  signals	  on	  presynaptic	  or	  postsynaptic	  receptors	  before	  diffusing	  away	  or	  being	  transported	  back	  into	  the	  neuron	  via	  high	  affinity	  plasma	  membrane	  transporters	   (MATs,	   Figure	   7D),	   either	   the	   dopamine	   transporter	   (DAT)	   on	  dopaminergic	   neurons,	   the	   norepinephrine	   transporter	   (NET)	   on	   noradrenergic	  neurons,	  or	  the	  serotonin	  transporter	  (SERT)	  on	  serotonergic	  neurons	  (see	  Chapter	  3	   for	   discussion	   of	   MATs).(39)	   	   After	   reuptake,	   the	   monoamine	   can	   be	   re-­‐vesicularized	  by	  VMAT2	  (Figure	  7B)	  or	  metabolized	  by	  monoamine	  oxidase	  (MAO)	  (Figure	  7E).	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Figure	   7:	   	   The	   life	   cycle	   of	   dopamine,	   as	   a	   representative	   monoamine	  neurotransmitter.	  	  A)	  	  Dopamine	  is	  synthesized	  by	  dopaminergic	  neurons	  in	  the	  cell	  bodies	  or	  axonal	  projections.	  B)	  	  Dopamine	  is	  vesicularized	  by	  VMAT2	  (blue	  ovals).	  C)	   Upon	   arrival	   of	   an	   action	   potential,	   synaptic	   vesicles	   fuse	   with	   the	   plasma	  membrane	   and	   release	   the	   packaged	   neurotransmitter	   into	   the	   synaptic	   cleft.	   	   D)	  	  Reuptake	   via	   DAT	   (gray	   boxes)	   controls	   the	   duration	   of	   the	   dopamine	   signal	   and	  allows	   the	   neuron	   to	   recycle	   a	   large	   proportion	   of	   the	   dopamine.	   	   E)	   Oxidative	  deamination	   by	   monoamine	   oxidase	   (MAO,	   orange	   structure)	   is	   a	   principle	  mechanism	  of	  dopamine	  metabolism.	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uncharacterized	   vesicular	   transporter.	   	   False	   neurotransmitters	   may	   have	  pharmacological	   activity	   at	   neurotransmitter	   receptors,	   may	   induce	   efflux	   of	  neurotransmitter	  from	  synaptic	  stores,	  or	  have	  other	  effects	  including	  replacement	  of	   presynaptic	  neurotransmitter	  with	  molecules	  with	   reduced	  or	   altered	   signaling	  capability.	  Early	  experiments	  demonstrated	  the	  ability	  of	  simple	  analogs	  of	  monoamine	  neurotransmitters	  to	  act	  as	  false	  neurotransmitters.	   	  This	  effect	  was	  demonstrated	  with	  metaraminol	  in	  cardiac	  tissue	  of	  cats.(40)	   	  It	  was	  later	  found	  that	  tyramine	  and	  
α-­‐methyltyramine	   can	   be	   accumulated	   by	   sympathetic	   noradrenergic	   nerve	  terminals,	  converted	  to	  β-­‐hydroxy	  analogs	  octopamine	  and	  α-­‐methyloctopamine	  in	  synaptic	   vesicles,	   and	   can	   be	   released	   with	   electrical	   impulse	   as	   is	  norepinephrine.(41)	   Further,	   it	   was	   demonstrated	   that	   phenethylamine,	  amphetamine,	   metatyramine,	   and	   α-­‐methyl-­‐metatyramine	   can	   act	   similarly,	   to	  various	   extents.	   p-­‐Hydroxyamphetamine	   was	   found	   to	   deplete	   releasable	  norepinephrine	   from	   peripheral	   noradrenergic	   synaptic	   elements,	   causing	   a	  commensurate	   decrease	   in	   blood	   pressure,	   as	   p-­‐hydroxyamphetamine	   is	   a	   less	  active	   “false	   neurotransmitter.”(42)	   While	   tyramine	   is	   a	   false	   neurotransmitter	  known	  to	  increase	  blood	  pressure	  due	  to	  its	  activity	  at	  adrenergic	  receptors,	  it	  was	  found	   that	   this	  effect	   can	  be	  abolished	  by	   treatment	  with	  p-­‐hydroxyamphetamine,	  which	   depletes	   catecholamines	   (or	   tyramine)	   from	   terminals	   while	   having	   little	  pressor	   activity	   compared	   to	   tyramine	   or	   norepinephrine.(42)	   	   These	   pieces	   of	  evidence	  highlight	   the	  possibility	   that	   false	  neurotransmitters	   can	  drastically	  alter	  the	  biological	   system	   that	   they	   are	   administered	   to,	   for	   example	   if	   their	   substrate	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activity	   is	   high	   enough	   to	   outcompete	   endogenous	   neurotransmitters	   at	   plasma	  membrane	   or	   vesicular	   transporters,	   or	   if	   they	   have	   other	   neuropharmacological	  activities.	  It	  was	  postulated	  that	  if	  a	  novel	  false	  neurotransmitter	  could	  be	  identified	  to	  be	   sufficiently	   fluorescent	   for	   2-­‐photon	   microscopy,	   it	   could	   act	   as	   a	   tracer	   of	  monoamine	  neurotransmitters	  in	  tissue	  and	  cultured	  cells.	  	  An	  analog	  of	  serotonin,	  5,7-­‐dihydroxytryptamine	   (5,7-­‐DHT),	  has	  been	  shown	   to	  be	  a	   fluorescent	   substrate	  for	   the	   dopamine	   transporter,	   and	   has	   been	   used	   to	   image	   neurons	   in	   culture.(43)	  5,7-­‐DHT	  is	  a	  poor	  choice	  as	  an	  imaging	  candidate,	  however,	  as	  it	  oxidizes	  readily	  to	  form	   toxic	   peroxide	   species,	   is	   not	   a	   particularly	   bright	   probe,	   and	  photobleaches	  readily,	  but	  proves	  the	  principle	  that	  fluorescent	  monoamine-­‐like	  substrates	  can	  be	  used	  in	  imaging	  applications.	  	  Our	  search	  for	  optimal	  FFNs	  has	  led	  to	  some	  success	  (Figure	   8),	   and	   has	   matured	   into	   the	   current	   research	   program	   into	   which	   this	  dissertation	  fits.	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Figure	   8:	   	   Structures	   of	   monoamine	   neurotransmitters,	   some	   select	   false	  neurotransmitters	   capable	   of	   being	   transported	   into	   neurons	   alongside	  neurotransmitters,	   and	   previously	   reported	   fluorescent	   false	   neurotransmitters	  developed	   in	   the	   Sames	   group.	   	   Our	   approach	   involves	   employing	   the	   neuron’s	  endogenous	   transporters	   to	   selectively	   load	   fluorescent	   reporters	   into	   synaptic	  vesicles.	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based	  studies	  of	  transporter-­‐dependent	  uptake,	  the	  behavior	  of	  these	  lead	  probes	  is	  evaluated	   in	   mouse	   brain	   tissue	   in	   the	   lab	   of	   Professor	   David	   Sulzer	   (Columbia	  University	   Medical	   Center)	   for	   ability	   to	   label	   neuronal	   structures,	   selectivity	   of	  labeling,	   and	   ability	   to	   visualize	   exocytotic	   release	   from	   vesicular	   stores,	   among	  other	  characteristics.	  
	   	  
Figure	  9:	   	  Concept	  of	  FFNs.	   	  A)	  Our	  approach	  has	  been	  to	  combine	  the	  ethylamine	  moiety,	   a	   key	   recognition	   element	   of	   binding	   and	   transport	   through	   MATs	   and	  VMAT,	  with	  a	  small	   fluorescent	  core.	   	  The	  resulting	   libraries	  of	  novel	  monoamine-­‐like	  fluorophores	  are	  evaluated	  for	  activity	  at	  relevant	  monoamine	  transporters,	  and	  leads	   are	   studied	   in	   brain	   tissue.	   	   B)	   At	   the	   synapse,	   FFNs	   are	   loaded	   into	  presynaptic	   terminals	   by	   action	   of	   plasma	   membrane	   transporters	   or	   by	   passive	  diffusion	   followed	   by	   concentration	   by	   VMAT2.	   	   FFNs	   can	   then	   be	   used	   to	   study	  morphology	  and	  synaptic	  activity	  of	  labeled	  neurons.	  	   For	  a	  FFN	  to	  be	  useful	  in	  cultured	  cells	  or	  primary	  tissue	  applications,	  it	  must	  exhibit	   a	   number	   of	   specific	   traits.	   	   First,	   FFNs	   must	   be	   sufficiently	   bright	   and	  photostable	   for	   fluorescence	   microscopy	   applications.	   	   To	   date,	   all	   FFNs	   share	  substrate	  activity	  at	  VMAT	  and	  use	  either	  this	  activity	  or	  additional	  activity	  as	  a	  dual	  substrate	  for	  VMAT	  and	  a	  MAT	  on	  the	  plasma	  membrane	  to	  load	  aminergic	  neurons	  selectively.	   	   Once	   inside	   the	   cell,	   FFNs	   must	   not	   become	   heavily	   localized	   in	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intracellular	  compartments	  other	  than	  vesicles,	  to	  avoid	  background	  uptake.	   	  FFNs	  must	   also	   have	   carefully-­‐tuned	   polarity,	   allowing	   them	   to	   either	   cross	   the	   plasma	  membrane	   sufficiently	   enough	   to	   become	   sequestered	   by	   VMAT	   but	   without	  labeling	   all	   cells	   nonspecifically,	   or	   polar	   enough	   to	   be	   excluded	   by	   all	   other	   cell	  types	   except	   those	   actively	   transporting	   the	   FFN	   by	   a	   plasma	   membrane	  transporter.	   Finally,	   while	   FFNs	   must	   have	   sufficient	   kinetic	   properties	   at	   the	  relevant	  transporters	  such	  that	  they	  selectively	  label	  target	  aminergic	  neurons,	  the	  kinetics	   of	   transport	   must	   not	   be	   so	   high	   that	   the	   FFNs	   displace	   endogenous	  neurotransmitters	   and	   concomitantly	   alter	   the	   signaling	   characteristics	   of	   the	  synapse	  (as	  some	  false	  neurotransmitters	  are	  known	  to	  do:	  see	  above).	  	  One	  benefit	  of	  fluorescence	  microscopy	  is	  that	  it	  is	  sufficiently	  sensitive	  to	  image	  a	  small	  number	  of	   vesicularized	   fluorophores;	   it	   is	   not	   necessary	   to	   displace	   endogenous	  monoamines	  in	  order	  to	  image	  the	  synapses.	  	  	  	  
FFNs	  Visualize	  Synaptic	  Activity	  Our	   lab	   is	   currently	   involved	   in	   pursuing	   FFNs	   that	   can	   selectively	   load	  aminergic	  neurons	  via	  MATs	  or	  through	  action	  of	  VMAT2,	  depending	  on	  the	  specific	  parameters	  of	   the	  FFN.	   	  When	  imaged	  in	  the	  dorsal	  striatum	  of	  acute	  mouse	  brain	  slice,	  a	  dopaminergic	  FFN	  will	  appear	  as	  points	  of	   fluorescence	  within	  each	  frame,	  herein	   referred	   to	   as	   “puncta.”	   	   These	   puncta	   can	   represent	   loaded	   aminergic	  presynaptic	   elements	   or	   other	   structures	   within	   the	   neuron	   or	   brain	   slice	  preparation,	  with	  each	  FFN	  offering	  unique	   labeling	  characteristics.	   	  A	  FFN	  with	  a	  well-­‐characterized	   mechanism	   of	   loading	   will	   serve	   as	   a	   tool	   to	   study	   how	   that	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uptake	   mechanism	   responds	   to	   various	   drugs,	   and	   how	   it	   behaves	   in	   disease	  models.	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different	  readouts.	  	  In	  release	  studies,	  a	  well-­‐characterized	  FFN	  can	  potentially	  give	  important	   information	  about	   the	  kinetics	  of	  vesicular	   fusion	  and	  neurotransmitter	  release	   under	   various	   conditions	   (drugs,	   disease	   models),	   possibly	   provide	  information	   about	   the	   different	   populations	   of	   vesicles	   in	   synaptic	   zones	   (reserve	  pool	   vs.	   releasable	   pool),	   the	   kinetics	   of	   vesicular	   recycling,	   and	   behavioral	  heterogeneity	   of	   distinct	   presynaptic	   elements	   under	   different	   conditions	  (frequency	   of	   electrical	   stimulation,	   effects	   of	   drugs	   or	   disease,	   various	  environmental	  stimuli	  in	  in	  vivo	  experiments,	  etc.).	  	  We	  are	  currently	  pursuing	  two	  FFN	  motifs	   that	  provide	  optical	   information	  upon	   vesicular	   fusion.	   	   The	   first	   is	   a	   non-­‐pH	   sensitive	   FFN	   family	   based	   on	  aminoethyl-­‐substituted	   7-­‐aminocoumarins.	   	   These	   compounds	   are	   loaded	   into	  aminergic	  neurons	  or	  VMAT2-­‐expressing	  cells	  by	  an	  indeterminate	  mechanism,	  but	  label	  synaptic	  areas	  in	  neurons,	  or	  VMAT2-­‐expressing	  organelles	  in	  heterologous	  or	  peripheral	  cells,	  in	  a	  VMAT2	  dependent	  manner.(44,	  45)	  	  It	  is	  thought	  that	  VMAT2	  may	  drive	   this	   accumulation	   or	   selective	   retention,	   although	   plasma	   membrane	  transporters	  cannot	  be	  ruled	  out	  at	  this	  time.	  	  Upon	  vesicular	  fusion	  and	  exocytotic	  release	   from	   neurons,	   these	   FFNs	   diffuse	   from	   their	   highly	   concentrated	   luminal	  environment	  into	  the	  synaptic	  cleft,	  where	  they	  dissipate	  below	  the	  detection	  limit	  of	  the	  fluorescence	  microscope.	  	  The	  result	  is	  a	  “destaining”	  of	  the	  labeled,	  punctate	  presynaptic	  elements	  (Figure	  10A).	  	  	  The	   second	   motif	   uses	   aminoethyl-­‐substituted,	   pH-­‐sensitive	   7-­‐hydroxycoumarins,	   which	   are	   ratiometric	   pH	   sensors	   with	   tuned	   pKa	   values	  between	  the	  relatively	  low	  pH	  of	  the	  acidic	  synaptic	  vesicles	  (pH~	  5.5-­‐6.0)	  and	  the	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neutral	   extracellular	   environment	   (pH	   =	   7.4),	   with	   an	   accompanying	   increase	   in	  brightness	  upon	  deprotonation.(46,	  47)	   	  These	  compounds	  are	  quite	  polar,	  have	  been	  found	  to	  be	  substrates	  for	  MATs	  (Chapter	  3),(47)	  and	  afford	  quite	  selective	  labeling	  of	  aminergic	   neurons.	   	   Due	   to	   the	   pH	   sensitivity	   of	   these	   probes,	   exocytotic	   release	  from	  vesicular	  stores	  results	  in	  a	  visible	  “flash”	  (Figure	  10B).	  	  	  The	   ultimate	   goal	   of	   this	   body	   of	   work	   is	   to	   generate	   a	   method	   with	  multitudinous	   applications,	   including	   but	   certainly	   not	   limited	   to	   the	   study	   of	  aminergic	   signaling	  with	   high	   spatiotemporal	   resolution,	   aminergic	  modulation	   of	  glutamatergic,	   cholinergic,	   or	   other	   synapses	   (as	  well	   as	   the	  modulation	   of	  whole	  signaling	  networks),	   the	  effects	  of	  acute	  and	   long-­‐term	  pharmacological	   treatment	  on	  aminergic	  signaling	   in	   the	  brain,	   trafficking	  of	   loaded	  vesicles	  within	   individual	  neurons,	  and	  the	  relationship	  between	  aminergic	  signaling	  and	  disease.	   	  The	  latter	  studies	   could	   focus	   on	   the	   effects	   of	   disease	   on	  monoamine	   release	   and	   reuptake	  within	   individual	   neurons,	   as	   well	   as	   the	   broader	   effects	   of	   disease	   on	   signaling	  networks	   involving	   aminergic	   neurons.	   	   Currently,	   FFNs	   exist	   for	   the	   study	   of	  dopaminergic	  synapses	  in	  the	  dorsal	  striatum	  of	  acute	  mouse	  brain,	  as	  fluorescent	  ratiometric	   pH	   sensors	   of	   VMAT2-­‐expressing	   vesicles	   or	   acidic	   organelles,	   and	   as	  high-­‐throughput	  amenable	  screening	  agents	  for	  VMAT2	  activity.	  	  This	  thesis	  details	  new	  advancements	  in	  these	  areas	  (Chapter	  2)	  and	  work	  toward	  the	  identification	  of	  FFNs	   as	   fluorescent	   probes	   for	   the	   study	   of	   systems	   beyond	   nigrostraital	  dopaminergic	  innervations	  (Chapters	  3-­‐5).	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IV	  -­‐	  Conclusions	  and	  Outlook	  From	  the	  formative	  days	  of	  modern	  neuroscience	  when	  a	  simple	  silver	  stain	  was	   used	   to	   visualize	   individual	   neurons	   with	   a	   light	   microscope,	   chemistry	   has	  contributed	  to	  the	  methodological	  engine	  driving	  new	  discoveries	  about	  the	  brain.	  	  Neuropharmacology	  has	  contributed	  to	  our	  understanding	  of	  the	  brain	  by	  helping	  to	  elucidate	   the	   effects	   of	   neurotransmitter	   receptor	   agonism	   or	   antagonism	   on	  behavior	   or	   CNS	   phenotypes.	   With	   emerging	   optical	   imaging	   technologies	   for	  determining	   functional	   connections	   in	   neural	   networks,	   chemical	   reporters	   have	  allowed	  for	  imaging	  of	  action	  potentials	  in	  individual	  neurons	  and	  in	  the	  context	  of	  signaling	   networks.	   	  With	   an	   emerging	   interest	   in	   detection	   of	   neurotransmitters	  with	   special	   engineered	   receptors,	   there	   is	   also	   opportunity	   for	   chemistry	   to	  develop	   optical	   tracers	   of	   neurotransmitters	   to	   directly	   image	   neurotransmitter	  release	  and	  reuptake.	  I	  posit	  that	  the	  use	  of	  pharmacologically	  selective,	  highly	  fluorescent	  tracers	  of	   neurotransmitters	   will	   contribute	   to	   our	   understanding	   of	   synaptic	  communication	   and	   the	   relationships	   between	   individual	   synapses	   and	   their	  interrelated	  signaling	  networks.	   	   	  Chemistry	  provides	  us	  with	  the	  tools	  to	  generate	  new	  optical	   imaging	  agents,	  and	  chemical	  biology	  provides	   tools	   to	  evaluate	   these	  agents	  for	  further	  chemical	  optimization.	   	  The	  problems	  we	  must	  solve	  concerning	  the	  brain	  lie	  at	  the	  interface	  of	  classical	  neuroscience,	  neuropharmacology,	  synthetic	  chemistry,	   microscopy	   and	   imaging,	   and	   chemical	   biology.	   	   The	   majority	   of	   this	  thesis	   deals	   with	   fundamental	   biochemical	   and	   imaging	   work	   toward	   the	  
	   30	  
development	   and	   optimization	   of	   new	   fluorescent	   false	   neurotransmitters	   for	   the	  study	  of	  monoaminergic	  neurotransmission.	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I:	  Introduction	  
	  
Vesicular	  Monoamine	  Transporter	  (VMAT)	  
	  
	   Transport	  of	  monoamines	  from	  the	  cytosol	  to	  synaptic	  or	  secretory	  vesicles	  is	   a	   centrally	   important	   parameter	   for	   the	   function	   of	   these	   signaling	   molecules.	  	  This	   translocation	   is	   accomplished	   by	   action	   of	   the	   Vesicular	   Monoamine	  Transporter,	   a	   member	   of	   the	   solute	   carrier	   family	   18	   of	   transporters	   (SLC18),	  which	   includes	   two	   distinct	   VMAT	   isoforms	   as	  well	   as	   the	   vesicular	   acetylcholine	  transporter	   (VAChT).(1)	   VMAT2	   plays	   a	   key	   role	   in	   monoaminergic	  neurotransmission:	   it	   is	   responsible	   for	   packaging	  monoamine	   neurotransmitters	  into	  synaptic	  vesicles	   for	  eventual	  exocytotic	   release	   into	   the	  synapse.(2-­‐5)	   	  VMAT2	  also	   exists	   in	   the	   periphery,	   to	   a	   large	   degree	   in	   the	   pancreatic	   β-­‐cells,	   where	  transport	   of	   monoamines	   has	   been	   shown	   to	   play	   a	   role	   in	   insulin	   secretion.(6)	  	  VMAT1	  exists	  solely	  in	  the	  periphery,	  most	  notably	  in	  adrenal	  chromaffin	  cells	  and	  endocrine	   cells	   of	   the	   gastrointestinal	   tract,	   where	   it	   packages	   monoamines	   into	  large	  dense	  core	  vesicles	  (LDCVs)	   for	  storage	  and	  exocytotic	  release	   for	  endocrine	  signaling.(2,	   7,	   8)	   The	   two	   distinct	   isoforms	   share	   approximately	   60%	   sequence	  homology,(9)	   both	   contain	   12	   transmembrane	   α-­‐helices,	   and	   both	   are	   capable	   of	  transporting	  monoamines.(1)	   	   Substrate	   and	   inhibition	   profiles	   are	   similar	   but	   not	  identical,	   with	   reserpine	   serving	   as	   a	   potent	   inhibitor	   of	   both	   isoforms	   and	  tetrabenazine	  (TBZ)	  displaying	  selectivity	  towards	  VMAT2.(7,	  10)	  	  	  	   VMAT	   is	   a	   monoamine/H+	   antiporter,(11)	   and	   functions	   by	   transporting	  monoamine	   substrates	   against	   their	   concentration	   gradient	   by	   effluxing	   two	  protons	  down	  a	  pH	  gradient,	  from	  the	  low	  pH	  of	  the	  vesicle	  to	  the	  higher	  pH	  of	  the	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cytosol.	   	   This	   pH	   gradient	   is	   generated	   and	   maintained	   by	   a	   vacuolar	   ATPase	  (vATPase),	   using	   energy	   from	   the	   conversion	   of	  ATP	   to	  ADP	   to	   transport	   protons	  into	  the	  vesicular	  lumen	  (Figure	  1B).(11,	  12)	  	  	  	  	  
	   	  
	  
Figure	   1:	   	   The	   vesicular	   monoamine	   transporter	   (VMAT)	   is	   responsible	   for	  vesicularizing	   monoamine	   neurotransmitters	   in	   the	   central	   nervous	   system	   and	  periphery.	  A)	  Monoaminergic	  presynaptic	  elements	  can	  accumulate	  FFNs	  either	  by	  action	  of	  plasma	  membrane	  transporters	  (shown	  in	  light	  blue)	  or	  passive	  diffusion	  followed	  by	  uptake	  by	  VMAT2	  (dark	  blue	  ovals).	   	  B)	  A	  representation	  of	  a	  synaptic	  vesicle,	   highlighting	   the	   relationship	   between	   VMAT	   and	   a	   vATPase	   (light	   blue),	  which	  is	  responsible	  for	  generating	  the	  pH	  gradient	  across	  the	  vesicular	  membrane,	  which	   VMAT	   uses	   to	   drive	   transport	   of	   monoamines.	   	   VMAT	   is	   capable	   of	  translocating	  a	  number	  of	  substrates,	  including	  endogenous	  monoamines	  and	  FFNs.	  	  C)	  A	  representation	  of	  FFNs	  interacting	  with	  VMAT	  in	  a	  peripheral	  cell	  (VMAT2	  in	  a	  pancreatic	   B-­‐cell	   or	   VMAT1	   in	   an	   adrenal	   chromaffin	   cell,	   for	   example),	   or	   in	   a	  heterologous	  VMAT2-­‐overexpressing	  cell.	  	  	  	   	  VMAT	   is	   quite	   functionally	   plastic,	   tolerating	   a	   relatively	   broad	   scope	   of	  substrates.	  Transported	  substrates	  include	  all	  of	  the	  monoamine	  neurotransmitters,	  various	   other	   phenethylamines	   or	   tryptamines,	   the	   structurally	   unrelated	  neurotoxin	  MPP+,	  rhodamine	  6G,	  and	  others.(12-­‐14)	  Relatedly,	  VMAT2	  is	   involved	  in	  neuroprotection	  for	  two	  distinct	  reasons.	  	  First,	  monoaminergic	  neurons	  exploit	  the	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broad	   substrate	   scope	   of	   VMAT	   in	   order	   to	   sequester	   small-­‐molecule	   toxins	   into	  synaptic	   vesicles	   for	   eventual	   exocytotic	   release.	   	   It	   has	  been	   shown,	   for	   example,	  that	  VMAT2	  activity	   can	   rescue	  cells	   from	  MPP+	   toxicity	   (discussed	   in	  Chapter	  4),	  and	   VMAT	   inhibition	   has	   been	   linked	   to	   an	   increase	   in	   cytotoxicity	   under	   certain	  circumstances.(14-­‐16)	  	  Second,	  VMAT2	  is	  protective	  of	  neurons	  simply	  by	  clearing	  the	  cytosol	   of	   monoamine	   neurotransmitters	   after	   biosynthesis	   or	   reuptake.	  	  Monoamines	   are	   principally	   catabolized	   via	   oxidative	   deamination,	   catalyzed	   by	  monoamine	   oxidases	   (MAOs),	   resulting	   in	   the	   generation	   of	   toxic	   reactive	   oxygen	  species	  (ROS).	  (17,	  18)	  Because	   of	   its	   role	   in	   neurotransmission,	   endocrine	   signaling,	   and	  neuroprotection,	   VMAT	   has	   historically	   been	   a	   drug	   target	   and	   is	   reemerging	   as	  potentially	  relevant	  for	  the	  treatment	  of	  several	  conditions.	  Correspondingly,	  VMAT	  is	  also	  a	  target	  for	  imaging	  agents.	  
	  
VMAT2	  as	  a	  Drug	  Target	  Because	  of	  its	  critical	  role	  in	  modulating	  neurotransmission,	  VMAT	  has	  long	  been	   considered	   as	   a	   target	   for	   therapeutics.	   	   VMAT	   is	   the	   target	   of	   reserpine,	   an	  early	  anti-­‐hypertensive	  and	  antipsychotic	  drug	  (Figure	  2A).(19)	  	  Reserpine	  is	  thought	  to	  interact	  with	  the	  monoamine	  binding	  site	  of	  VMAT,	  and	  its	  mechanism	  of	  action	  involves	   depletion	   of	   monoamines	   in	   aminergic	   synapses.(20)	   The	   narrow	  therapeutic	  index	  and	  serious	  side	  effects	  including	  sedation,	  anxiety,	  parkinsonism,	  and	  gastrointestinal	  distress	  (caused	  by	  inhibition	  of	  VMAT1	  in	  the	  gastrointestinal	  tract),	   have	   led	   to	   reserpine	   being	   phased	   out	   as	   a	   drug	   and	   has	   cast	   a	   negative	  image	  on	  VMAT	  as	   a	  pharmacological	   target.(17)	  However,	   there	  has	   recently	  been	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renewed	   interest	   in	   targeting	   VMAT,	   particularly	   in	   the	   context	   of	   terminally	   ill	  patients(21)	  and	  for	  diabetes	  treatment.(6)	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VMAT2.(25)	   Lobeline	   and	   its	   derivatives	   inhibit	   methamphetamine-­‐induced	  dopamine	   release,	   as	   well	   as	   methamphetamine	   self-­‐administration	   in	   animal	  models,	  and	  these	  compounds	  are	  currently	  being	  pursued	  as	  novel	  therapeutics	  in	  preclinical	  and	  clinical	  studies	  for	  the	  treatment	  of	  methamphetamine	  abuse.	  (26)	  
	  	   Additionally,	   there	  has	  been	   some	   interest	   in	  developing	  VMAT2	   inhibitors	  for	  the	  treatment	  of	  diabetes,	  as	  inhibition	  of	  VMAT2	  in	  pancreatic	  β-­‐cells	  has	  been	  shown	  to	  increase	  insulin	  secretion,	  increase	  overall	  insulin	  sensitivity,	  and	  improve	  glucose	   metabolism	   in	   animal	   studies.(6,	   27)	   	   As	   such,	   there	   would	   be	   interest	   in	  developing	  a	  potent,	  selective	  VMAT2	  substrate	  that	  does	  not	  cross	  the	  blood-­‐brain	  barrier,	  in	  order	  to	  treat	  diabetes	  and	  insulin	  resistance	  without	  neurological	  effects	  or	  gastrointestinal	  effects	  from	  VMAT1	  inhibition	  in	  the	  digestive	  tract,	  as	  seen	  with	  reserpine.	  	  Further	  screening	  and	  development	  of	  inhibitors	  would	  be	  necessary	  to	  reach	  this	  goal,	  and	  a	  high-­‐throughput	  (HT)	  screening	  method	  for	  VMAT2	  inhibition	  would	  greatly	  assist	  this	  process	  (Section	  II).	  	  
VMAT	  as	  a	  Target	  of	  Imaging	  Agents	  	   Because	  if	  its	  centrality	  to	  monoaminergic	  neurotransmission	  and	  endocrine	  processes,	  there	  has	  been	  significant	  interest	  in	  the	  use	  of	  imaging	  agents	  targeting	  VMAT.	   To	   these	   ends,	   various	   radiotracers	   have	   been	   used	   to	   study	   VMAT.	  	  Radiolabeled	   11C-­‐TBZ	   and	   11C-­‐DTBZ,	   18F-­‐FE-­‐DTBZ	   have	   been	   introduced	   as	   PET	  imaging	  agents.(28-­‐31)	   (Figure	  2B)	  enabling	  study	  of	  VMAT2	  in	  the	  striatum.	   	  Using	  these	  tools,	  different	  expression	  levels	  have	  been	  observed	  in	  neurological	  diseases	  bipolar	  I	  and	  schizophrenia,(28)	  and	  a	  decrease	  of	  VMAT2	  in	  the	  pancreas,	  which	  has	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been	  associated	  with	  the	  onset	  of	  diabetes.(30,	  31)	  These	  imaging	  agents,	  while	  useful	  for	  in	  vivo	  studies	  of	  VMAT-­‐expressing	  tissues,	  are	  inherently	  limited	  by	  the	  spatial	  resolution	   of	   PET.	   	   The	   study	   of	   VMAT2	   expression	   and	   activity	   in	   individual	  presynaptic	   elements	   or	   within	   single	   pancreatic	   beta	   cells	   would	   require	   the	  development	  of	  other	  imaging	  techniques.	  To	  address	  this,	  we	  have	  been	  pursuing	  a	  fluorescence-­‐based	  approach.	  	  
	  
VMAT2	  and	  FFNs	  
	   VMAT2	  was	  the	  initial	  molecular	  target	  of	  the	  FFN	  program,(32)	  and	  continues	  to	   be	   centrally	   important	   to	   the	   development	   of	   new	   fluorescence-­‐based	   optical	  tracers	   of	   monoamine	   neurotransmitters.	   	   Since	   VMAT2	   is	   the	   transporter	  responsible	  for	  packaging	  monoamines	  into	  the	  synaptic	  vesicles,	  substrate	  activity	  at	  VMAT2	   is	  essential	   for	  any	  FFN’s	  ability	   to	   label	  aminergic	   synapses	  and	   image	  synaptic	  vesicle	  fusion.(33)	  Since	  no	  crystal	  structure	  has	  been	  solved	  for	  VMAT,	  we	  systematically	   employ	   rational	  molecular	   design	   to	   incorporate	   small,	   fluorescent	  aromatic	   moieties	   with	   known	   functionalities	   common	   to	   VMAT	   substrates	  (aminoethyl	  groups,	  hydrogen	  bond	  donors/acceptors,	  etc;	  Figure	  3).	  	  	  A	   number	   of	   functional	   VMAT2	   probes	   have	   been	   developed	   in	   our	   group,	  including	   pH-­‐responsive	   FFNs	   based	   on	   aminoethyl-­‐substituted	   7-­‐hydroxycoumarins.(34)	   One	   of	   these	   probes	   has	   been	   demonstrated	   to	   be	   a	   dual	  functional	  DAT-­‐VMAT2	  substrate	  in	  acute	  mouse	  brain	  slice,(35)	  serving	  as	  a	  proof	  of	  principle	   for	  dual-­‐substrate	  activity	  of	  FFNs	  (See	  Chapters	  1	  and	  3	  for	  discussion).	  	  Other	   FFNs	   based	   on	   a	   7-­‐aminocoumarin	   core	   have	   been	   studied	   as	   superior	  analogs	  of	  FFN511,	  and	  the	  development	  of	  a	  HT	  screening	  agent	  for	  VMAT2	  activity	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and	   inhibition	   in	   cultured	   cells	   has	   been	   reported	   and	   is	   described	   below	   (Part	  II).(36)	   Substrate	   activity	   at	  VMAT2	   is	   centrally	   important	   to	   the	  behavior	   of	   FFNs,	  and	  remains	  the	  only	  truly	  unifying	  characteristic	  of	  each	  of	  these	  FFNs.	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II:	   	  A	  new	   fluorescent	   substrate	  allows	   for	  examination	  and	  high-­‐
throughput	   screening	   (HTS)	   of	   VMAT2	   activity	   and	   inhibition	   in	  
cultured	  cells.(36)	  	  	   	  
A.	  	  Introduction	  	  	   	  Within	   the	   framework	   of	   our	   FFN	   program,	   we	   hypothesized	   that	   a	  fluorescent	   VMAT2	   substrate	   could	   be	   developed	   for	   the	   study	   of	   VMAT2	   activity	  and	   inhibition	   in	   cultured	   cells.	   	   Any	   such	   probe	   would	   require	   highly	   VMAT2-­‐specific	   cellular	   uptake,	   stable	   photophysical	   properties,	   and	   pharmacological	  properties	   similar	   to	   endogenous	   substrates.	   	   If	   identified,	   this	   probe	   could	   be	  developed	   into	   a	   fluorescence-­‐based	   microscopy	   assay	   for	   VMAT2	   activity	   and	  subcellular	   location;	   we	   also	   hypothesized	   that	   such	   an	   imaging	   agent	   could	   be	  extended	   to	  microplate-­‐based	   systems	   for	  HT	   examination	   of	   VMAT2	   activity	   and	  inhibition.	   	  This	  section	  details	  the	  previous	  characterization	  of	  FFN206,	  as	  well	  as	  my	   collaboration	   with	   Dr.	   Adam	   Henke	   for	   the	   validation	   of	   FFN206	   as	   a	   high-­‐throughput	  amenable	  screening	  agent	  for	  VMAT2	  in	  cultured	  cells.	  
	  
FFN206	  Enables	  Examination	  of	  VMAT2	  Activity,	  Distribution,	  and	   Inhibition	  
in	  Cultured	  Cells	  	   FFN206	   was	   designed	   and	   developed	   under	   the	   rationale	   of	   the	   FFN	  program,	  as	  described	  above.	  	  The	  synthesis	  of	  FFN206	  was	  completed	  by	  Dr.	  Gang	  Hu	   as	   part	   of	   a	   broad	   screen	   of	   approximately	   40	   aminocoumarin-­‐based	   probes	  toward	  VMAT2.	  	  FFN206	  was	  found	  to	  have	  favorable	  photophysical	  properties,	  and	  was	   first	  evaluated	   in	  cultured	  cells	  with	  wide-­‐field	   fluorescence	  microscopy.	   	  The	  cellular	   system	   employed	   to	   test	   VMAT2-­‐dependent	   uptake	   was	   transfected	   to	  heterologously	   express	   rVMAT2	   (VMAT2-­‐HEK).	   	   These	   cells	   were	   developed	   and	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fully	   characterized	   in	   the	   lab	   of	   our	   collaborator,	   Professor	   Robert	   Edwards	  (UCSF).(9)	   It	   was	   found	   that	   FFN206	   enabled	   visualization	   of	   VMAT2	   activity	   in	  individual	   VMAT2-­‐HEK	   cells,	   as	   well	   as	   the	   intracellular	   distribution	   of	   labeled	  compartments	   in	   a	   manner	   strongly	   sensitive	   to	   VMAT2	   inhibitors	   (Figure	   4).	  Treatment	   of	   FFN206-­‐labeled	   VMAT2-­‐HEK	   cells	   with	   the	   lipophilic	   weak	   base	  chloroquine,	  which	  crosses	  membranes	  and	  collapses	  the	  proton	  gradient	  between	  the	   lumen	  of	   acidic	   compartments	   and	   cytosol	   (the	   “weak	  base	   effect”),(37)	   caused	  redistribution	  of	  the	  probe	  from	  punctate	  VMAT2-­‐expressing	  compartments	  to	  the	  cytosol,	   confirming	   that	   FFN206	   accumulates	   in	   acidic	   organelles	   as	   opposed	   to	  simply	   binding	   to	   the	   protein	   target.	   The	   observation	   that	   FFN206	   does	   not	  considerably	   label	  other	  organelles	   renders	   this	  compound	  a	  useful	   imaging	  agent	  for	  subcellular	  localization	  of	  VMAT2	  activity.	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Dr.	   Hu	   showed	   that	   this	   wide-­‐field	   microscopy-­‐based	   assay	   for	   VMAT2	  activity	   and	   subcellular	   distribution	   could	   be	   extended	   to	   a	   quantitative	  fluorometric	  microplate	  assay	   for	  VMAT2	  activity,	   specifically	  with	  examination	  of	  dose-­‐response	   studies	  of	   inhibitors	   and	  high	   throughput	   screening	  applications	   in	  mind.	  A	  number	  of	   established	  VMAT2	   inhibitors,	   including	   reserpine,	  TBZ,	  DTBZ,	  lobeline,	   fluoxetine,	   S(+)-­‐methamphetamine,	   ketanserin,	   and	   haloperidol	   were	  chosen	  to	  validate	  the	  assay’s	  ability	  to	  accurately	  quantify	   inhibition	  (IC50	  values)	  of	  inhibitors	  with	  a	  wide	  range	  of	  reported	  potencies	  (Figure	  5).(38,	  39)	  Each	  of	  these	  compounds	  was	  found	  to	  inhibit	  the	  uptake	  of	  FFN206	  in	  a	  dose-­‐dependent	  manner.	  Inhibition	  constants	  (Ki	  values)	  were	  calculated	  by	  substitution	  of	  the	  apparent	  Km	  value	   of	   FFN206	   (determined	   during	   optimization	   of	   this	   assay	   platform)	   and	  measured	   IC50	   values	   of	   each	   inhibitor	   into	   the	   Cheng-­‐Prusoff	   equation	  (Ki=IC50(1+[S]/Km)).	   	   These	  Ki	   values	  were	   found	   to	   closely	   agree	  with	  previously	  reported	  potencies	  determined	  by	  other	  methods	  (Figure	  5).	  	  Thus,	  FFN206	  enables	  rapid	  determination	  of	  quantitative	  inhibition	  parameters	  of	  VMAT2	  inhibitors	  over	  a	  wide	  range	  of	  potencies	  in	  intact	  cells	  using	  a	  plate	  reader.	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Figure	   5:	   FFN206	   can	   be	   used	   to	  measure	   inhibition	   constants	   of	   known	  VMAT2	  inhibitors	  and	  can	  be	  used	  as	  a	  screening	  agent	  for	  VMAT2	  inhibition.	  	  IC50	  values	  of	  known	   VMAT2	   inhibitors	   were	   measured	   in	   the	   FFN206	   uptake	   assay.	   The	   final	  concentration	   for	   FFN206	   is	   1	   µM.	   Error	   bars	   are	   standard	   errors	   (S.E.)	   derived	  from	  4	  independent	  experiments.	  Each	  experiment	  was	  run	  in	  triplicate/plate	  and	  2	  plates	  total.	  IC50	  values	  were	  listed	  as	  [inhibitor]	  ±	  S.E.	  Reserpine:	  IC50=0.019±0.001	  
µM;	   haloperidol:	   IC50=0.071±0.003	   µM;	   TBZ:	   IC50=0.32±0.01	   µM;	   Lobeline:	  IC50=1.01±0.07	   µM;	   DTBZ:	   IC50=0.017±0.001	   µM;	   Fluoxetine:	   IC50=1.07±0.05	   µM;	  Ketanserin:	   IC50=0.105±0.005	  µM;	   S(+)-­‐Methamphetamine	   (Meth):	   IC50=4.53±1.42	  
µM.	  	  Results	  are	  courtesy	  of	  Dr.	  Gang	  Hu.	  	  	  	   A	  representative	  screen	  of	  small	  compounds	  with	  various	  known	  effects	  on	  VMAT2	  and	  vesicular	  pH	  was	  used	  to	  characterize	  FFN206	  as	  a	  screening	  agent	   in	  practice,	   and	   the	   results	  of	   this	   screen	   correlated	  with	  known	  behavior	  of	   each	  of	  the	  tested	  compounds	  (for	  detailed	  information,	  see	  our	  report).(36)	  	  With	  the	  invaluable	  assistance	  of	  a	  Dr.	  Adam	  Henke,	  a	  postdoc	  who	  I	  trained	  in	  mammalian	  cell	  culture	  and	  cell-­‐based	  FFN	  studies,	   I	  set	  out	   to	  study	  a	   few	  key	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parameters	   necessary	   for	   use	   of	   FFN206	   in	   high	   throughput	   screening.	   	   It	   was	  necessary	   to	   confirm	   that	   the	   observed	   kinetics	   of	   VMAT2-­‐dependent	   FFN206	  uptake	   are	   not	   limited	   by	   either	   passive	   diffusion	   or	   transporter-­‐dependent	  accumulation	  of	  FFN206	  across	  the	  plasma	  membrane.	  	  It	  was	  also	  incumbent	  upon	  us	  to	  establish	  the	  Z’-­‐factor,	  a	  widely	  used	  measure	  of	  the	  quality	  of	  a	  HT	  assay,	  of	  FFN206	  for	  our	  microplate	  reader.	  	  Because	  a	  FFN206-­‐based	  assay	  may	  be	  adapted	  to	   a	   system	   requiring	   repeated	  measurements,	   the	   photostability	   of	   FFN206	  was	  also	  investigated.	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B.	  	  Results	  and	  Discussion:	  
	  
FFN206	  Uptake	  Kinetics	  are	  Not	  Limited	  by	  the	  Plasma	  Membrane:	  	   To	  provide	  a	  quantitative	  measure	  of	  FFN206’s	  interaction	  with	  VMAT2,	  we	  measured	  cellular	  uptake	  kinetics	  using	  fluorometry.	   	  Dr.	  Hu	  initially	  characterized	  the	  apparent	  Km	  of	  FFN206	  at	  VMAT2	  using	  this	  assay,	  and	  found	  it	  to	  be	  1.16	  ±	  0.10	  
µM,	   similar	   to	   that	   of	   dopamine.	   	   It	   was	   determined	   that	   the	   initial	   fluorescence	  uptake	   velocity	   of	   FFN206	   in	   VMAT2-­‐HEK	   cells	   remains	   linear	   for	   12	   min	   for	  concentrations	  up	  to	  6	  µM,	  and	  the	  initial	  rates	  were	  measured	  in	  the	  linear	  interval	  at	  various	  FFN206	  concentrations.	  	  A	  similar	  Km	  to	  that	  observed	  by	  Dr.	  Hu	  was	  measured	  using	  a	  more	  modern	  plate	  reader	   (Km	  =	  1.12	  ±	  0.24	  µM,	  (mean	  ±	   SEM,	  n	  =	  2	   independent	  experiments;	  
Figure	   6A)).	   Since	   the	   vast	   majority	   of	   VMAT2	   in	   these	   cells	   is	   expressed	   on	  intracellular	  compartments,	  it	  was	  necessary	  to	  establish	  whether	  the	  observed	  Km	  was	  in	  fact	  due	  to	  interaction	  of	  FFN206	  with	  VMAT2	  or	  if	  the	  measured	  affinity	  was	  actually	   the	   rate	   of	   diffusion	   or	   transport	   across	   the	   plasma	   membrane.	   	   To	  accomplish	  this,	   the	  apparent	  Km	  was	  also	  measured	  when	  cells	  were	  treated	  with	  digitonin	  to	  permeabilize	  the	  membrane.	  	  This	  experiment	  was	  adapted	  from	  earlier	  procedures	   to	   study	   VMAT	   transport,(13)	   and	   membrane	   permeabilization	   was	  confirmed	   in	  an	   independent	  control	  experiment	  by	   trypan	  blue	  (0.4%,	  10	  minute	  treatment)	   uptake	   into	   cells	   under	   permeabilizing	   conditions.	   	   The	   uptake	   of	  FFN206	  under	   these	   conditions	  was	   found	   to	   be	   linear	   for	   9	  minutes,	   and	   the	  Km	  was	  determined	  to	  be	  2.26	  ±	  0.92	  µM	  (mean	  ±	  SEM,	  n	  =	  3	  independent	  experiments,	  
Figure	   6B),	   suggesting	   that	   diffusion	   across	   the	   plasma	   membrane	   or	   transport	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through	   a	   hypothetical	   plasma	  membrane	   transporter	   is	   not	   the	   rate-­‐determining	  step	  of	  uptake	  in	  the	  whole	  cell	  assay	  (where	  the	  vast	  majority	  of	  VMAT2	  protein	  is	  intracellular).	  	  To	   confirm	   the	  apparent	  Km	  obtained	  by	   the	   fluorescence	  assay	  with	   intact	  and	   permeabilized	   cells,	   the	   affinity	   of	   FFN206	   for	   VMAT2	  was	  measured	   by	   the	  inhibition	   of	   [3H]-­‐serotonin	   uptake	   in	   membrane	   preparations	   obtained	   from	  VMAT2-­‐HEK	   cells	   in	   the	   laboratory	   of	   Professor	   Robert	   Edwards	   (UCSF).	   An	   IC50	  value	   of	   1.15	   µM	   was	   obtained	   (Figure	   6C),	   showing	   good	   agreement	   with	   the	  apparent	  Km	  for	  FFN206	  determined	  by	  fluorescence.	  The	  modest	  affinity	  of	  FFN206	  for	  VMAT2	  compares	  well	  with	  endogenous	  substrates	  such	  as	  dopamine	  (Km	  =	  0.82	  -­‐	  0.95	  µM(40,	  41)	  and	  IC50	  =	  0.92	  ±	  0.05	  µM(40)).	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Figure	  6:	   	  FFN206	  Km	  apparent	  is	  not	  rate-­‐limited	  by	  transport	  or	  diffusion	  across	  the	  plasma	  membrane	  of	  VMAT2-­‐HEK	  cells.	  	  A)	  Michaelis-­‐Menten	  plot	  of	  FFN206	  as	  measured	  by	  initial	  rates	  of	  accumulation	  of	  specific	  fluorescence	  uptake	  in	  VMAT2-­‐HEK	  cells	   (subtracted	  background	   is	   from	  DTBZ-­‐treated	  wells,	  2	  µM);	  Km	  =	  1.12	  ±	  0.24	  µM,	  (mean	  ±	  SEM).	  	  B)	  Pretreatment	  with	  10	  µM	  digitonin	  (to	  permeabilize	  the	  plasma	  membrane)	   does	  not	   increase	   the	   apparent	   affinity	   of	   FFN206	   for	  VMAT2	  (Km	   =	   2.26	   ±	   0.92	   µM).	   C)	   FFN206	   inhibits	   3H-­‐5HT	   uptake	   in	   membrane	  preparations	  of	  VMAT2	  from	  the	  same	  VMAT2-­‐HEK	  cells.	  	  IC50	  was	  found	  to	  be	  1.15	  
±	   0.24	  µM	   (mean	  ±	   SEM).	   	   Results	   for	   C	   are	   courtesy	   of	   the	   Edwards	   Laboratory	  (USCF).	  
	  
	  
FFN206	  As	  a	  HTS-­‐Amenable	  VMAT2	  Substrate	  
	   High-­‐throughput	   screening	   assays	   are	   evaluated	   for	   robustness	   by	  determining	   the	   dynamic	   range	   of	   the	   assay	   and	   experimental	   variability	  (determined	  as	  standard	  deviations	  of	  control	  data	  sets),	  and	  HT	  assays	  are	  held	  to	  high	  standards	  to	  minimize	  occurrences	  of	  false	  positives	  or	  negatives	  arising	  from	  statistical	  variations	  of	  the	  normal	  distributions	  of	  the	  data.	  	  The	  Z’-­‐factor	  has	  been	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introduced	   as	   an	   important	   means	   of	   quantifying	   this	   robustness.(42)	   A	   Z’-­‐factor	  greater	   than	   0.5	   indicates	   an	   assay	   is	   acceptable	   for	   HT	   screening.	   In	   order	   to	  determine	   the	  applicability	  of	   the	  FFN206-­‐based	  VMAT2	  assay	   to	  high	   throughput	  applications,	   control	   experiments	  were	   conducted	   from	  which	   this	  parameter	  was	  calculated	  (Z’-­‐factor	  =	  0.68	  ±	  0.07;	  calculated	  from	  the	  arithmetic	  means	  determined	  from	  5	  independent	  experiments,	  each	  consisting	  of	  2	  identical	  plates;	  Table	  1,	  see	  
Figure	   7	   for	   equations	   used).	   	   Additionally,	   it	  was	   found	   that	   by	  measuring	   area	  scans	   of	   each	   well	   (versus	   the	   single-­‐point	   scans),	   this	   parameter	   can	   be	   further	  improved	  	  (Table	  1),	  although	  area	  scans	  considerably	  slow	  the	  reading,	  making	  it	  less	  attractive	  for	  HT	  application.	  	  	  	  
𝑍! =   1− 3  ×   𝜎(!) + 𝜎(!)𝜇(!) − 𝜇(!) 	  	  𝐶𝑉 =   𝜎𝜇   ×  100	  	  𝑆 𝐵 =   𝜇(!)𝜇(!)	  	  
Figure7:	  Equations	  used	   to	  calculate	  high-­‐throughput	  screening	  parameters.	  CV	   is	  the	  coefficient	  of	  variation	  for	  each	  data	  set.	   	  S/B	  is	  the	  signal	  to	  background	  ratio.	  	  	  𝜇	  =	  control	  means,	  positive	  (+)	  or	  negative	  (-­‐);	  𝜎	  =	  stdev	  of	  controls.	  	  	   The	   fluorometric	  assay	  utilizing	  FFN206	   is	  well	   suited	   for	  HTS	  as	   indicated	  by	  the	  statistical	  evaluation	  of	  its	  performance	  (Z’>	  0.5	  is	  recommended	  for	  HTS).	  It	  should	   be	   noted	   that	   automation	   of	   the	   assay,	   from	   cell	   counting	   to	   automated	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Table	   1	   	  High	   throughput	   screening	   parameters	   as	  measured	   by	   a	   BioTek	  H1MF	  plate	  reader	  recoring	  single	  points	  from	  each	  well	  (fastest	  for	  HT)	  compared	  to	  area	  scans	   of	   various	   dimensions.	   	   Values	   are	   reported	   as	   means	   ±	   SD.	   Data	   were	  collected	  in	  collaboration	  with	  Dr.	  Adam	  Henke.	  	  
	   Single	  Point	   Area	  Scan	  (3x3)	   Area	  Scan	  (5x5)	  
Z’	   0.68±0.07	   0.79±0.03	   0.82±0.03	  
CV	  (-­‐)	   7.0±2.1	   4.6±0.7	   4.0±0.5	  
CV	  (+)	   11.0±1.0	   7.2±0.8	   7.2±1.0	  
S/B	   5.4±0.9	   6.2±0.9	   6.4±1.0	  	  	  	  	  
Photostability	  of	  FFN206	  	   As	  some	  applications	  of	  FFN206	  in	  the	  study	  of	  VMAT2	  may	  require	  repeated	  measurements,	  the	  photostability	  of	  FFN206	  was	  tested	  using	  our	  plate	  reader.	   	  In	  order	   to	   determine	   the	   photostability	   of	   FFN206	   under	   the	   fluorometric	   assay	  conditions,	   fluorescence	   emission	   of	   a	   solution	   of	   FFN206	   (0.5	   µM	   in	   PBS)	   was	  repeatedly	  measured	  on	  a	  BioTek	  H1MF	  plate	  reader	  using	  the	  same	  excitation	  and	  emission	  wavelengths	  as	  above	  (λex	  =	  368	  nm,	  λem	  =	  464	  nm).	  	  Measurements	  were	  taken	  every	  15	  s	  for	  10	  min.	   	  No	  significant	  decrease	  in	  fluorescence	  intensity	  was	  observed	  over	  this	  time	  period.	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Figure	   8:	   Photostability	   of	   FFN206.	   	   No	   significant	   attenuation	   of	   FFN206	   signal	  was	   observed	   after	   repeated	   measurements	   using	   a	   plate	   reader.	   	   Data	   are	  representative	  of	  2	  independent	  experiments.	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C.	  	  Conclusions	  and	  Outlook	  (Part	  II)	  
	   We	  have	  introduced	  FFN206	  as	  a	  new	  optical	  probe	  with	  several	  applications	  in	   the	   study	   of	   VMAT2	   in	   cell	   culture.	   	   This	   small,	   highly	   fluorescent	   coumarin	  analog	  is	  capable	  of	  sensitively	  detecting	  VMAT2	  activity	  on	  wide-­‐field	  microscopic	  or	  fluorometric	  platforms.	  FFN206	  is	  capable	  of	  determining	  subcellular	  location	  of	  VMAT2-­‐expressing	   organelles	  with	   high	   selectivity;	   it	   does	   not	   considerably	   label	  non-­‐VMAT2-­‐expressing	   structures	   or	   other	   cellular	   components,	   including	  mitochondria.	   	   It	   is	   also	   capable	   of	   reporting	  on	  VMAT2	  activity	   in	   a	   fluorometric	  format	   highly	   amenable	   to	   high	   throughput	   screening;	   the	   assay	   features	   simple	  operations	  amenable	   for	  automation,	  excellent	  Z’-­‐factor,	  as	  well	  as	  reproducibility.	  As	   such,	   FFN206	   represents	   an	   excellent	  HTS	   candidate	   capable	   of	   facilitating	   the	  search	  for	  next	  generations	  of	  VMAT2	  modulators	  including	  inhibitors,	  substrates	  or	  enhancers.	  	  As	  is	  the	  case	  for	  all	  HTS	  campaigns,	  secondary	  assays	  are	  needed	  to	  address	  and	   filter	   false	  positives.	   	   It	  would	  be	  most	   important	   to	  have	  secondary	  assays	  to	  address	  potential	  collapse	  of	  pH	  gradient	  across	  the	  vesicular	  membrane	  by	  action	  of	  experimental	  compounds	  via	  the	  weak	  base	  effect	  or	  inhibition	  of	  v-­‐ATPase.	  	  Such	  a	   secondary	   assay	   could	   take	   the	   same	   format	   as	   the	   FFN206	   assay,	   using	   a	  lysotracker	  probe	  or	  acridine	  orange.	   	  These	  dyes	  are	  amphiphilic	  weak	  bases	  that	  accumulate	   in	   acidic	   organelles	   independent	   of	   transporters,	   in	   a	   manner	  proportional	   to	   the	   pH	   of	   the	   compartments,	   allowing	   for	  measurement	   of	   pH	   of	  acidic	  compartments	  within	  the	  cell,	  and	  in	  this	  case,	  providing	  a	  secondary	  screen	  for	  pH	  collapse	  by	  hits	  identified	  by	  FFN206.	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III:	  	  New	  FFNs	  for	  Imaging	  VMAT2	  in	  Brain	  Tissue	  
	  
A. Introduction	  –	  	  
	   As	  discussed	   in	   the	   introduction,	   our	   lab	   is	   focused	   on	  developing	   FFNs	   as	  optical	   tracers	   of	   monoamine	   neurotransmitters	   in	   brain	   tissue,	   and	   VMAT2	  substrate	   activity	   is	   an	   essential	   parameter	   for	   these	   probes.	   	   Within	   the	   FFN	  program,	  there	  is	  always	  the	  need	  to	  find	  superior	  VMAT	  substrates	  with	  optimized	  kinetic	   parameters	   (Vmax,	   Km),	   tuned	   lipophilicity,	   and	   low	   nonspecific	   uptake	   by	  secondary	   transporters	   or	   other	   mechanisms.	   	   The	   interplay	   between	   these	  parameters	   is	  manifest	   in	   selectivity	   of	   the	   FFN	   for	   aminergic	   terminals,	   signal	   to	  background	  ratio,	  and	  destaining	  characteristics	  of	  the	  FFN	  in	  the	  overall	  observed	  behavior	   of	   the	   FFN	   in	   acute	   brain	   slice,	   primary	   neuronal	   culture,	   or	   other	  advanced	  experimental	  systems.	  	  	  In	   search	   of	   high-­‐quality	   FFNs,	   a	   number	   of	   probes	   have	   been	   synthesized	  and	   screened	   for	   activity	   at	   VMAT2,	   either	   previously	   by	   former	  members	   of	   the	  Sames	   group	   or	   concurrently	   with	   this	   work	   by	   Dr.	   Adam	   Henke.	   The	   results	   of	  these	   screens	   are	   briefly	   summarized	   in	   Figure	   9.	   Of	   the	   numerous	   compounds	  screened	   in	   VMAT2-­‐HEK	   cells,	   promising	   leads	  were	   tested	   in	   acute	  mouse	   brain	  slice	   preparations	   by	   Sames	   Lab	  members	   working	   in	   the	   lab	   of	   Professor	   David	  Sulzer	   (CUMC),	   or	   were	   sent	   to	   other	   collaborators	   for	   characterization	   in	   other	  advanced	   systems.	   	   A	   number	   of	   these	   compounds	   are	   currently	   used	   to	   study	  VMAT2	   activity,	   distribution,	   and	   pharmacology	   in	   cultured	   neurons	   (Dr.	   Yvonne	  Schmitz,	  Sulzer	  Group),	  and	  monoaminergic	  neurotransmission	  in	  whole	  brains	  of	  d.	  
melanogaster	  (Dr.	  Mark	  Sonders	  and	  Dr.	  Zachary	  Freyberg,	  Javitch	  Group)	  and	  acute	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mouse	   brain	   slice	   (Dr.	   Daniela	   Pereira,	   Sulzer	   Group;	   Matt	   Dunn	   and	   Paolomi	  Merchant,	   Sames	   Group).	   	   The	   7-­‐hydroxycoumarin-­‐based	   FFN102	   has	   previously	  been	   described	   by	   our	   groups	   for	   the	   latter	   purpose,	   and	   functions	   as	   a	   “flashing	  FFN,”	   affording	   a	   signal	   increase	   upon	   exocytotic	   release	   into	   the	   synapse,	   as	  described	  in	  Chapter	  1.(33,	  35)	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The	  Need	  for	  a	  Better	  7-­‐Aminocoumarin	  for	  Use	  in	  Acute	  Mouse	  Brain	  Slice	  The	  Sames	  and	  Sulzer	  groups	  have	  been	  pursuing	  studies	   in	   the	  brain	  with	  FFN200,	   as	   it	   is	   the	  most	   selective	   “destaining”	   FFN	   currently	   available,	   although	  labeling	  and	  destaining	  properties	  are	  not	  optimal.	  	  We	  are	  yet	  unsure	  what	  drives	  FFN200	   uptake	   into	   aminergic	   neurons	   in	   acute	  mouse	   brain	   slice,	   although	   it	   is	  possible	   that	   plasma	   membrane	   transporters	   are	   involved.	   	   Conversely,	   VMAT2-­‐driven	  uptake	  or	  VMAT2-­‐dependent	  selective	  retention	  of	  FFN200	  during	  washout	  could	  be	  responsible	  for	  the	  observed	  labeling	  selectivity	  for	  dopaminergic	  neurons,	  as	  determined	  by	  anatomical	  coincidence	  with	  GFP	  expressed	  under	  the	  control	  of	  the	  promoter	  for	  tyrosine	  hydroxylase	  (TH-­‐GFP)	  in	  the	  dorsal	  striatum	  or	  midbrain	  of	  acute	  mouse	  brain	  slice.	   	  Dr.	  Daniela	  Pereira	  and	  Paolomi	  Merchant	  have	  shown	  an	   approximate	   25%	   reduction	   in	   the	   number	   of	   labeled	   puncta,	   thought	   to	   be	  dopaminergic	   terminals,	   in	   the	   presence	   of	   VMAT2	   inhibitors,	   and	   similar	  reductions	   are	   noticed	   in	   VMAT2	   hypomorph	   mice.	   	   This	   contrasts	   with	   the	  approximate	  80%	  colocalization	  with	  TH-­‐GFP.	  	  I	  hypothesized	  that	  if	  we	  could	  find	  a	  VMAT2	   substrate	   similar	   to	   FFN206	   that	  was	  more	   selective	   in	   culture,	  we	   could	  identify	  an	  aminocoumarin-­‐based	  “destaining”	  FFN	  that	  is	  more	  useful	  in	  examining	  aminergic	  innervation	  and	  synaptic	  activity	  in	  the	  brain.	  	  We	  have	  been	  motivated	  to	  search	  for	  a	  probe	  with	  superior	  VMAT2	  uptake	  kinetics	  with	  minimal	  background	   labeling	   in	  mouse	  brain,	   as	   this	  would	   increase	  selectivity	   toward	   aminergic	   synapses	   as	   well	   as	   possibly	   result	   in	   a	   probe	   with	  more	   ideal	   destaining	   kinetics	   (assuming	   vesicular	   recycling	   is	   necessary	   for	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complete	  destaining	  of	  puncta).	  	  Completion	  of	  the	  structure-­‐activity	  mapping	  of	  the	  7-­‐aminocoumarin	  library	  was	  one	  approach	  to	  meet	  this	  goal.	  	  	  
	  
Screened	  Libraries	  of	  Coumarin-­‐Based	  Probes	  7-­‐Aminocoumarin	   and	   7-­‐hydroxycoumarin-­‐based	   FFNs	   with	   aminoethyl	  groups	  in	  the	  3-­‐	  and	  4-­‐	  positions	  have	  been	  previously	  synthesized	  by	  members	  of	  the	  Sames	  group,	  due	  to	  the	  readily	  accessible	  nature	  of	  these	  compounds	  (Dr.	  Paul	  Vadola	   &	   Dr.	  Mini	   Lee,	   unpublished	   results).(34,	  47)	   	   I	   proposed	   that	   completion	   of	  these	   libraries	   with	   regioisomers	   containing	   aminoethyl	   groups	   in	   the	   6	   and	   8	  positions	  would	  afford	  us	  with	  a	  more	  complete	  understanding	  of	  structure-­‐function	  relationships	   between	   these	   probes	   and	   VMAT,	   as	   well	   as	   afford	   the	   potential	   to	  discover	   a	   superior	   probe.	   	   Both	   the	   7-­‐hydroxycoumarin	   and	   7-­‐aminocoumarin	  libraries	   were	   expanded	   with	   the	   help	   of	   Dr.	   Adam	   Henke.	   	   An	   expanded	   7-­‐hydroxycoumarin	  library	  has	  been	  screened	  for	  substrate	  activity	  at	  VMAT2	  by	  Dr.	  Henke	  (paper	  in	  progress),	  including	  regioisomers	  containing	  the	  aminoethyl	  group	  in	   the	   3-­‐,	   4-­‐,	   6-­‐,	   and	   8-­‐positions,	   and	   some	   select	   aminomethyl	   analogs.	   	   I	   have	  screened	   this	   library	   for	   DAT,	   NET,	   SERT,	   and	   Uptake2	   substrate	   activity	   (for	  structures	  of	  compounds	  and	  results,	  see	  Chapter	  3	  for	  DAT/NET/SERT	  and	  Chapter	  5	  for	  Uptake2).	  	  	  From	   this	   expanded	   library,	   we	   have	   identified	   and	   introduced	   a	   new	   7-­‐aminocoumarin-­‐based	   VMAT2	   substrate	   that	   may	   prove	   useful	   as	   a	   “destaining”	  FFN	  in	  the	  brain.	  	  I	  have	  also	  uncovered	  substrate	  activity	  at	  VMAT2	  of	  a	  new	  class	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B.	  	  Results	  and	  Discussion	   	  	  	  
AGH180	  is	  a	  Substrate	  of	  VMAT2	  in	  Cultured	  Cells	  	   In	   a	   continuing	   effort	   to	   search	   for	   VMAT2	   substrates	   as	   FFN	   leads,	   I	   was	  curious	  to	  test	  other	  regioisomers	  of	  7-­‐aminocoumarins.	  	  With	  the	  help	  of	  Dr.	  Adam	  Henke,	  AGH180	  was	  synthesized	  as	  a	  lead.	   	  AGH180	  is	  a	  6-­‐aminoethyl	  regioisomer	  of	  FFN200	  (Figure	  10A).	  	  Our	  screening	  studies	  in	  VMAT2-­‐HEK	  cells	  confirmed	  that	  AGH180	  exhibits	  punctate	   labeling	  of	  VMAT2-­‐expressing	  compartments,	  similar	   to	  results	  obtained	  with	  FFN206.	  In	  each	  of	   three	   fluorescence	  microscopy	  experiments	  conducted	  by	  myself	  and	  Dr.	  Adam	  Henke,	  it	  was	  found	  that	  AGH180	  compares	  favorably	  to	  FFN206,	  and	  is	  a	  considerably	  brighter	  label	  than	  FFN200	  (5	  µM,	  60	  min,	  Figure	  10	  B,C).	  	  When	  incubated	   in	   the	  presence	  of	  DTBZ	   (2	  µM),	   the	   labeling	  of	  AGH180	   is	   significantly	  attenuated.	  	  These	  results	  were	  confirmed	  on	  a	  microplate	  reader	  by	  comparing	  the	  total	   uninhibited	   and	   DTBZ	   (2	   µM)-­‐inhibited	   uptake	   of	   FFN206,	   FFN200,	   and	  AGH180.	   As	   seen	   in	   Figure	   10D,	   FFN206	   is	   best	   for	   use	   in	   cell	   culture	   with	   the	  highest	   specific	   uptake,	   and	   AGH180	   displays	   an	   intermediate	   to	   high	   uptake	  compared	  to	  FFN200	  under	  standard	  treatment	  conditions	  (5	  µM	  probes,	  15	  minute	  treatment,	  n	  =	  2	  plates).	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Figure	  10:	  	  Comparison	  of	  some	  advanced	  7-­‐aminocoumarin	  FFNs.	  	  A)	  Structures	  of	  FFN206,	   FFN200,	   and	   FFN180,	   with	   indicated	   properties	   including	   Km	   at	   VMAT2	  (mean	   ±	   SEM,	   see	   Figure	   11),	   and	   the	   calculated	   topological	   polar	   surface	   area	  (tPSA;	  ChemBioDraw	  Ultra).	  	  B)	  Direct	  comparison	  of	  uninhibited	  VMAT2	  uptake	  (5	  µM	   probe,	   60	   minutes)	   and	   C)	   DTBZ	   (2	   µM)-­‐inhibited	   uptake	   of	   these	   probes	   in	  VMAT2-­‐HEK	   cells,	   in	   the	   same	   order	   as	   listed	   in	   A.	   	   While	   FFN200	   is	   a	   VMAT	  substrate	  with	  low	  background	  uptake,	  it	  is	  nearly	  invisible	  when	  uptake	  images	  are	  contrasted	   identically	  with	   FFN206	   and	   AGH180.	   	   Images	   are	   representative	   of	   3	  independent	  experiments,	  at	  least	  3	  images	  per	  well.	  	  D)	  Representative	  comparison	  of	  FFN206,	  FFN200	  and	  AGH180	  uptake	  and	  inhibition	  using	  a	  plate	  reader	  (5	  µM	  probe,	  15	  minute	  treatment.	  	  Error	  bars	  represent	  SEM,	  n	  =	  2	  plates).	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Although	   FFN200	   is	   a	   clear	   VMAT2	   substrate,	   when	   compared	   directly	  alongside	  FFN206	  and	  AGH180	  in	  cultured	  VMAT2-­‐HEK	  cells,	  the	  uptake	  of	  FFN200	  is	   nearly	   invisible	   after	   60	  minutes	   as	   determined	   by	   epifluorescence	  microscopy	  (Figure	  10B).	  	  If	  the	  images	  were	  contrasted	  independently	  for	  each	  probe	  relative	  to	  its	  inhibited	  uptake,	  VMAT2-­‐specific	  uptake	  would	  become	  visible	  for	  FFN200,	  as	  background	  uptake	  (as	  measured	  in	  the	  presence	  of	  TBZ	  2	  µM)	  at	  5	  µM	  is	  lowest	  for	  FFN200	   (Figure	   10C,D).	   The	   topological	   polar	   surface	   area	   (tPSA)	   of	   AGH180	   is	  similar	   to	   that	   of	   FFN200	   (as	   predicted	   by	   ChemBioDraw	   Ultra,	   Figure	   10A),	  suggesting	   that	   lipophilic	   uptake	   may	   be	   comparable	   for	   AGH180	   and	   FFN200,	  although	  nonspecific	  uptake	  of	  AGH180	  appears	  closer	   to	   that	  of	  FFN206,	  and	  can	  be	  rationalized	  by	  the	  amphipathic	  nature	  of	  AGH180,	  where	  both	  moieties	  capable	  of	  carrying	  charge	  are	  on	  the	  same	  side	  of	  the	  molecule.	  	  
Comparison	  of	  Apparent	  Km	  of	  FFN206,	  FFN200,	  and	  AGH180	  for	  VMAT2	  	  	  
	   The	   Km	   for	   each	   compound	   was	   determined	   by	   initial	   rates	   experiments	  within	   the	   linear	   region	   of	   time-­‐dependent	   accumulation.	   These	   results	   are	  summarized	   in	   Figure	   11,	   showing	   representative	   Michaelis-­‐Menten	   plots	   for	  FFN200	  and	  AGH180.	   	   Indeed,	  FFN206	  has	  the	  highest	  apparent	  affinity	   for	  VMAT	  (results	  from	  above,	  1.16	  ±	  0.1	  µM,	  n	  =	  5	  independent	  experiments	  in	  collaboration	  with	  Dr.	  Gang	  Hu),	  FFN200	  appears	  lower	  (Km	  =	  13.74	  ±	  2.66	  µM,	  mean	  ±	  SEM,	  n	  =	  3	  independent	   experiments),	   and	   AGH180	   preliminarily	   has	   an	   intermediate	   Km	   at	  approximately	  9	  µM	  (preliminary	  results,	  n	  =	  1).	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Figure	  11:	  Representative	  Michaelis-­‐Menten	  plots	  of	  initial	  rates	  of	  VMAT2-­‐specific	  uptake	  for	  FFN200	  (left,	  Km	  =	  13.74	  ±	  2.66	  µM,	  mean	  ±	  SEM,	  n	  =	  3	  independent	  experiments)	  and	  AGH180,	  (right,	  Km	  ~	  9	  µM.)	  	  By	  comparison,	  the	  Km	  of	  FFN206	  was	  previously	  determined	  to	  be	  1.16	  ±	  0.1	  µM,	  n	  =	  5,	  using	  a	  similar	  method,	  and	  verified	  in	  Part	  II	  of	  this	  chapter.	  	  While	   it	   was	   prohibitive	   for	   us	   to	   measure	   Vmax	   in	   these	   systems,	   direct	  comparisons	   of	   the	   specific	   uptake	   of	   each	   probe	   at	   a	   single	   concentration	   is	  sufficient	  to	  derive	  relative	   information	  about	  VMAT2-­‐dependent	  uptake.	   	  At	  5	  µM	  with	  a	  corresponding	  15	  minute	  treatment	  (Figure	  10),	  FFN206	  is	  above	  its	  Km	  and	  specific	  uptake	  is	  quite	  high,	  FFN200	  is	  below	  its	  Km	  and	  total	  and	  specific	  uptakes	  are	   low,	   and	  AGH180	   is	   near	   its	   Km,	   and	   total	   uptake	   is	   greater	   than	   for	   FFN200.	  	  	  These	   results	   suggest	   that	  AGH180	  may	   serve	   as	   an	   alternative,	   stronger	  VMAT2-­‐dependent	  FFN	  compared	  to	  FFN200.	  	  	  
AGH180	   is	   Potentially	   a	   Useful	   FFN	   in	   Acute	  Mouse	  Brain	   Slice:	   Preliminary	  
Results	  	  	   In	  collaboration	  with	  Paolomi	  Merchant,	  these	  probes	  have	  been	  evaluated	  in	  the	   dorsal	   striatum	   of	   acute	   mouse	   brain	   tissue.	   	   FFN206	   has	   been	   found	   to	   be	  inappropriate	   for	   use	   in	   acute	   mouse	   brain	   slice,	   as	   we	   have	   noticed	   that	  substitution	   of	   the	   aniline	   of	   7-­‐aminocoumarins	   appears	   to	   reduce	   selectivity	   of	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labeling	   in	   acute	   mouse	   brain	   slice	   by	   a	   yet	   unknown	   mechanism	   (Paolomi	  Merchant,	   Dr.	   Shu	   Li,	   Dr.	   Daniela	   Pereira;	   Figure	   12B,	   left).	   	   This	   is	   true	   for	   a	  number	  of	  probes	  including	  FFN206,	  and	  this	  is	  despite	  favorable	  VMAT2	  activity	  in	  secondary	   cell-­‐based	   systems	   (Figure	   10B-­‐D,	   and	   Part	   III	   of	   this	   chapter).	   	   The	  behavior	  of	  FFN200	  in	  mouse	  brain	  slice	  is	  currently	  being	  characterized	  in	  detail	  by	  Dr.	  Daniela	  Pereira,	  and	  FFN200	  is	  found	  to	  colocalize	  to	  a	  high	  degree	  with	  TH-­‐GFP	  (Figure	   12B,	   right).	   	   AGH180	   shows	   a	   similar	   or	   possibly	   higher	   degree	   of	  colocalization,	   with	  more	   defined	   labeling	   compared	   to	   the	   other	   probes	   (Figure	  
12A).	   	   AGH180	   is	   also	   inhibited	   to	   a	   slightly	   higher	   degree	   by	   reserpine	   than	  FFN200	  (~37%	  reduction	  in	  puncta	  for	  AGH180	  compared	  to	  ~25%	  reduction	  for	  FFN200	   in	   preliminary	   experiments,	   data	   not	   shown,	   Paolomi	  Merchant).	   	   If	   true,	  this	  would	   indicate	   that	   AGH180	   is	   a	  more	   VMAT2-­‐selective	   FFN,	   consistent	  with	  favorable	  uptake	  results	  observed	  in	  cell	  culture	  (Figures	  10	  &	  11).	  	  	  
	  




Figure	  12:	  AGH180	  and	  related	  FFNs	  labels	  dopaminergic	  presynaptic	  terminals	  in	  dorsal	  striatum	  of	  acute	  mouse	  brain	  slices.	  	  A)	  AGH180	  (red)	  and	  TH-­‐GFP	  (Green)	  puncta	  colocalize	  approximately	  85%	  with	  respect	  to	  AGH180	  in	  the	  dorsal	  striatum	  of	  acute	  mouse	  brain	  slice,	  when	  analyzed	  as	  previously	  reported.(35)	  	  B)	  Side-­‐by-­‐side	  comparisons	  of	  FFN206,	  FFN200,	  and	  AGH180	  labeling	  and	  colocalization	  with	  TH-­‐GFP	   in	   the	   dorsal	   striatum	   of	   acute	   mouse	   brain	   slice.	   	   As	   above,	   each	   probe	   is	  shown	   in	   the	   pseudocolor	   red,	   TH-­‐GFP	   is	   shown	   in	   green.	   	   Yellow	   indicates	  colocalization.	   AGH180	   displays	   a	   colocalization	   similar	   to,	   if	   not	   better	   than,	  FFN200.	   	   Each	   image	   represents	   a	   30-­‐minute	   treatment	   of	   the	   slice	   with	   10	   µM	  probe,	   followed	   by	   a	   30-­‐minute	   wash	   period	   with	   artificial	   cerebral	   spinal	   fluid	  (ASCF).	  	  Images	  are	  courtesy	  of	  Paolomi	  Merchant.	  	  
	  
A	   Note	   Regarding	   7-­‐Aminocoumarin	   Labeling	   of	   Aminergic	   Neurons	   in	   the	  
Mouse	  Brain	  
	   If	   one	   assumes	   that	   these	   7-­‐aminocoumarins	   are	   indeed	   driven	   into	  aminergic	  neurons	  in	  brain	  tissue	  primarily	  by	  action	  of	  VMAT2,	  then	  the	  interplay	  between	  an	  FFN’s	  kinetic	  parameters	  at	  VMAT	  (Km	  and	  Vmax)	  and	  nonspecific	  uptake	  (or	  uptake/binding	  via	  secondary	  mechanisms)	  will	  define	  the	  labeling	  selectivity	  of	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the	   probe.	   	   If	   VMAT2	   uptake	   outcompetes	   background	   labeling,	   the	   FFN	   will	  accumulate	   to	   a	   greater	   extent	   in	   aminergic	   neurons	   than	   the	   surrounding,	   non-­‐aminergic	  cells.	  	  After	  a	  brief	  wash	  to	  remove	  background	  extracellular	  and	  cytosolic	  FFN	   from	  the	  brain	  slice,	   the	  result	   is	  a	   fairly	  selective	   label	  of	  VMAT2-­‐expressing	  neurons.	   	   While	   it	   is	   impossible	   for	   such	   an	   FFN	   exhibiting	   this	   behavior	   to	  selectively	   label	   one	   type	   of	   aminergic	   neuron	   over	   another,	   as	   each	   expresses	  VMAT2,	   it	  would	  be	  possible	   to	  observe	  areas	   in	  the	  brain	  where	  only	  one	  type	  of	  aminergic	   synapse	   is	   present,	   such	   as	   the	   dorsal	   striatum	   for	   dopaminergic	  synapses	  or	  the	  hippocampus	  for	  5HT-­‐ergic	  synapses.	  	  FFN206	  is	  one	  example	  of	  a	  series	  of	  7-­‐aminocoumarins,	  with	  substitutions	  on	  the	  aniline,	  which	  seems	  to	  become	  heavily	  accumulated	  in	  other	  cells	  in	  mouse	  brain	   slice	  despite	  excellent	  VMAT2	  uptake	   in	   culture	  and	  excellent	  behavior	   in	  d.	  
melanogaster	  whole-­‐brain	  preparations	  (Sonders	  et	  al.,	  manuscript	  in	  preparation).	  	  As	  shown	  above,	  AGH180	  is	  a	  better	  VMAT2	  substrate	  than	  FFN200	  in	  culture,	  and	  is	  a	  cleaner	  label	  than	  FFN206	  in	  the	  dorsal	  striatum	  of	  the	  mouse	  brain.	  	  As	  such,	  it	  could	  prove	  to	  be	  an	  important	  FFN	  for	  future	  studies.	  	  	  	  	  
NG54:	  Revisiting	  a	  First-­‐Generation	  Probe	  
	   NG54	  was	  synthesized	  and	  tested	  in	  chromaffin	  cells	  and	  acute	  mouse	  brain	  slice	  by	  Dr.	  Niko	  Gubernator.	   	  Although	  NG54	  displayed	  a	  highly	  punctate	  signal	  in	  preliminary	   studies	   in	   the	   dorsal	   striatum	   of	   acute	   mouse	   brain	   slice,	   it	   was	   not	  pursued	   further,	   as	   it	   appeared	   to	   photobleach	   rapidly	   under	   imaging	   conditions	  used	   at	   that	   time.	   	   Additionally,	   it	   was	   found	   not	   to	   be	   clearly	   accumulated	   by	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VMAT1	   in	   mouse	   primary	   chromaffin	   cells.(48)	   Because	   of	   the	   apparent	   punctate	  labeling	  in	  the	  dorsal	  striatum,	  we	  chose	  to	  include	  NG54	  in	  our	  plasma	  membrane	  monoamine	  transporter	  screens,	  where	  it	  was	  found	  to	  be	  a	  substrate	  for	  DAT,	  NET,	  and	   SERT	   (Chapter	   3).	   	   We	   then	   chose	   to	   investigate	   the	   behavior	   of	   NG54	   at	  VMAT2.	  	  	  
	  
Figure	  13:	  	  Structure	  and	  fluorescence	  spectra	  of	  NG54.	  λmax(excitation)	  =	  390	  nm,	  
λ	   max(emission)	   =	   422	   nm.	   Fluorescence	   excitation	   and	   emission	   were	   recorded	  slightly	  off	  maxima,	  at	  446	  nm	  and	  380	  nm	  respectively,	  as	  to	  observe	  clear	  peaks	  and	  overlap	  of	  the	  spectra.	  	  	   	  When	  VMAT2-­‐HEK	  cells	  and	  TetR-­‐HEK	  (control)	  cells	  are	  treated	  with	  20	  µM	  NG54	   for	   30	   minutes	   and	   imaged	   with	   an	   epifluorescence	   microscope,	   NG54	  displays	  a	  punctate	  labeling	  pattern	  that	  is	  VMAT2-­‐dependent	  (Figure	  14),	  although	  there	   is	   considerable	   background	   uptake	   (Figure	   14A)	   presumably	   due	   to	  lipophilicity	   of	   the	   compound	   (logP	   predicted	   ~	   1.8).	   As	   in	   the	   case	   of	   FFN206	  above,	   a	   hypothetical	   transporter	   on	   the	   plasma	  membrane	   can	   not	   be	   ruled	   out.	  	  The	   difference	   in	   brightness	   between	   control	   cells	   and	   VMAT2-­‐HEK	   cells	   was	  quantified	   by	   contrasting	   images	   to	   the	   same	   level	   using	   ImageJ,	   measuring	   the	  mean	   fluorescence	   intensity	   of	   each	   image,	   and	   normalizing	   each	   image	   to	   the	  number	  of	  cells	  in	  the	  frame.	  	  This	  was	  repeated	  for	  three	  images	  per	  condition,	  over	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three	   independent	   experiments.	   	   The	   resulting	   normalized	   mean	   fluorescence	  intensities	  were	  plotted	  with	   the	  mean	  brightness	  of	  TetR-­‐HEK	  =	  1	   (Figure	   14C).	  	  Specifically,	   it	   was	   found	   that	   NG54	   is	   1.24	  ±	   0.02	   times	   brighter	   in	   VMAT2-­‐HEK	  cells	  than	  control	  cells.	  	  When	  taken	  together	  with	  the	  punctate	  label	  in	  VMAT2-­‐HEK	  cells,	   these	   results	   suggest	   VMAT2-­‐dependent	   accumulation	   (mean	   ±	   SD,	   n	   =	   3	  independent	  experiments).	  	  	  
	  
Figure	   14:	   	   NG54	   uptake	   is	   VMAT2-­‐dependent.	   	   A)	   TetR-­‐HEK	   cells	   treated	   with	  NG54	   (20	  µM,	   30	  min)	   and	   B)	   	   VMAT2-­‐HEK	   cells	   under	   the	   same	   conditions.	   	   C)	  Normalized	   mean	   fluorescence	   uptake	   per	   cell	   indicates	   that	   VMAT2-­‐HEK	   cells	  preferentially	   accumulate	   NG54	   by	   a	   factor	   of	   1.24	   ±	   0.02	   (mean	   ±	   SD,	   n=3	  independent	  experiments,	  3	  images	  per	  condition	  per	  experiment	  contrasted	  to	  the	  same	   level).	   	   There	   is	   considerable	   background	   uptake	   in	   the	   empty	   vector-­‐transfected	  cells,	  although	  the	  difference	  in	  labeling	  morphology	  is	  clear.	  	  This	   punctate	   labeling	   can	   be	   inhibited	   by	  TBZ	   (Figure	   15).	   	   Interestingly,	  the	   VMAT2-­‐HEK	   cells	   are	   still	   quite	   bright	   in	   the	   presence	   of	   the	   TBZ	   inhibitor	  (Figure	   14),	   possibly	   due	   to	   a	   secondary	   uptake	  mechanism	   as	   the	   VMAT2-­‐HEK	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cells	  are	  not	  isogenic	  with	  the	  control	  TetR-­‐HEK	  cells	  (the	  VMAT2	  transfection	  was	  selected	  under	  pressure	  of	  MPP+).	  	  











Figure	   15:	  NG54	   labeling	  morphology	   is	  altered	  by	   the	  VMAT2	   inhibitor	  TBZ.	   	  A)	  Uninhibited	   20	  µM	  NG54	   in	   VMAT2-­‐HEK	   cells	   affords	   a	   punctate	   label	   consistent	  with	  previous	  VMAT2	  substrates	   in	   the	  same	  cell	   line.(34,	  36)	  B)	   	  2	  µM	  TBZ	  changes	  the	   morphology	   of	   the	   NG54	   label.	   Inhibited	   cells	   appear	   far	   less	   punctate.	   	   C)	  Corresponding	   brightfield	   image	   of	   uninhibited	   and	   D)	   corresponding	   brightfield	  image	   of	   TBZ-­‐inhibited	   conditions.	   E)	   Dr.	   Adam	  Henke	   and	   Yekaterina	   Kovalyova	  (an	  undergraduate	  student	   trained	  and	  advised	  by	  RJK)	  have	  found	  that	   the	   initial	  rates	   of	   NG54	   uptake	   can	   be	   estimated	   from	   this	   system	   following	   a	   30	   minute	  period	   of	   washing	   with	   PBS,	   where	   selective	   retention	   of	   NG54	   by	   VMAT2-­‐expressing	   intracellular	   compartments	   allows	   for	   detection	   of	   vesicularized	  NG54	  with	  minimal	   contributions	   from	  background	  cytosolic	   staining.	   	  Km	   (estimated)	  =	  12.5	  ±	  2.3	  µM	  (mean	  ±	  SEM,	  3	  independent	  experiments).	  	  Retention	  of	  NG54	  during	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this	   period	   is	   not	   affected	   by	   2	   µM	   TBZ	   in	   the	   wash	   buffer.	   	   All	   images	   are	  representative	  of	  3	  independent	  experiments.	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C.	  Conclusions	  and	  Outlook	  (Part	  III)	  	   A	   new	   FFN,	   AGH180,	   has	   been	   characterized	   as	   a	   VMAT2	   substrate	  comparable	   to	   FFN206	   in	   VMAT2-­‐HEK	   cells.	   	   Because	   of	   nonspecific	   staining	   in	  mouse	  brain	  slice,	  FFN206	  is	  not	  an	  acceptable	  FFN	  despite	  superior	  VMAT2	  uptake	  in	   cultured	   cells.	   FFN200,	   a	   poorer	  VMAT2	   substrate	   in	   culture,	   appears	   far	  more	  selective	   in	   acute	   mouse	   brain	   tissue	   for	   dopaminergic	   terminals	   in	   the	   dorsal	  striatum,	   and	   is	   used	   in	   the	   Sulzer	   Lab	   as	   a	   “destaining”	   aminergic-­‐selective	   FFN.	  	  Although	   the	  mechanism	   of	   FFN200	   labeling	   appears	   VMAT2-­‐dependent	   in	   brain	  slice,	   inhibition	   only	   partially	   reduces	   the	   number	   of	   labeled	   structures	   and	  brightness	   of	   FFN200	   signal	   in	   the	   dorsal	   striatum,	   despite	   a	   moderate	   to	   high	  degree	   of	   colocalization	   with	   dopaminergic	   markers.	   	   AGH180,	   a	   regioisomer	   of	  FFN200,	   has	   been	   identified	   herein	   as	   an	   excellent	   VMAT	   substrate	   compared	   to	  FFN200	  in	  cell	  culture.	  	  Moreover,	  preliminary	  results	  from	  acute	  mouse	  brain	  slice	  suggest	   that	   AGH180	   behaves	   as	   a	   more	   VMAT2-­‐dependent	   FFN	   in	   the	   dorsal	  striatum.	  	  Thus,	  AGH180	  may	  serve	  as	  a	  more	  selective	  “destaining”	  FFN	  for	  imaging	  synaptic	   activity	   in	   the	   dorsal	   striatum	   and	   other	   areas	   containing	   aminergic	  synapses.	  Studies	  of	  AGH180	  may	  also	  contribute	  to	  a	  more	  complete	  understanding	  the	  behavior	  of	  aminocoumarin-­‐based	  FFNs	  in	  the	  mouse	  brain.	  In	   this	   section,	   I	   have	   also	   identified	   substrate	   activity	   of	   NG54	   at	   VMAT2.	  	  This	  probe	  has	  also	  been	  identified	  as	  a	  substrate	  for	  hDAT,	  hNET,	  and	  hSERT,	  and	  is	  currently	  being	  pursued	  as	  an	  FFN	  in	  brain	  tissue	  as	  a	  next-­‐generation	  FFN	  capable	  of	  moving	  beyond	  dopaminergic	  activity	  (see	  Chapter	  3	  for	  a	  full	  discussion).	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IV:	  Experimental	  	  
	  
	  
General	  Cell	  Culture	  A	   HEK	   cell	   line	   stably	   expressing	   rVMAT2	   (VMAT2-­‐HEK)	   and	   an	   empty-­‐vector	   transfected	   HEK	   cell	   line	   to	   serve	   as	   a	   control	   (TetR-­‐HEK)	   were	   kindly	  provided	   by	   Professor	   Robert	   Edwards	   of	   the	   Department	   of	   Neurology	   at	   the	  University	   of	   California	   San	   Francisco	   (UCSF).	   	   Cells	   were	   grown	   on	   10	   cm	  polystyrene	   plates	   (Corning).	   	   Complete	   growth	   medium	   consisted	   of	   DMEM	   +	  Glutamax	   (Invitrogen)	   with	   10%	   Fetal	   Bovine	   Serum	   (FBS)	   (Atlanta	   Biologicals),	  100	  U/mL	  penicillin	  (Invitrogen),	  and	  100	  µg/mL	  streptomycin	  (Invitrogen).	   	  Cells	  were	  maintained	  at	  37°C	  in	  a	  humidified	  atmosphere	  containing	  5%	  CO2,	  and	  were	  subcultured	  approximately	  every	  3	  days,	  or	  before	  reaching	  75%	  confluence.	  
	  
Km	  determinations	  of	  FFN206	  	  	  To	  determine	  if	  the	  rate	  determining	  step	  of	  FFN206	  uptake	  is	  dependent	  on	  the	   plasma	   membrane,	   an	   experiment	   using	   digitonin	   to	   permeabilize	   the	  membrane	  was	  adapted	  from	  Schuldiner,	  et	  al.(13)	  Measurements	  were	  taken	  using	  a	  BioTek	   H1MF	   plate	   reader	   in	   bottom	   read	   mode,	   and	   a	   similar	   protocol	   to	   that	  described	  above	  (see	  Methods).	  	  First,	  Km	  was	  measured	  on	  this	  platform	  under	  non-­‐permeabilizing	   conditions	   to	   serve	   as	   an	   independent	   control.	   	   Cells	   stably	  transfected	   with	   VMAT2	   (VMAT2-­‐HEK)	   were	   seeded	   at	   a	   density	   of	   3.0	   x	   104	  cells/well	  in	  white	  clear-­‐bottom	  96-­‐well	  plates	  and	  allowed	  to	  proliferate	  in	  growth	  medium	   for	  ~2	   days	   at	   37	   ºC	   to	   reach	   confluence.	   On	   the	   day	   of	   experiment,	   the	  growth	   medium	   of	   confluent	   VMAT2-­‐HEK	   cells	   was	   aspirated	   and	   the	   cells	   were	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incubated	   with	   DTBZ	   (2	   µM,	   100	   µL/well)	   or	   DMSO	   vehicle	   for	   1	   hour	   in	  experimental	   medium.	   Experimental	   medium	   (100	   µL/well)	   containing	   either	  FFN206	   or	   a	   cocktail	   of	   FFN206	   and	  DTBZ	   (2	  µM)	  was	   added	   and	   the	   cells	  were	  incubated	   for	   the	   required	  duration	  of	   time.	  The	  uptake	  was	   terminated	  with	   two	  rapid	   PBS	   washes	   (2x200	   µL/well)	   and	   the	   cells	   were	   maintained	   in	   fresh	   PBS	  buffer	  (120	  µL).	  The	  fluorescence	  uptake	  in	  each	  well	  was	  immediately	  recorded	  in	  a	  plate	  reader	  BioTek	  Synergy	  H1MF	  Hybrid	  Reader	  (3x3	  and	  5x5	  area	  scan,	  bottom	  read	  mode)	  with	  excitation	  and	  emission	  wavelengths	  set	  at	  369	  nm	  and	  464	  nm,	  respectively.	   The	   specific	   uptake	   was	   defined	   as	   the	   overall	   fluorescence	   uptake	  (with	  DMSO	  vehicle)	  subtracted	  by	  that	  in	  the	  presence	  of	  DTBZ.	  The	  specific	  uptake	  rates	  were	   linear	   for	   concentrations	   of	   FFN206	   up	   to	   6	  µM	  with	   a	   corresponding	  incubation	  time	  of	  12	  min.	  The	  initial	  uptake	  rates	  for	  each	  concentration	  were	  fit	  to	  the	  Michaelis-­‐Menten	  equation	  using	  GraphPad	  Prism	  5	  software	   to	  give	  apparent	  Km	  value	  for	  FFN206	  uptake.	   	  Each	  independent	  experiment	  consisted	  of	  duplicate	  plates.	  	   For	   experiments	   using	   digitonin,	   cells	   were	   treated	   as	   above	   with	   an	  additional	  pretreatment	  of	  digitonin	  (10	  µM,	  10	  min)	  in	  DMEM	  (without	  phenol	  red)	  +	   25	   mM	   HEPES	   containing	   1%	   BSA	   immediately	   before	   initiating	   uptake.	   After	  digitonin	   pretreatment,	   the	   permeabilization	   medium	   was	   removed,	   cells	   were	  washed	   (100	   µL	   PBS),	   and	   FFN206	   solutions	   in	   the	   same	   experimental	   medium	  (without	   digitonin)	   supplemented	   with	   5	   mM	   Na2ATP	   were	   applied.	   	   Treatment	  times	  and	  wash	  protocols	  were	  otherwise	  the	  same	  as	  described	  above.	  	  Disruption	  of	  membrane	   integrity	   by	   digitonin	  was	   verified	   in	   an	   independent	   control	   using	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trypan	   blue	   (0.4%	   in	   PBS,	   10	   minute	   treatment)	   to	   indicate	   that	   the	   majority	   of	  VMAT2-­‐HEK	   cells	   permeabilized	   as	   above	   were	   labeled	   by	   the	   dye.	   The	   specific	  uptake	  rates	  of	  FFN206	  in	  digitonin-­‐treated	  cells	  were	  linear	  for	  concentrations	  up	  to	  6	  µM	  for	  a	  corresponding	  incubation	  time	  of	  9	  min.	  	  	  
	  
Determination	  of	  High-­‐Throughput	  Screening	  (HTS)	  Parameters	  	  	  Data	  for	  the	  HTS	  assay	  were	  recorded	  on	  BioTek	  Synergy	  H1MF	  Hybrid	  Plate	  Reader	   using	   poly-­‐D-­‐lysine	   coated	   96-­‐well	   micro–assay	   plates.	   VMAT2-­‐HEK	   cells	  were	   seeded	   at	   a	   density	   of	   3.0	   x	   104	   cells/well	   (by	   addition	   of	   200	   μL	   of	   a	   pre-­‐diluted	  cell	  suspension)	  in	  white	  clear-­‐bottom	  96-­‐well	  plates	  (allowed	  to	  attach	  the	  plate	   in	   the	   biosafety	   cabinet	   for	   ~20	  min)	   and	   allowed	   to	   proliferate	   in	   growth	  medium	  for	  50-­‐54	  h	  at	  37	  ºC	  to	  reach	  full	  confluence.	  On	  the	  day	  of	  experiment,	  the	  growth	   medium	   was	   aspirated	   and	   the	   cells	   were	   incubated	   for	   30	   min	   in	  experimental	  media	  with	  DTBZ	  (2	  μM,	  100	  μL/well)	  or	  DMSO	  vehicle.	  A	  solution	  of	  FFN206	  (2	  μM)	  or	  a	  cocktail	  of	  FFN206	  (2	  μM)	  and	  DTBZ	  (2	  μM)	  in	  the	  experimental	  medium	  (100	  μL/well)	  were	  added	  and	  the	  cells	  were	   incubated	   for	  1	  h.	  The	   final	  concentration	  of	  FFN206	  in	  each	  well	  was	  1	  μM,	  and	  the	  final	  concentration	  of	  DTBZ	  inhibitor	  was	  2	  μM.	  The	  layout	  of	  the	  plate	  consisted	  of	  48	  wells	  of	  positive	  control	  (2	   µM	   DTBZ)	   and	   48	   wells	   of	   uninhibited	   negative	   control	   (DMSO	   vehicle).	   The	  uptake	  was	   terminated	   by	  washing	  with	   PBS	   (2x200	   μL/well)	   and	   the	   cells	  were	  maintained	  in	  fresh	  PBS	  buffer	  (120	  μL).	  The	  fluorescence	  uptake	  in	  each	  well	  was	  immediately	  recorded	  in	  bottom-­‐read	  mode	  (using	  three	  different	  methods	  –	  single	  point,	  area	  scan	  (matrix	  3x3)	  and	  area	  scan	  (matrix	  5x5))	   in	  the	  plate	  reader	  with	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excitation	   and	   emission	   wavelengths	   set	   at	   369	   nm	   and	   464	   nm	   respectively.	   Z’	  value,	  coefficient	  of	  variation	  (CV)	  and	  signal	  to	  basal	  ratio	  (S/B)	  were	  calculated	  for	  each	  plate	  run	  in	  duplicate	  per	  experiment.	  	  Presented	  are	  the	  arithmetic	  means	  of	  these	   values	   calculated	   from	   5	   independent	   experiments	   consisting	   of	   duplicate	  plates.	  
	  
Procedure	   for	   Kinetic	   Study	   of	   FFN200	   and	   AGH180	   Uptake	   in	   VMAT2-­‐HEK	  
Cells	  	  	   The	   apparent	   Km	   of	   FFN200	   at	   VMAT2	   was	   determined	   using	   a	   similar	  protocol	   to	   that	   employed	   above.	   After	   pre-­‐treatment	  with	   experimental	  medium	  with	   and	   without	   TBZ(2	   μM)	   or	   DMSO	   vehicle	   (0.02%	   v/v),	   the	   medium	   was	  aspirated	  and	  a	  cocktail	  containing	  the	  probe	  at	  indicated	  concentrations	  and	  TBZ	  (2	  μM)	   or	   DMSO	   vehicle	   (0.02%	   v/v)	   was	   added	   (100	   μL/well)	   and	   the	   cells	   were	  incubated	   for	   12	   minutes.	   Uptake	   was	   terminated	   with	   two	   PBS	   washes	   (200	  μL/well)	  and	  the	  cells	  were	  treated	  with	  fresh	  PBS	  buffer	  (120	  μL).	  The	  fluorescence	  uptake	  in	  each	  well	  was	  immediately	  recorded	  with	  a	  BioTek	  H1MF	  plate	  reader	  in	  bottom	  read	  mode	  with	  excitation	  and	  emission	  wavelengths	  set	  to	  352	  nm	  and	  451	  nm,	  respectively.	  The	  specific	  uptake	  was	  defined	  as	  the	  overall	  fluorescence	  uptake	  from	   uninhibited	   wells	   subtracted	   by	   that	   in	   the	   presence	   of	   TBZ.	   The	   specific	  uptake	   was	   linear	   for	   concentrations	   of	   FFN200	   at	   50	   μM	   or	   less	   with	   a	  corresponding	   incubation	   time	   of	   12	   min.	   The	   initial	   rates	   of	   uptake	   for	   each	  concentration	  were	   fit	   to	   the	  Michaelis-­‐Menten	   equation	   using	   GraphPad	   Prism	   5	  software	   to	  give	  apparent	  Km	  value	   for	  probe	  uptake	  by	  VMAT2.	  Each	  experiment	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consisted	  of	  duplicate	  plates,	  and	  Km	  for	  FFN200	  was	  calculated	  from	  the	  arithmetic	  mean	  of	  three	  independent	  experiments,	  and	  Km	  of	  AGH180	  is	  from	  one	  preliminary	  experiment.	  
	  
	  
Examination	  of	  FFNs	  in	  VMAT2-­‐HEK	  Cells	  For	  fluorescence	  microscopy	  experiments,	  cells	  were	  plated	  on	  poly-­‐D-­‐lysine	  (Sigma-­‐Aldrich,	  0.1	  mg/mL)	  coated	  six-­‐well	  plates	  (Falcon)	  at	  a	  density	  of	  100,000	  cells/well	   and	   were	   incubated	   until	   confluence	   (4	   days	   at	   37˚C	   in	   a	   humidified	  atmosphere	  containing	  5%	  CO2).	  	  The	  medium	  was	  then	  removed	  by	  aspiration	  and	  wells	   were	   carefully	   washed	   with	   PBS.	   	   Cells	   were	   then	   treated	   with	   900µL	   of	  experimental	   medium	   (DMEM	   minus	   phenol	   red	   containing	   25	   mM	   HEPES	  (Invitrogen)	  with	  1%	  FBS	   (Atlanta	  Biologicals))	   for	  1-­‐3h	  with	  or	  without	  DTBZ	  or	  reserpine	  as	  inhibitors	  at	  the	  indicated	  concentrations.	  	  Cells	  were	  then	  treated	  with	  100	   µL	   of	   FFN,	   or	   a	   cocktail	   of	   FFN	   with	   inhibitor	   for	   final	   concentrations	   as	  indicated	   for	   the	   indicated	   time.	   	  Wells	  were	   aspirated,	  washed	   once	  with	   PBS	   (2	  mL/well),	  and	  wells	  were	   filled	  with	  warm	  experimental	  medium.	   	  Brightfield	  and	  fluorescence	   images	   were	   acquired	   using	   a	   Leica	   DMI	   4000B	   inverted	  epifluorescence	   microscope	   equipped	   with	   a	   Leica	   DFC	   360	   FX	   digital	   camera	  controlled	   through	   Leica	   LAS	   AF	   6000E	   software.	   	   Bright	   field	   and	   fluorescence	  images	   were	   acquired	   sequentially	   (BF	   acquisition	   time	   =	   37	   ms).	   	   Fluorescence	  images	   were	   acquired	   using	   dichroic	   filter	   cubes	   to	   selectively	   excite	   and	   record	  emission	   wavelengths	   for	   each	   FFN	   probe.	   	   All	   fluorescence	   images	   of	   each	  respective	   fluorophore	   under	   different	   conditions	   were	   adjusted	   to	   the	   same	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brightness	   and	   contrast	   level,	   respectively,	   using	   ImageJ	   (National	   Institutes	   of	  Health).	   	  For	  direct	  comparison	  of	  the	  brightness	  of	  FFN206,	  FFN200,	  and	  AGH180	  in	   VMAT2-­‐HEK	   cells,	   all	   images	   were	   contrasted	   to	   the	   same	   level	   optimal	   for	  FFN206,	  for	  direct	  comparison.	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I:	  Introduction	  
	  	   Within	  the	  FFN	  program,	  it	  has	  previously	  been	  established	  that	  VMAT2	  can	  drive	  FFN	  uptake	  into	  monoaminergic	  synapses.(1)	  We	  envisioned	  the	  possibility	  of	  selectively	   loading	   a	   fluorescent	  VMAT	   substrate	   into	  monoaminergic	  neurons	   via	  action	   of	   plasma	   membrane	   monoamine	   neurotransmitter	   transporters	   (MATs),	  akin	  to	  a	  false	  neurotransmitter	  (introduced	  in	  Chapter	  1).	  	  Such	  a	  compound	  would	  be	   a	   more	   realistic	   fluorescent	   false	   neurotransmitter,	   capable	   of	   labeling	  monoaminergic	  neurons	  by	  action	  of	  the	  high	  affinity	  transporter	  MATs	  in	  addition	  to	  labeling	  synaptic	  vesicles	  by	  action	  of	  VMAT2.	  	  A	  MAT-­‐active	  FFN	  would	  similarly	  provide	   information	   on	   VMAT2	   function,	   vesicle	   fusion	   and	   quantal	   release	   of	  neurotransmitter,	   with	   the	   added	   possibly	   of	   observing	   monoamine	   reuptake	  (Figure	   1).	   	   In	   order	   for	   a	   FFN	   to	   act	   as	   a	   true	   tracer	   of	   monoamine	  neurotransmitters	   in	   the	   brain,	   it	   must	   exhibit	   substrate	   behavior	   at	   the	  transporters	   involved	   in	   monoamine	   neurotransmission,	   including	   VMAT	   (as	  discussed	   in	   Chapter	   2)	   and	   at	   least	   one	   of	   the	   MATs,	   specifically	   the	   dopamine	  transporter	   (DAT),	   the	   norepinephrine	   transporter	   (NET),	   or	   the	   serotonin	  transporter	  (SERT).	   	  Because	  MATs	  are	  expressed	  primarily	  by	  neurons	  that	  signal	  with	   their	   cognate	   neurotransmitter,	  we	   hypothesized	   that	  MAT	   activity	   could	   be	  exploited	  to	  selectively	  label	  a	  subset	  of	  monoaminergic	  neurons	  in	  the	  brain.(2)	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Figure	  1:	  	  A.)	  	  Representation	  of	  a	  dopaminergic	  synapse	  in	  the	  dorsal	  striatum.	  	  B)	  Representation	  of	  a	  dual	  MAT/VMAT2	  substrate	  FFN	  in	  a	  dopaminergic	  presynaptic	  release	   site.	   	   While	   FFNs	   were	   designed	   specifically	   as	   VMAT	   substrates,	   a	   large	  number	   were	   identified	   and	   it	   was	   hoped	   that	   the	   structural	   similarity	   to	  monoamine	  neurotransmitters	  would	  also	   lead	  to	  substrate	  activity	  of	  FFNs	  at	   the	  more	   discriminating	   MATs	   (gray	   ovals).	   	   Screening	   was	   undertaken	   to	   identify	  potential	  MAT	  substrate	  activity	  of	  several	  fluorescent	  probes.	  	  	  	  	  
Brief	  Introduction	  to	  Monoamine	  Transporter	  Expression,	  Pharmacology,	  and	  
Contributions	  to	  Pathophysiology	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are	   involved	   in	   the	  mechanism	   of	   numerous	   diseases,	   and	   are	   attractive	   imaging	  targets	   in	   the	  brain.	   	  Each	  transporter	   is	  briefly	   introduced	  below,	  with	  a	   focus	  on	  function,	  expression,	  involvement	  in	  disease,	  and	  pharmacology.	  	  For	  a	  discussion	  of	  the	  life	  cycle	  and	  signaling	  of	  monoamine	  neurotransmitters,	  see	  Chapter	  1.	  	  	  
The	  Dopamine	  Transporter	  (DAT)	  
	   While	   the	   DAT	   was	   understood	   to	   exist	   as	   the	   mechanism	   for	   dopamine	  clearance	   of	   the	   synapse	   for	   quite	   some	   time,(6)	   it	   was	   first	   cloned	   and	   fully	  characterized	  in	  the	  early	  1990s.(7-­‐9)	  DAT	  is	  primarily	  responsible	  for	  translocating	  dopamine	   from	   the	   extracellular	   space	   into	   the	   cytosol,	   thus	   acting	   as	   a	   reuptake	  transporter,	   although	   it	   is	   also	   capable	   of	   carrying	   some	   select	   small	   molecules	  (Figure	  2).	  	  Based	  on	  results	  from	  DAT	  knockout	  studies,	  it	  has	  been	  suggested	  that	  approximately	   75-­‐95%	   of	   the	   dopamine	   in	   synaptic	   vesicles	   of	   dopaminergic	  neurons	  has	  been	   recycled	   through	  DAT.(2,	  10,	  11)	  DAT	   relies	  on	   the	   electrochemical	  potential	  across	  the	  plasma	  membrane	  established	  by	  Na+/K+	  ATPase	  to	  drive	  the	  transport	  of	  monoamines.(2)	  It	  has	  been	  shown	  that	  DAT	  binds	  two	  sodium	  ions	  and	  one	  chloride	  along	  with	  dopamine,	  and	  couples	  the	  inward,	  energetically	  favorable	  transport	  of	  sodium	  ions	  with	  the	  transport	  of	  dopamine	  or	  other	  organic	  substrates	  against	   their	   concentration	   gradient.	   	   DAT	   is	   widely	   expressed	   in	   dopaminergic	  neurons	   of	   the	   substantia	   nigra	   and	   ventral	   tegmental	   area,	  which	   project	   to	   and	  modulate	   signaling	   in	   the	   cortex	   and	   striatum,(12)	  with	   its	   expression	   and	   activity	  tightly	  regulated	  by	  a	  number	  of	  signaling	  mechanisms.(13-­‐15)	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As	  dopamine	  signaling	  plays	  a	  central	  role	  in	  the	  modulation	  of	  behavior,(16)	  DAT	  serves	  as	  a	  target	  for	  a	  myriad	  of	  recreational	  and	  pharmaceutical	  drugs.(4,	  5,	  17,	  
18)	  A	  classic	  example	  is	  cocaine,	  which	  exerts	  its	  psychoactive	  and	  stimulatory	  effects	  by	   inhibiting	   dopamine	   reuptake	   through	   DAT,	   resulting	   in	   an	   increase	   in	   the	  synaptic	  concentration	  of	  DA.	  	  Additionally,	  methylphenidate	  is	  a	  widely	  prescribed	  drug	  for	  the	  treatment	  of	  attention	  deficit	  hyperactivity	  disorder	  (ADHD),	  and	  exerts	  its	   action	   through	   inhibition	   of	   DAT.	   	   Amphetamines	   are	   also	   substrates	   for	   DAT,	  and	   have	   been	   shown	   to	   induce	   reverse	   transport	   of	   cytosolic	   DA	   via	   DAT,	   thus	  increasing	  extracellular/synaptic	  concentrations	  of	  the	  neurotransmitter.(17)	  DAT	  is	  also	  known	  to	  transport	  the	  neurotoxin	  MPP+,	  and	  DAT	  activity	  plays	  a	  key	  role	  in	  the	  mechanism	  of	  neurotoxicity	  of	  this	  compound.(19,	  20)	  	  	  Changes	  in	  expression	  of	  DAT	  are	  characteristic	  of	  a	  number	  of	  neurological	  and	   psychiatric	   conditions.	   Dysregulation	   or	   altered	   function	   by	   an	   increase	   or	  decrease	  in	  expression	  or	  activity	  of	  DAT	  is	  characteristic	  of	  a	  number	  of	  psychiatric	  disorders,	   including	   attention	   deficit	   hyperactivity	   disorder	   (ADHD)	   and	   bipolar	  disorder.(21,	   22)	   	   	   DAT	   is	   lost	   along	   with	   dopamine	   neurons	   as	   a	   consequence	   of	  neurodegenerative	   diseases	   such	   as	   Parkinson’s	   disease	   (PD)	   and	   Huntington’s	  disease	   (HD).	   	  Because	  of	   its	   role	   in	   the	  etiologies	  of	  neurological	  diseases	  and	   its	  potential	  use	  as	  a	  marker	  for	  dopaminergic	  innervation,	  DAT	  is	  actively	  pursued	  as	  an	   imaging	   target,	   and	   a	   number	   of	   PET	   probes	   have	   been	   developed	   for	   this	  purpose.(23)	  While	   DAT	   has	   been	   widely	   studied,	   numerous	   questions	   remain	  unanswered	  about	  its	  role	  in	  disease	  and	  pharmacological	  treatment	  thereof,	  and	  it	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is	   quite	   likely	   that	   a	   DAT-­‐selective,	   fluorescence-­‐based	   imaging	   agent	   could	   be	  useful	  in	  the	  study	  of	  dopaminergic	  neurotransmission	  in	  both	  healthy	  and	  diseased	  tissue.	  
	  
The	  Norepinephrine	  Transporter	  (NET)	  
	   NET	   is	   expressed	   in	   noradrenergic	   neurons	   originating	   in	   the	   locus	  coeruleus,	  which	  project	   to	   and	  modulate	   signaling	   in	  many	   regions	   including	   the	  hippocampus	  and	  cortex.(12,	  24)	  	  NET	  was	  cloned	  and	  fully	  characterized	  in	  the	  early	  1990s.(25)	   Like	  DAT,	  NET	   relies	  on	   the	  electrochemical	   gradient	   across	   the	  plasma	  membrane	   to	   transport	  monoamine	  substrates,	  although	  only	  one	  Na+	  and	  one	  Cl-­‐	  ion	  are	  co-­‐transported	  along	  with	  the	  organic	  substrates.	  	  	  Currently,	   only	   one	   polymorphism	   of	   NET	   is	   known	   to	   cause	   disease,	  ALA457PRO	   in	   the	   transmembrane	   region	   TM9,	   which	   manifests	   in	   orthostatic	  intolerance	  and	  tachycardia.(26,	  27)	  	  Epigenetic	  attenuation	  of	  NET	  expression	  through	  hypermethylation	   of	   the	   promoter	   region	   has	   been	   linked	   to	   panic	   disorder.(28)	  While	   it	   has	   been	   hypothesized	   that	   dysregulation	   of	   NET	   is	   responsible	   for	   a	  number	  of	  psychiatric	  illnesses,	  a	  causal	  link	  has	  not	  been	  rigorously	  established,(27)	  though	  NET	  remains	  a	  drug	  target	  owing	  to	  the	  importance	  of	  norepinephrine	  (NE)	  in	   mood	   and	   homeostasis.(27)	   Development	   of	   a	   noradrenergic	   FFN	   could	   lead	   to	  methods	  facilitating	  observation	  of	  individual	  adrenergic	  inputs	  in	  real	  time	  as	  they	  modulate	   cortical	   or	   other	   neurons.	   	   Such	   a	   method	   would	   allow	   for	   a	   greater	  understanding	  of	  endogenous	  NE	  signaling	   in	  healthy	  brains	  as	  well	  as	   the	  role	  of	  NE	  in	  disease.	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The	  Serotonin	  Transporter	  (SERT)	  	   SERT	   is	   analogously	   important	   in	   the	   regulation	   of	   extracellular	  concentrations	  of	  serotonin	  (5HT).	  As	  with	  DAT	  and	  NET,	  SERT	  function	  also	  relies	  on	   the	   electrochemical	   potential	   of	   the	   plasma	   membrane,	   and	   like	   NET,	   co-­‐transports	   one	   Na+	   and	   one	   Cl-­‐	   ion	   along	   with	   the	   organic	   substrates.	   Numerous	  polymorphisms	   in	   SERT	   have	   been	   characterized,	   and	   many	   are	   linked	   to	  neuropsychiatric	   conditions,	   including	   obsessive	   compulsive	   disorder	   and	   severe	  depression.(29)	  	  The	  serotonin	  hypothesis	  of	  depression	  has	  led	  to	  development	  of	  serotonin	  reuptake	  inhibitors,	  and	  later,	  selective	  serotonin	  reuptake	  inhibitors	  (SSRIs).	  	  SSRIs	  are	   efficacious	   treatments	   for	   many	   depressed	   patients,	   although	   there	   are	   still	  variables	   in	   phenotype	  which	   give	   rise	   to	   treatment-­‐resistant	   depression	   in	   some	  individuals	   (see	   Chapter	   5	   for	   a	   discussion	   of	   a	   possible	   compensatory	   5HT	  transport	   mechanism	   in	   some	   individuals).	   	   As	   with	   DAT	   and	   NET,	   exogenous	  substrates	   can	   induce	   reverse	   transport	   through	   SERT.(5)	   	   For	   example,	   MDMA	  exerts	  its	  empathogenic	  effects	  by	  acting	  as	  a	  substrate	  for	  SERT	  and	  releasing	  5HT	  into	  the	  synapse	  from	  cytosolic	  stores.(30)	  Because	  of	  its	  role	  in	  depression	  and	  mood	  disorders,	   and	   the	   still	   poorly	   understood	   relationship	   between	   SERT	   expression,	  function,	   and	   resultant	   disease	   states,(31,	   32)	   development	   of	   an	   imaging	   agent	   to	  study	   serotonergic	   signaling	   on	   the	   synaptic	   level	   could	   reveal	   much	   about	   the	  pathophysiology	  of	  various	  mood	  disorders.	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Figure	  2:	  	  Some	  representative	  MAT	  substrates.(5,	  33-­‐37)	  	  A)	  Endogenous	  monoamines	  and	  some	  related	  metabolites	  are	  known	  to	  be	  transported	  by	  MATs.	  	  B.)	  A	  selection	  of	  exogenous	  DAT,	  NET,	  and	  SERT	  substrates.	  	  Most	  are	  small	  aromatic	  ethylamines,	  with	   a	   few	  notable	   exceptions.	   	   PAL-­‐287	   inspired	  us	   to	   pursue	   larger,	   fluorescent	  substrates	  as	  FFNs.	  C)	  Some	  fluorescent	  substrates	  of	  MATs.	  	  None	  have	  been	  shown	  to	   be	   appropriate	   FFNs,	   although	   the	   recently	   reported	   compounds	  Wilson	   5	   and	  Wilson	  6	  may	  serve	  as	  future	  leads	  if	  shown	  to	  function	  as	  VMAT2	  substrates.	  	  
Our	  Approach	  to	  the	  Design	  of	  Fluorescent	  Dual	  MAT/VMAT	  Substrates	  	   While	   the	   substrate	   scopes	   of	   the	   MATs	   are	   slightly	   broader	   than	   their	  namesake	   neurotransmitters,(5,	   33-­‐37)	   it	   is	   understood	   that	   they	   are	   more	  discriminating	  than	  the	  intracellular	  vesicular	  monoamine	  transporter	  (VMAT2)	  as	  a	  mechanism	  of	  protection	  from	  toxins	  (see	  Chapter	  2	  for	  discussion).	  (38)	  	  Substrate	  scopes	   of	   the	   three	  MATs	   overlap	   considerably,	   although	   there	   are	   some	   notable	  
A. Endogenous Substrates:
B. Representative Exogenous Substrates:
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divergences	   which	   lead	   us	   to	   consider	   the	   possibility	   of	   achieving	   FFN	   labeling	  selectivity	   not	   just	   for	   monoaminergic	   neurons	   over	   surrounding	   tissue,	   but	   for	  additional	  selectivity	  between	  classes	  of	  monoaminergic	  neurons.	  	  In	   order	   for	   a	   substrate	   to	   be	   sufficiently	   fluorescent	   for	   imaging	  applications,	   the	   fluorophore	   must	   intrinsically	   be	   larger	   than	   a	   simple	  catecholamine	   or	   tryptamine,	   posing	   a	   challenge	   for	   molecular	   design.	   	   Several	  fluorescent	   substrates	   of	   MATs	   have	   been	   reported	   and	   studied,	   although	   none	  function	   as	   FFNs	   due	   to	   inadequate	   photophysical	   and	   biological	   properties	  (discussion	  and	  example	  study	  in	  Chapter	  4).	  	  The	  fluorescent	  pyridinium	  analog	  of	  MPP+,	   4-­‐(4-­‐dimethylaminostyryl)-­‐N-­‐methylpyridinium	   (ASP+),	   has	   been	   shown	   to	  act	  as	  a	  substrate	  of	  plasma	  membrane	  monoamine	  neurotransmitter	  transporters,	  demonstrating	   that	   activity	   of	   these	   transporters	   can	   be	   monitored	   using	  fluorescent	  substrates.(33)	  ASP+	  has	  been	  widely	  used	  to	  study	  MAT	  expression	  and	  pharmacology	  in	  a	  number	  of	  contexts,(39-­‐41)	  although	  this	  probe	  has	  slow	  transport	  kinetics	   at	   all	  MATs(39)	  with	   especially	   poor	   uptake	   at	   SERT.(33,	  42)	  APP+,	   a	   smaller	  pyridinium	   analog	   was	   recently	   introduced	   to	   overcome	   this,	   and	   we	  simultaneously	   became	   interested	   in	   studying	   this	   compound	   as	   a	   potential	   FFN	  (Chapter	  4).(43)	  	  Other	  larger	  pyridinium	  analogs	  have	  been	  used	  to	  study	  transport	  and	  binding	   in	  MATs,(44)	  although	  due	   to	  poor	  substrate	  kinetics,	  high	  background	  uptake	   in	   cells	   through	   passive	   diffusion,	   and	   mitochondrial	   localization	   of	   the	  compounds,	  only	  APP+	  was	  pursued	  as	  a	  FFN	  lead	  (Chapter	  4).	  	  	  Recent	  reports	  identified	  a	  naphthalene-­‐based	  amphetamine	  analog	  PAL-­‐287	  as	   a	   DAT	   and	   SERT	   substrate.(35,	   36)	   This	   served	   as	   a	   proof	   of	   principle	   that	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monoamine	   transporters	   could	   indeed	   accept	   larger,	   polycyclic	   aromatic,	   non-­‐pyridinium	  substrates.	  Additionally,	  two	  fluorescent	  ethylamines	  have	  recently	  been	  identified	   to	   have	   likely	   MAT	   activity	   (Figure	   2),	   although	   no	   VMAT	   activity	   has	  been	  examined.(37)	  	  Within	  our	  research	  group,	  it	  was	  discovered	  by	  Dr.	  Pamela	  Rodriguez	  of	  the	  Sames	  and	  Sulzer	  labs	  that	  FFN102	  is	  a	  DAT	  substrate	  in	  acute	  mouse	  brain	  slice.(45)	  FFN102	  has	  been	  fully	  characterized	  as	  a	  dopaminergic	  FFN,	  deriving	  its	  selectivity	  from	  DAT	  substrate	  activity.	   	  FFN102	   is	  also	  a	  VMAT2	  substrate	  and	  a	  ratiometric	  pH	   sensor,(46)	   undergoing	   an	   increase	   in	   brightness	   upon	   exocytotic	   release.	  	  Importantly,	   FFN102	   served	   as	   a	   proof	   of	   principle	   that	   fluorescent	   probes	   could	  serve	   as	   dual	   substrates	   for	   a	   monoamine	   transporter	   and	   VMAT2,	   affording	  selective	   labeling	  of	  monoaminergic	  neurons	  compared	  to	  surrounding	  cells	   in	  the	  tissue	  while	  allowing	  the	  probe	  to	  act	  as	  a	  tracer	  of	  monoamine	  uptake	  and	  release.	  	  As	   discussed	   in	   Chapter	   1,	   our	   approach	   has	   largely	   been	   to	   incorporate	   a	  minimal	   recognition	   element	   into	   our	  molecular	   design	   by	   adding	   an	   aminoethyl	  group	   to	   small	   fluorophores.	   	   The	   vast	  majority	   of	   compounds	   screened	   here	   are	  novel	  compounds	  synthesized	  within	  the	  Sames	  Lab	  as	  potential	  VMAT	  substrates,	  and	   later	   as	   potential	   dual	   substrates	   (unpublished	   results).(46)	   Promising	  compounds	   identified	   from	   initial	   screening	   in	   heterologous	   cell-­‐based	   systems	  (expressing	  hDAT,	  hNET,	  or	  hSERT)	  are	  thoroughly	  characterized	  in	  mouse	  coronal	  brain	  slice	  by	  members	  of	  the	  Sames	  and	  Sulzer	  groups.	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II:	  	  Results	  and	  Discussion	  
	  
Screening	  of	  Probes	  at	  hDAT,	  hNET,	  and	  hSERT	  
	   A	   structurally	   diverse	   library	   of	   fluorescent	   probes	   was	   screened	   for	  substrate	  activity	  at	  DAT,	  NET,	  and	  SERT	  using	  epifluorescence	  microscopy.	   	  Many	  of	   the	   screened	   compounds	  were	   chosen	   based	   on	   their	   known	  VMAT2	   substrate	  activity	   (unpublished	   results),(46,	   47)	   as	   this	   parameter	   is	   essential	   for	   imaging	  quantal	   release	   of	   neurotransmitter	   in	   the	   brain.(1,	   45)	   Other	   compounds	   were	  included	  based	  on	  suspected	  structural	   similarity	   to	  known	  substrates	   in	  order	   to	  examine	  the	  limits	  of	  substrate	  tolerance.	  	  	  For	   DAT	   experiments,	   hDAT-­‐EM4	   and	   empty	   vector-­‐transfected	   EM4	   cells	  were	  provided	  by	  Dr.	  Mark	  Sonders	  and	  Professor	  Jonathan	  Javitch	  of	  the	  New	  York	  State	  Psychiatric	  Institute.	  	  For	  hSERT	  experiments,	  EGFP-­‐hSERT	  Flp-­‐in	  MDCK	  cells	  and	   control	   Flp-­‐in	   MDCK	   cells	   were	   also	   provided	   by	   Dr.	   Sonders	   and	   Professor	  Javitch.	   	  Additionally,	  hSERT-­‐HEK	  and	  hNET-­‐HEK	  cells	  were	  provided	  by	  Professor	  Brian	  Roth	  of	  The	  University	  of	  North	  Carolina,	  Chapel	  Hill.	  	  	  In	  each	  experiment,	  the	  known	   MAT	   substrate	   ASP+,	   or	   later,	   APP+,	   was	   used	   as	   a	   control	   to	   validate	  transporter	  expression	  and	  activity	  (Figure	  3).	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Figure	   3:	   	   A	   pyridinium-­‐based	  MAT	   substrate	  was	   used	   as	   a	   positive	   control	   for	  transporter	   activity	   and	   for	   inhibitor	   efficacy	   in	   each	   independent	   experiment	  during	  this	  screen.	  	  Shown	  here	  is	  a	  representative	  image	  of	  APP+	  (2	  µM)	  uptake	  in	  10	   minutes	   by	   A)	   hNET,	   showing	   a	   high	   degree	   of	   transporter-­‐specific	   labeling	  compared	   to	   B)	   uptake	   in	   control	   HEK293T	   cells,	   C)	   uptake	   in	   the	   presence	   of	  nomifensine	  (2	  µM,	  NET/DAT	   inhibitor).	   	  D)	  Nomifensine	  (2	  µM)	  had	  no	  effect	  on	  the	  uptake	  of	  APP+	  by	  control	  HEK293T	  cells.	   	  While	  APP+	  is	  a	  substrate	   for	  DAT,	  NET,	   and	   SERT,	   it	   is	   not	   appropriate	   for	   use	   as	   a	   FFN	   in	   our	   systems	   (detailed	   in	  Chapter	  4).	   	   Images	  are	  representative	  of	  control	  results	  acquired	  for	  validation	  of	  hDAT,	  hNET,	  and	  hSERT	  expression	  and	  function	  in	  screening	  experiments.	  	   Each	  experimental	  compound	  was	  screened	  initially	  at	  20	  µM	  concentration	  in	   transporter-­‐transfected	  cells	  and	  directly	   compared	   to	   transporter-­‐independent	  uptake	   in	   control	   cells.	   If	   substrate	   activity	  was	   suspected	  based	  on	   these	   results,	  further	   evaluation	  was	   conducted	   including	   inhibition	   by	   nomifensine	   (2	  µM)	   for	  DAT	  and	  NET,	  or	  imipramine	  (2	  µM)	  for	  SERT.	  	  Each	  probe	  identified	  as	  a	  substrate	  here	  was	   found	   to	   accumulate	   in	   a	   transporter-­‐dependent	   and	   inhibitor-­‐sensitive	  manner	   in	   at	   least	   three	   independent	   experiments.	   	   This	   screen	   was	   divided	  between	   myself	   and	   Dr.	   Adam	   Henke,	   and	   the	   results	   are	   shown	   in	  Table	   1	   (7-­‐hydroxycoumrins)	  and	  Table	  2	  (7-­‐aminocoumarins	  and	  other	  structures).	   	  Results	  from	   inhibition	   experiments	   conducted	  with	   identified	   hits	   are	   detailed	   below	   as	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confirmation	   of	   substrate	   activity	   of	   the	   indicated	   probes.	   	   Each	   uptake	   and	  inhibition	  result	  was	  confirmed	  in	  at	  least	  three	  independent	  experiments.	  	  
Table	  1:	  	  7-­‐Hydroxycoumarins	  Screened	  for	  Substrate	  Activity	  at	  MATs	  
Name Structure hDAT hSERT hNET Name Structure hDAT hSERT hNET 
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X X X 
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X X X AGH113‡ 
 
X X X 
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X X X AGH105 
 
X X X 
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X X X 
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X X X AGH038 
 
X X X 
Mini110‡ 
 
X X X AGH144 
 
X X X 
Mini201‡ 
 
X X *** AGH039 
 
X X X 
Mini202‡ 
 
X X * AGH106 
 
X X X 
AGH093‡ 
 
X X ** AGH128 
 
X X X 
‡ = Compounds have been previously identified as VMAT2 substrates by our lab.   
* = Minimal but discernable transporter-dependent labeling; possibly a weak substrate.   
** = Transporter-dependent labeling, clear inhibitor-sensitive uptake.   
*** = Strong substrate, inhibited cleanly, Km determined (see below).   
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Table2:	  	  7-­‐Aminocoumarins	  and	  Other	  Probes	  Screened	  for	  Substrate	  Activity	  
at	  MATs	  
Name Structure hDAT hSERT hNET Name Structure hDAT hSERT hNET 
FFN200‡ 
 
X X * G257 
 
X X  
FFN206‡ 
 
X X X G180‡ 
 
X X  
AGH180‡ 
 
X X * VB404 
 
X X X 
VB505‡ 
 
X X X JAM127‡ 
 
X X X 
NG38‡ 
 
X X X JAM138‡ 
 
X X  
PV139‡ 
 
X X X JAM157 
 
X X  
NG54‡ 
 
*** *** *** 
‡ = Compounds have been previously identified as VMAT2 substrates by our lab.   
* = Minimal but discernable transporter-dependent labeling; possibly a weak substrate.  
*** = Strong substrate, inhibited cleanly, Km determined (see below).  	  
X = no transporter-dependent accumulation 	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HEK293T	   cells	   with	   20	   µM	   AGH093	   indicated	   transporter	   dependent	   uptake,	   as	  evidenced	  by	  bright	  labeling	  of	  hNET-­‐HEK	  cells	  (Figure	  4A),	  and	  a	  relatively	  lower	  label	  in	  control	  cells	  (Figure	  4B).	  	  Pretreatment	  of	  each	  cell	  type	  with	  nomifensine	  (2	  µM)	   followed	   by	   co-­‐treatment	  with	   AGH093	   (20	  µM)	   and	   nomifensine	   (2	  µM)	  indicates	  that	  this	  label	  is	  sensitive	  to	  NET	  inhibition,	  with	  no	  effect	  of	  the	  inhibitor	  on	  control	   cells	   (Figure	   4C,D).	   	  Further,	   the	  morphology	  of	   the	   label	   is	   consistent	  with	   a	   general,	   cytosolic	   label	   rather	   than	   a	  membrane	   label,	  where	   the	   junctions	  between	  cells	  would	  be	  bright.	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Figure	  5:	   	  FFN201	  is	  also	  a	  substrate	  for	  hNET.	  	  A)	  hNET	  accumulates	  FFN201	  (20	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   This	   is	  not	   surprising	   considering	   the	   relatively	   similar	   steric	  properties	  of	  AGH093	  and	  FFN201,	  as	  an	  sp2	  hybridized	  C-­‐F	  bond	  is	  only	  marginally	  longer	  than	  that	  of	  an	  sp2	  hybridized	  C-­‐H	  bond.	  	  What	  is	  most	  surprising	  is	  the	  observation	  that	  FFN201	  is	  consistently	  brighter	  in	  hNET-­‐HEK	  cells	  (Figure	  6),	  despite	  the	  fact	  that	  it	  is	  a	  dimmer	  probe	  at	  cytosolic	  pH.(46)	  	  It	  should	  also	  be	  noted	  that	  the	  structurally-­‐related	   compounds	   FFN101	   and	   FFN102	   are	   not	   substrates,	   revealing	   the	   limited	  tolerance	  of	  hNET	   for	   the	   location	  of	   the	  ethylamine	  with	  respect	   to	   the	  coumarin	  ring.	  
	  
Figure	   6:	   Direct	   comparison	   of	   select	   7-­‐hydroxycoumarins	   of	   similar	   structure	  reveals	   substrate	  preferences	  of	   hNET.	   	  All	   images	   are	   from	   the	   same	  experiment	  (20	   µM	   probe,	   60	   min	   treatment)	   and	   adjusted	   to	   the	   same	   levels	   of	   brightness	  (ImageJ,	   NIH)	   to	   highlight	   similar	   labeling	   of	   hNET-­‐HEK	   and	  HEK293	   by	   FFN202,	  thus	  highlighting	   increasing	  brightness	  relative	  to	  background	  uptake	  as	  the	  steric	  bulk	  at	  position	  6	  is	  reduced	  (Cl	  <	  F	  <	  H)	  and	  no	  uptake	  by	  4-­‐aminoethyl	  coumarins.	  	  	  Amphetamine	   (AMPH)	   is	   known	   to	   induce	   reverse	   transport	   of	   MATs,	   including	  NET.	   To	   further	   confirm	   substrate	   activity	   of	   these	   probes,	   hNET-­‐HEK	   cells	   pre-­‐loaded	  with	  FFN201	  (20	  µM,	  1	  hour),	  followed	  by	  treatment	  with	  amphetamine	  (1	  
µM,	  10	  min)	  or	  MeOH	  vehicle	  (0.03%	  v/v)	  in	  experimental	  medium.	  	  Images	  taken	  immediately	  after	  wells	  were	  washed	  show	  attenuation	  of	  probe	  signal	   relative	   to	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images	   recorded	   immediately	   after	  uptake	   is	   terminated,	  with	  a	   greater	  degree	  of	  destaining	   in	   cells	   treated	   with	   1	   µM	   AMPH	   (Figure	   7).	   	   The	   decrease	   in	   signal	  common	  to	  both	  conditions	  can	  be	  ascribed	  to	  washout	  via	  passive	  diffusion	  across	  the	  plasma	  membrane	  over	  the	  ten-­‐minute	  wash	  period	  or	  through	  leaking	  via	  basal	  reverse	  transport	  through	  NET.	  	  The	  greater	  amount	  of	  destaining	  in	  the	  presence	  of	  AMPH	   is	   likely	   caused	   by	   AMPH-­‐induced	   reverse	   transport	   through	   NET,	   further	  suggesting	  substrate	  activity	  of	  FFN201.	  
	  	  
Figure	  7:	  	  FFN201	  labeling	  of	  hNET-­‐HEK	  cells	  (20	  µM,	  30	  min)	  can	  be	  considerably	  reduced	  by	  treatment	  with	  A)	  amphetamine	  (AMPH,	  1	  µM,	  10	  minutes)	  compared	  to	  B)	  vehicle	  control	  (MeOH	  0.03%).	  	  This	  result	  is	  preliminary	  and	  should	  be	  repeated	  in	   order	   to	   be	   conclusive,	   but	   it	   is	   suggestive	   of	   reverse	   transport	   of	   a	   cytosolic	  population	   of	   probe.	   	   This	  would	   imply	   true	   substrate	   activity	   rather	   than	   simple	  interaction	   with	   the	   transporter.	   	   Representative	   images	   from	   one	   preliminary	  experiment.	  	  	  
Determination	  of	  Km	  for	  FFN201	  and	  AGH093	  at	  hNET	  
	  
	   In	  order	  to	  provide	  a	  quantitative	  measure	  of	  the	  interactions	  of	  FFN201	  and	  AGH093	  with	  hNET,	  cellular	  uptake	  kinetics	  were	  measured	  fluorometrically.	  Initial	  rates	   of	   NET-­‐dependent	   uptake	   of	   FFN201	   and	   AGH093	   were	   observed	   and	  compared	  using	  hNET-­‐HEK	  cells	  grown	  on	  96-­‐well	  plates.	  	  It	  was	  found	  that	  specific	  uptake	  of	  each	  probe	  was	  linear	  within	  12	  minutes.	   	  Initial	  rates	  of	  specific	  uptake	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were	  determined	  by	  measuring	  the	  total	  fluorescence	  of	  different	  concentrations	  of	  both	   AGH093	   and	   FFN201	   after	   12	   minutes	   of	   treatment	   in	   8	   uninhibited	   wells	  (treated	   with	   a	   DMSO	   vehicle	   control,	   0.02%	   v/v),	   and	   by	   subtracting	   the	  background	   fluorescence	   of	   the	   same	   concentration	   of	   probe	   in	   the	   presence	   of	  nomifensine	  (2	  µM,	  8	   inhibited	  wells).	   	  Fitting	  the	  resulting	  plots	   to	   the	  Michaelis-­‐Menten	   equation	   afforded	   an	   interesting	   result.	   	   The	   Km	   of	   FFN201	   at	   hNET	  was	  determined	  to	  be	  5.0	  ±	  0.3	  µM	  (mean	  ±	  SEM,	  3	  independent	  experiments,	  two	  plates	  per	  experiment).	   	  AGH093	  was	   found	  to	  have	  a	  considerably	   lower	  affinity	   for	   the	  transporter,	   as	   I	   was	   unable	   to	   saturate	   the	   transporter	   with	   a	   reasonable	  concentration	  of	  the	  compound	  (Km	  >	  60	  µM	  in	  each	  of	  2	  independent	  experiments,	  
Figure	   8).	   	   Additionally,	   FFN201	   consistently	   displayed	   a	   higher	   specific	   uptake	  compared	  to	  AGH093,	  consistent	  with	  the	  images	  in	  Figure	  6.	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contribute	   to	   the	   lower	   apparent	   affinity	   for	   the	   transporter.	   	   Second,	   if	   the	  substrate	   is	   in	   fact	   the	  protonated	  phenol	   rather	   than	   the	  phenolate,	   the	   effective	  concentration	  will	  be	  lower	  than	  that	  of	  FFN201	  in	  uptake	  medium	  (pH	  =	  7.4).	  	  This	  is	   because	   the	   pKa	   of	   AGH093	   is	   significantly	   lower	   than	   the	   pKa	   of	   FFN201	   (pKa	  AGH093	  =	  6.2,	  pKa	  FFN201	  =	  8.1,	  Dr.	  Adam	  Henke	  and	  Dr.	  Minhee	  Lee,	  respectively).	  	  Preliminary	  experiments	  suggest	  that	  there	  is	  a	  pH-­‐dependent	  difference	  in	  uptake	  behavior	   of	   these	   two	   compounds	   (data	   not	   shown),	   although	  more	   experimental	  evidence	  would	  be	  needed	  to	  test	  this	  hypothesis.	  	  	  
Preliminary	  Results	  from	  the	  Mouse	  Cortex	  	   Matt	  Dunn	  has	  conducted	  preliminary	   two-­‐photon	  microscopy	  experiments	  using	   the	   identified	   hNET	   substrates	   in	   the	   barrel	   cortex	   of	   acute	   mouse	   brain	  tissue.	  	  The	  barrel	  cortex	  is	  innervated	  by	  noradrenergic	  projections	  from	  the	  locus	  coeruleus	  (LC),(48)	  and	  may	  serve	  as	  a	  useful	  experimental	  system	  for	  characterizing	  the	  behavior	  of	  NET-­‐FFNs.	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Figure	  9:	   	   Images	  of	  FFN202,	  AGH093,	  and	  FFN202	  (10	  µM,	  30	  min)	   in	  the	  barrel	  cortex	   of	   a	  mouse	   coronal	   brain	   slice.	   	   All	   images	   are	   z-­‐projections	   of	   10	   images	  taken	  using	  a	  two-­‐photon	  microscope.	  	  A)	  FFN202	  appears	  to	  sparsely	  label	  axonal	  structures	  (red	  arrows).	  The	  large,	  bright	  structures	  are	  blood	  vessels	  (blue	  arrow).	  	  B)	  AGH093	  brightly	  labels	  axonal	  structures	  to	  a	  greater	  extent	  than	  FFN202	  in	  the	  same	  area	  of	  the	  brain.	  C)	  FFN201	  labels	  structures	  with	  intermediate	  density	  and	  lower	   brightness	   than	   AGH093.	   	   D)	   The	   AGH093	   label	   can	   be	   inhibited	   by	  nomifensine	  (1	  µM).	  	  	  Representative	  images	  are	  courtesy	  of	  Matt	  Dunn.	  	  	  When	  an	  acute	  mouse	  brain	  slice	  comprising	  the	  barrel	  cortex	  is	  treated	  with	  hNET	   substrate	   FFNs	   (10	   µM	   perfusion,	   30	   min),	   some	   interesting	   results	   arise.	  	  Each	  FFN	  appears	  to	  label	  axonal	  structures	  to	  different	  degrees,	  depending	  on	  the	  probe	   (Figure	   9).	   	   It	   should	   be	   noted	   that	   the	   label	   of	   FFN202	   (Figure	   9A)	  may	  result	   from	  dopaminergic	   projections	   to	   the	   cortex,	   as	   FFN202	   is	   a	   known	  mDAT	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substrate	   (unpublished	   results,	  Matt	   Dunn).	   	   AGH093	   and	   FFN201	   labeled	   axonal	  structures	   more	   densely,	   and	   these	   structures	   are	   thought	   to	   represent	  noradrenergic	   innervation.	   	   While	   the	   morphology	   of	   labeled	   structures	   is	  consistent	   with	   noradrenergic	   axons	   and	   presynaptic	   elements,	   we	   are	   in	   the	  process	   of	   developing	   a	   positive	   control	   for	   noradrenergic	   innervations	   in	   this	  region	   of	   the	   brain,	   as	   the	   TH-­‐GFP	   signal	   is	   too	   weak	   to	   visualize	   even	   with	  multiphoton	   fluorescence	  microscopy.	   	   These	   preliminary	   results	   support	   further	  study	   of	   FFN201	   and	   AGH093	   in	   the	   brain,	   and	   suggest	   that	   they	  may	   represent	  noradrenergic	   FFNs.	   	   Collaboration	   is	   currently	   emerging	  with	   Prof.	   Randy	  Bruno	  (CUMC)	  to	  develop	  an	   in	  vivo	   imaging	  experiment	  for	  noradrenergic	  modulation	  of	  cortical	  neurons,	  using	  either	  FFN201	  or	  AGH093	  as	  a	  tracer.	  	   One	   interesting	   discrepancy	   to	   note	   is	   that	   FFN201,	   while	   it	   appears	   the	  better	  substrate	  for	  hNET	  in	  transfected	  HEK	  cells,	  it	  is	  considerably	  dimmer	  in	  the	  mouse	   brain.	   	   If	   indeed	   these	   labeled	   structures	   are	   noradrenergic,	   as	   suspected,	  this	  disparity	  could	  have	  a	  few	  causes.	  	  First,	  it	  is	  possible	  that	  there	  is	  a	  species-­‐	  or	  system-­‐dependent	  variation	  in	  transporter	  function	  that	  is	  responsible	  for	  different	  substrate	   tolerances	   (Km,	   Vmax).	   	   Second,	   these	   compounds	   are	   ratiometric	   pH	  sensors	  with	   different	   pKa	   values	   (see	   above).	   	   FFN201	  will	   consequently	   be	   less	  bright	   at	   environments	   of	   lower	   pH,	   including	   synaptic	   vesicles.	   	   In	   fact,	   upon	  release,	  FFN201	  produces	  a	  bright	  “flash”	  despite	   its	  higher	  pKa,	  suggesting	   that	   it	  may	  be	  well	   vesicularized	   (preliminary	   results	   from	  Matt	  Dunn,	   not	   shown).	   	   The	  Sames	   lab	   is	   currently	   pursuing	   comparative	   studies	   of	   hNET	   and	  mNET	   (mouse	  NET)	  in	  HEK	  cells,	  to	  determine	  if	  the	  cause	  of	  such	  disparity	  is	  indeed	  the	  slightly	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different	  sequence	  homology	  of	  the	  transporter	  between	  species,	  or	  if	  it	  is	  caused	  by	  the	  experimental	  system	  itself	  (acute	  brain	  slice	  versus	  cultured	  HEK	  cells).	  	  
Identification	  of	  AGH180	  as	  a	  Possible	  Substrate	  for	  NET	  
	  
	   From	   the	   screen	   (Table	   2)	   it	   was	   also	   found	   that	   two	   of	   the	   7-­‐aminocoumarins,	   FFN200	   and	   AGH180,	   displayed	   a	   small	   transporter-­‐dependent	  increase	   in	   fluorescence	   in	   hNET-­‐HEK	   cells	   compared	   to	   background	   uptake	   in	  control	   HEK293T	   cells.	   Detailed	   inhibition	   results	   seem	   to	   suggest	   that	   there	   is	  indeed	  a	  small	  amount	  of	  nomifensine-­‐sensitive	  uptake	  of	  the	  probes	  (Figure	  10	  for	  a	   representative	   example,	   representative	   of	   3	   independent	   experiments).	   	   This	  amount	  of	  labeling	  is	  minimal,	  however.	  	  It	  will	  be	  important	  to	  consider	  this	  result	  in	   the	   context	   of	   mouse	   brain	   slice	   or	   other	   advanced	   experimental	   systems,	  although	  the	  utility	  of	  these	  compounds	  in	  cell	  culture	  is	  minimal	  at	  best.	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effect	  on	  control	  cells	  in	  the	  presence	  of	  the	  probe.	  	  FFN200	  afforded	  similar	  results.	  Representative	  images	  from	  3	  independent	  experiments.	  	  	  	  	  
NG54:	  A	  Substrate	  for	  hDAT,	  hNET,	  and	  hSERT,	  and	  a	  New	  Lead	  for	  Future	  FFNs	  	   NG54	  was	   an	   early-­‐generation	   FFN	   lead	   originally	   synthesized	   and	   studied	  by	  Dr.	  Niko	  Gubernator	   of	   the	   Sames	   laboratory.	   	  NG54	  was	   set	   aside	   after	   initial	  studies	  in	  acute	  mouse	  brain	  slice	  by	  Dr.	  Niko	  Gubernator	  revealed	  a	  high	  degree	  of	  photobleaching	   under	   the	   imaging	   conditions	   used	   at	   the	   time.	   	   However,	   it	   was	  noted	  that	  NG54	  displayed	  a	  highly	  punctate	  label	  in	  the	  dorsal	  striatum	  suggestive	  of	   dopaminergic	   morphology.	   Additionally,	   uptake	   studies	   in	   VMAT1-­‐expressing	  primary	  mouse	  adrenal	  chromaffin	  cells	  showed	  little	  difference	  in	  uptake	  between	  reserpine-­‐inhibited	   and	   uninhibited	   conditions.(49)As	   part	   of	   our	   screening	   in	  hDAT/hNET/hSERT	   cells,	   we	   included	   this	   compound	   because	   of	   the	   highly	  punctate	  label	  in	  the	  dorsal	  striatum	  that	  had	  been	  observed	  years	  prior.	  NG54	  was	  first	  identified	  as	  a	  substrate	  for	  hNET.	  	  Inhibition	  studies	  similar	  to	  those	  conducted	  above	  confirmed	  this	  result	  (Figure	  11).	  	  This	  positive	  result	  was	  surprising	  but	  not	  inconceivable,	   as	   the	   extended	   aromatic	   system	   is	   reminiscent	   of	   the	   DAT/SERT	  substrate	  PAL-­‐287,(35)	  	  	  as	  well	  as	  the	  likely	  MAT	  substrates	  Wilson	  5	  and	  Wilson	  6	  (Figure	  2).(37)	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Figure	  11:	   	  NG54	  is	  a	  fluorescent	  substrate	  for	  hNET.	  	  A)	  hNET	  accumulates	  NG54	  (2.5	   µM,	   60	   min)	   in	   transfected	   HEK	   cells.	   B)	   Nonspecific	   uptake	   accounts	   for	   a	  considerably	   lower	   amount	   of	   NG54	   staining	   in	   control	   HEK293T	   cells.	   C)	  Nomifensine	  (2µM)	  abolishes	  NG54	  uptake	  in	  hNET-­‐HEK	  cells,	  and	  D.)	  nomifensine	  (2µM)	  has	  no	  effect	  on	   control	   cells	   in	   the	  presence	  of	   the	  probe.	   	  Representative	  images	  from	  3	  independent	  experiments.	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NG54	  has	   also	   been	  demonstrated	   to	   be	   a	   substrate	   for	   hDAT	   (Figure	   12)	  and	  hSERT	  (Figure	  13).	  	  In	  each	  case,	  the	  compound	  labeled	  cells	  in	  a	  transporter-­‐dependent	  and	  inhibitor-­‐sensitive	  manner.	  	  Dr.	  Adam	  Henke	  has	  measured	  the	  Km	  of	  NG54	  uptake	  at	  each	  transporter,	  and	   it	  was	  found	  to	  have	  reasonable	  Kms	  for	  the	  MATs	  (Km	  hDAT	  =	  6.3	  ±	  0.7,	  Km	  hNET	  =	  7.9	  ±	  3.6,	  and	  Km	  hSERT	  =	  3.84	  ±	  1.0;	  mean	  ±	  SEM	  from	  3	  independent	  experiments).	  	  I	  have	  also	  found	  NG54	  to	  be	  a	  fluorescent	  substrate	  for	  VMAT2	  (Chapter	  2).	  	  Thus,	  NG54	  will	  serve	  as	  a	  foundational	  lead	  for	  further	  structure-­‐activity	  relationships	  designed	  to	  examine	  the	   limits	  of	  substrate	  tolerance	  at	   each	   transporter.	   	   Preliminary	   results	   from	  a	   small	   library	  of	   analogs	  suggest	  that	  functionalization	  of	  the	  acridone	  core	  can	  lead	  to	  differential	  activities	  at	  the	  various	  MATs	  while	  retaining	  VMAT2	  activity	  (data	  not	  shown).	   	  Along	  with	  yielding	   information	   regarding	   the	   substrate	   tolerances	   of	   each	   transporter,	   this	  study	  may	  furnish	  FFN	  probes	  selective	  for	  each	  of	  the	  MATs.	  	  
	  	  
Figure	   13:	   	   NG54	   is	   a	   fluorescent	   substrate	   for	   hSERT.	   	   A)	   A	   fluorescent	   SERT	  construct	   (EGFP-­‐hSERT)	   accumulates	   NG54	   (30	   µM,	   60	   minutes)	   in	   transfected	  EGFP-­‐hSERT	   MDCK	   cells.	   B)	   Imipramine	   (2	   µM,	   SERT	   inhibitor)	   abolishes	   NG54	  uptake	  in	  EGPF-­‐hSERT	  MDCK	  cells.	  	  In	  these	  images,	  the	  pseudocolor	  green	  coronal	  signal	  corresponds	  to	  EGFP-­‐hSERT,	  where	  the	  vast	  majority	  of	   the	  signal	   is	  on	  the	  membrane.	   	  The	  pseudocolor	  purple	  corresponds	  to	  NG54.	   	  Representative	  images	  from	  3	  independent	  experiments.	  	  Also	  confirmed	  twice	  in	  hSERT-­‐HEK	  by	  Dr.	  Adam	  Henke	  (not	  shown).	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NG54	  is	  a	  Fluorescent	  False	  Neurotransmitter	  in	  the	  Mouse	  Brain	  	   NG54	  is	  currently	  being	  characterized	  as	  a	  FFN	  in	  mouse	  coronal	  brain	  slice	  by	  Matt	  Dunn	  and	  Paolomi	  Merchant,	  colleagues	  in	  the	  Sames	  group.	  NG54	  uptake	  has	  been	  studied	  in	  the	  dorsal	  striatum,	  where	  nigrostriatal	  dopaminergic	  neurons	  project	  and	  modulate	  cortical	  and	  other	  inputs.(50)	  Preliminary	  experiments	  show	  a	  very	   strong	   degree	   of	   colocalization	   with	   signal	   from	   TH-­‐GFP	   (where	   GFP	  expression	   driven	   by	   the	   promoter	   for	   tyrosine	   hydroxylase),	   a	   control	   for	  aminergic	   innervation	   (~90%	   colocalization,	   preliminary	   results	   from	   Paolomi	  Merchant,	   Figure	   14	   A-­‐C).	   The	   observed	   high	   level	   of	   anatomical	   coincidence	  between	   NG54	   and	   the	   TH-­‐GFP	   signals	   suggests	   dopaminergic	   labeling	   by	   NG54.	  	  This	   labeling	   is	   also	   sensitive	   to	   nomifensine	   (1	  µM,	  data	  not	   shown,	  Matt	  Dunn).	  	  NG54	  (10	  µM)	  also	  appears	  to	  label	  dopaminergic	  cell	  bodies	  in	  the	  substantia	  nigra	  (Figure	  14	  D,E).	  	  These	  results	  indicate	  that	  NG54	  is	  indeed	  a	  dopaminergic	  label	  in	  areas	  of	  dopaminergic	   innervation,	   supporting	   the	  hypotheses	   that	  NG54	   is	  a	  DAT	  substrate	  and	  that	  positive	  results	  gathered	  from	  cell	  culture-­‐based	  screening	  may	  translate	  into	  functional	  dual	  MAT/VMAT	  substrates	  FFN	  in	  brain	  tissue.	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Figure	  14:	  NG54	  colocalizes	  to	  a	  high	  degree	  ~90%	  with	  a	  marker	  for	  dopaminergic	  neurons	   A)	   NG54	   affords	   a	   punctate	   label	   in	   the	   dorsal	   striatum	   of	   acute	   mouse	  brain	   tissue	   (10	  µM,	  30	  minute	   treatment,	  15	  minute	  wash	  with	  artificial	   cerebral	  spinal	  fluid	  (ACSF)).	  B)	  TH-­‐GFP	  is	  a	  marker	  of	  dopamine	  neurons	  (GFP	  expression	  is	  driven	  by	   the	  promoter	   for	   tyrosine	  hydroxylase).	  C)	  Overlay	  of	  NG54	   signal	  with	  that	  of	  TH-­‐GFP	  reveals	  a	  strong	  colocalization	  (~90%,	  preliminary	  results).	  D)	  In	  the	  substantia	   nigra,	   NG54	   (10	   µM)	   also	   labels	   cell	   bodies.	   	   E)	   Examination	   of	   TH-­‐positive	  dopamine	  neurons	  reveals	   that	  NG54	   labels	  dopaminergic	  cell	  bodies	   in	  a	  manner	   similar	   in	   to	   FFN102,(45)	   a	   confirmed	   dopaminergic	   FFN.	   Representative	  images	  are	  courtesy	  of	  Paolomi	  Merchant	  (A-­‐C),	  and	  Matt	  Dunn	  (D,E).	  	  	  	  It	   is	   known	   that	   high	   concentrations	   of	   potassium	   can	   induce	   neuronal	  depolarization	   and	   subsequent	   exocytotic	   release	   of	   neurotransmitter	   from	  presynaptic	   elements;	   destaining	   by	   KCl	   is	   a	   requisite	   behavior	   of	   FFNs.	   	   Indeed,	  upon	   application	   of	   KCl	   (80	   µM)	   to	   a	   coronal	   mouse	   brain	   slice	   comprising	   the	  dorsal	   striatum	   that	   has	   been	   pre-­‐loaded	   with	   10	   µM	   NG54	   (30	   minute	   NG54	  treatment),	   this	   probe	   is	   released	   similar	   to	   reported	   FFNs	   (Figure	   15).	   Upon	  treatment	   with	   KCl,	   there	   is	   a	   noticeable	   increase	   in	   the	   total	   signal	   background	  signal	  of	   the	   images	   (Figure	   15B)	  as	   the	  punctate	  signal	   is	   lost.	   	  As	  acridones	  are	  known	  to	  experience	  a	  small	  degree	  of	  self-­‐quenching,(51)	   	  NG54	  is	  currently	  being	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investigated	   as	   a	   potential	   “flashing”	   FFN	   that	   derives	   its	   release	   readout	   from	   a	  distinctly	   different	   process	   from	   the	   hydroxycoumarins.(52)	   	   NG54	   may	   be	   a	   new	  “unquenching”	   FFN,	   capable	   of	   signaling	   release	   from	   presynaptic	   stores	   by	  diffusing	   from	   high	   concentration	   in	   the	   synaptic	   vesicles	   where	   the	   compound	  quenches	  its	  fluorescence,	  to	  lower	  concentrations	  in	  the	  extracellular	  space	  where	  the	  compound	  fluoresces	  more	  brightly.	  	  
	  	  
Figure	  15:	  	  NG54	  is	  released	  by	  action	  of	  KCl	  A.)	  NG54	  labels	  punctate	  structures	  in	  the	   dorsal	   striatum	   (10	  µM,	   30	  min).	   B)	   Action	   of	   KCl	   (80	  µM,	   3	  minutes)	   on	   the	  same	  field	  of	  view	  induces	  release	  of	  NG54	  in	  a	  manner	  similar	  to	  other	  confirmed	  FFNs.(45)	  Images	  are	  courtesy	  of	  Matt	  Dunn.	  	  	  
A	  Note	  About	  Disparities	  Between	  Experimental	  Systems	  	  	   It	  is	  important	  to	  note	  that	  while	  cell-­‐based	  experiments	  have	  proven	  useful	  for	   identification	   of	   FFNs	   that	   are	   functional	   in	   the	   brain,	   there	   is	   an	   important	  inconsistency	  in	  our	  data	  in	  the	  case	  of	  DAT.	  	  In	  the	  mouse	  brain	  slice,	  FFN102	  and	  FFN202	   (see	  Table	   1	   for	   structures)	   are	   substrates	   for	  DAT,	   despite	   the	   fact	   that	  neither	   is	   a	   substrate	   in	   cultured	   cells	   heterologously	   overexpressing	   hDAT.	   	   The	  hDAT	   cell	   system	   seems	   to	   work	   for	   other	   probes,	   as	   the	   fluorescent	   pyridinium	  APP+	   and	   NG54	   are	   both	   substrates	   in	   our	   hDAT-­‐EM4	   cells.	   	   There	   are	   a	   few	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possible	   causes	  of	   this	  disparity	   concerning	  FFN102	  and	  202.	   	   First,	   the	   sequence	  homology	  differences	  between	  the	  human	  and	  mouse	  transporters	  may	  give	  rise	  to	  dissimilar	   substrate	   tolerances.	   	   Although	   the	   homology	   between	   species	   is	   quite	  high,	   it	   is	   possible	   that	   minor	   differences	   in	   transporter	   sequence	   can	   have	  noticeable	   effects	   on	   the	   extrema	   of	   the	   transporter’s	   substrate	   tolerance.	   	   Some	  functional	   differences	   in	   DAT	   transport	   between	   species	   have	   previously	   been	  characterized,(53)	  although	  the	  pharmacological	  profile	  of	  inhibitors	  has	  been	  shown	  to	  be	  similar	  between	  hDAT	  and	  mDAT.(54)	  Another	  possible	  explanation	  is	  that	  DAT	  function	  and	  substrate	  scope	  are	  somewhat	  dependent	  on	  the	  context	  in	  which	  it	  is	  expressed,	   ie:	   when	   overexpressed	   in	   HEK	   cells	   compared	   to	   endogenous	  expression	   in	   the	   native	   environment	   of	   brain	   tissue.	   	   In	   order	   to	   address	   this	  important	   discrepancy,	   we	   will	   transfect	   HEK293T	   cells	   with	  mDAT	   in	   order	   to	  compare	  substrate	  activity	  of	  probes	  between	  hDAT	  and	  mDAT.	  	  If	  no	  difference	  is	  observed,	   this	   would	   suggest	   that	   system-­‐specific	   differences	   in	   transporter	  function	  give	  rise	  to	  the	  different	  apparent	  substrate	  scope.	  	  If	  FFN102	  and	  202	  act	  as	   substrates	   in	   mDAT-­‐transfected	   HEK	   cells,	   then	   it	   is	   quite	   likely	   that	   species-­‐specific	  differences	  in	  transporter	  sequence	  are	  responsible.	  	   A	  similar	   inconsistency,	  albeit	  not	  as	  blatant,	  may	  exist	   in	   the	  case	  of	  hNET	  (above).	  	  If	  preliminary	  studies	  from	  the	  brain	  confirm	  that	  the	  labeled	  structures	  in	  the	   barrel	   cortex	   (Figure	   9)	   are	   indeed	   noradrenergic	   axons	   and	   presynaptic	  elements,	   and	   the	   opposite	   substrate	   activity	   in	   brain	   slice	   as	   compared	   to	   the	  activity	   in	   cell	   culture	   is	   verified	   for	   AGH093	   and	   FFN201,	   we	   will	   undertake	   a	  similar	  study	  with	  mNET.	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III:	  	  Conclusions	  and	  Outlook	  
	  
	   As	  mentioned	  above,	  the	  discovery	  of	  FFN102	  as	  a	  mDAT	  substrate	  in	  mouse	  coronal	  brain	  slice	  led	  to	  the	  development	  of	  a	  new	  method	  for	  the	  selective	  imaging	  of	  dopaminergic	  signaling	  at	  the	  synaptic	  level.	   	  The	  identification	  of	  an	  FFN	  active	  at	   or	   selective	   for	   SERT	   or	   NET	   would	   facilitate	   the	   study	   of	   serotonergic	   and	  noradrenergic	  neurons,	  respectively,	  in	  a	  similar	  manner.	  	  After	  screening	  a	  number	  of	   small,	   fluorescent,	   aminoethyl-­‐functionalized	   fluorescent	   probes	   for	   specific	  transporter-­‐dependent	   uptake	   in	   epifluorescence	   microscopy	   experiments,	   it	   was	  determined	  that	  a	  select	  few	  of	  the	  previously-­‐developed	  and	  new	  FFNs	  are	  indeed	  substrates	  of	  MATs.	  	  	  With	   the	   caveat	   that	   the	   human	   dopamine	   transporter,	   when	   expressed	  heterologously	  in	  HEK	  cells,	  seems	  more	  discriminating	  than	  its	  mouse	  counterpart	  in	   brain	   slice	   preparations,	  we	   can	  make	   some	  preliminary	   conclusions	   about	   the	  extent	   of	   the	   substrate	   scopes	   of	   these	   transporters.	   	   Interestingly,	   the	   large	  acridone	   NG54	   is	   tolerated	   as	   a	   substrate	   for	   each	   transporter.	   Along	   with	   the	  putative	   substrates	   from	   the	  Wilson	   lab	  discussed	   above,	   this	   suggests	   that	  MATs	  are	   indeed	   capable	   of	   transporting	   larger,	   non-­‐pyridinium	   based	   substrates.	  	  Additionally,	  the	  3-­‐aminoethyl-­‐7-­‐hydroxycoumarins	  AGH093	  and	  FFN201	  behave	  as	  selective	  hNET	  substrates	   in	  cultured	  HEK	  cells,	  supporting	  the	  notion	  that	  DAT	  is	  more	  discriminating	  than	  NET.	  These	   larger,	   fluorescent	  substrates	  push	   the	   functional	   limits	  of	   the	  MATs.	  	  As	   environmental	   exposure	   to	   neurotoxins	   is	   hypothesized	   to	   be	   involved	   in	   the	  development	   of	   some	   forms	   of	   idiopathic	   parkinsonism,	   this	   expanded	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understanding	   of	   the	   substrate	   scope	  may	   prove	   useful.	   	   Additionally,	   because	   no	  crystal	  structure	  has	  been	  solved	  for	  any	  of	  these	  transporters,	  any	  pharmacological	  data	   indicating	  substrate	  scope	  may	  prove	  helpful	   in	   the	  design	  of	  pharmaceutical	  agents.	  	  	  AGH093	  and	  FFN201	  represent	  a	  new	  development	  within	  the	  FFN	  program,	  as	   they	   are	   pH-­‐sensitive	   NET/VMAT	   FFNs.	   	   Both	   compounds	   have	   demonstrated	  substrate	   activity	   at	   VMAT2,	   and	   both	   are	   currently	   being	   investigated	   in	  noradrenergic	   systems,	   including	   the	   cortex	   of	   mouse	   brain	   slice.	   	   Preliminary	  results	  suggest	  that	  they	  function	  as	  “flashing	  FFNs,”	  as	  expected.	  	  We	  are	  initiating	  a	  collaboration	   with	   Professor	   Randy	   Bruno	   (CUMC)	   for	   the	   purpose	   of	   in	   vivo	  investigation	   of	   aminergic	   signaling	   in	   the	   cortex	   of	   living,	   behaving	   mice	   using	  AGH093	   (or	   FFN201)	   as	   an	   optical	   tracer	   with	   sufficient	   imaging	   properties	   to	  resolve	   neurotransmitter	   release	   at	   individual	   presynaptic	   terminals.	   	   Since	  noradrenergic	  (and	  dopaminergic)	  inputs	  are	  known	  to	  modulate	  cortical	  signaling	  networks,	   these	   compounds	   could	   lead	   to	   a	   breakthrough	   discovery	   of	   how	  individual	  synaptic	   inputs	  or	  collections	  of	  synaptic	   inputs	  modulate	  these	  cortical	  neurons.	   	   Ultimately,	   such	   a	   program	   could	   be	   used	   in	   preliminary,	   animal	   based	  experiments	   relating	   to	   the	   Brain	   Activity	  Map	   Project	   (introduced	   in	   Chapter	   1).	  	  Since	  noradrenergic	   neurons	   also	   innervate	   the	  periphery,	   these	  probes	  may	  play	  additional	   roles	   in	   the	   investigation	   of	   NE	   signaling	   in	   the	   peripheral	   nervous	  system	  as	  well.	  NG54	   was	   found	   to	   be	   a	   substrate	   for	   hDAT,	   hNET,	   and	   hSERT,	   with	  reasonable	   Michaelis	   constants	   at	   each	   (Km	   apparent	   <	   10	   µM),	   and	   is	   currently	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under	   investigation	   in	   the	   lab	   of	   Professor	   Scott	   Thompson	   (UMD)	   as	   a	   potential	  serotonergic	   FFN	   lead.	   Because	   NG54	   is	   a	   substrate	   for	   each	   of	   the	   MATs,	  derivatization	  of	  this	  acridone	  core	  could	  provide	  a	  new	  toolkit	  of	  FFNs	  selective	  for	  subsets	   of	   monoaminergic	   neurons	   (as	   discussed	   above).	   	   The	   Sames	   group	   is	  currently	   undertaking	   the	   synthesis	   and	   evaluation	   of	   a	   series	   of	   derivatized	  aminoethyl-­‐acridones	   for	   the	   purpose	   of	   identifying	   selective	   FFNs	   for	  dopaminergic,	   noradrenergic,	   or	   serotonergic	   synapses	   based	   on	   differential	  substrate	  activity	  at	  the	  respective	  plasma	  membrane	  transporters.	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IV:	  Experimental	  
Cell	  Culture	  
For	  hDAT-­‐EM4	  Experiments:	  	  	  An	  EM4	  cell	   line	  stably	  expressing	  hDAT	  (hDAT-­‐EM4)	  and	  an	  empty-­‐vector	  transfected	  EM4	  cell	  line	  to	  serve	  as	  a	  control	  were	  kindly	  provided	  by	  Drs.	  Jonathan	  Javitch	  and	  Mark	  Sonders	  of	   the	  Department	  of	  Psychiatry	  at	  Columbia	  University	  Medical	   Center.	   	   Cells	  were	   grown	   on	   10	   cm	   culture	   plates	   (corning)	   in	   DMEM	   +	  GlutaMAX	   (Invitrogen	   #10569)	   with	   10%	   Fetal	   Bovine	   Serum	   (FBS)	   (Atlanta	  Biologicals),	   100	   U/mL	   penicillin	   (Invitrogen),	   and	   100	   µg/mL	   streptomycin	  (Invitrogen).	  	  	  Cultures	  were	  maintained	  at	  37˚C	  in	  a	  humidified	  atmosphere	  of	  5%	  CO2.	  	  
For	  hSERT-­‐HEK	  and	  hNET-­‐HEK	  Experiments:	  
	   HEK293	  cell	  lines	  stably	  expressing	  hNET	  or	  hSERT	  were	  obtained	  from	  the	  laboratory	   of	   Professor	   Bryan	   Roth	   (University	   of	   North	   Carolina	   at	   Chapel	   Hill).	  	  hNET-­‐HEK	   and	   hSERT-­‐HEK	   cells	   were	   treated	   as	   above,	   and	   maintained	   in	   the	  complete	  growth	  medium	  above	  with	  additional	  500	  µg/mL	  G418	  (Calbiochem)	  to	  maintain	  the	  transfection.	   	  HET293T	  cells	  were	  grown	  in	  parallel	  as	  untransfected	  controls	  for	  background	  uptake.	  	  
For	  EGFP-­‐hSERT	  Experiments:	  MDCK	   cells	   expressing	   EGFP-­‐hSERT	   under	   the	   Flp-­‐in	   T-­‐REx	   inducible	   expression	  system	   were	   treated	   as	   the	   HEK	   cells	   above,	   and	   maintained	   in	   the	   same	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conditioned	  medium	   containing	   additional	   150	   µg/mL	   hygromycin	   B	   to	  maintain	  the	  transfection.	  	  	  	  
Screening	  of	  Probes	  at	  Neurotransmitter	  Transporters	  For	   epifluorescence	  microscopy	   experiments,	   cells	   expressing	   either	   hDAT,	  hNET,	   or	   hSERT	  were	   plated	   on	   poly-­‐D-­‐lysine	   (Sigma-­‐Aldrich,	   0.1	  mg/mL)	   coated	  six-­‐well	  plates	  (Falcon)	  at	  a	  density	  of	  ~100,000	  cells/well	  and	  were	  incubated	  until	  confluence	  (3-­‐4	  days	  at	  37˚C	  in	  a	  humidified	  atmosphere	  containing	  5%	  CO2).	   	  For	  Flp-­‐TetR	  MDCK	  cells	  expressing	  EGFP-­‐hSERT	  or	  an	  empty	  vector,	  expression	  of	  the	  transporter	  was	  induced	  with	  2	  µg/mL	  tetracycline	  in	  growth	  medium	  24	  h	  prior	  to	  the	   experiment.	   	   On	   the	   day	   of	   the	   experiment,	   complete	   growth	   medium	   was	  removed	  by	  aspiration	  and	  wells	  were	  carefully	  washed	  with	  PBS	  (1	  mL/well).	  	  Cells	  were	   then	   treated	  with	  900µL	  of	   experimental	  medium	  (DMEM	  minus	  phenol	   red	  containing	  25	  mM	  HEPES	  (Invitrogen)	  with	  1%	  FBS	  (Atlanta	  Biologicals)),	  for	  1-­‐3	  h.	  	  100	  	  µL	  of	  200	  µL	  probe	  solutions	  were	  added	  to	  each	  well,	  for	  a	  final	  concentration	  of	  20	  µM	  probe.	  	  Cells	  were	  treated	  for	  approximately	  30	  minutes	  with	  experimental	  probes	   at	   37˚C	   before	   uptake	   medium	   was	   removed	   by	   aspiration,	   wells	   were	  carefully	   washed	   with	   PBS.	   	   Cells	   were	   maintained	   in	   1	   mL	   warm	   experimental	  medium.	   	   Images	   were	   taken	   using	   a	   Leica	   DMI	   4000B	   inverted	   epifluorescence	  microscope	   equipped	  with	   a	   Leica	   DFC	   360	   FX	   digital	   camera	   controlled	   through	  Leica	  LAS	  AF	  6000E	  software.	   	  Bright	  field	  and	  fluorescence	  images	  were	  acquired	  sequentially	   (BF	   acquisition	   time	   =	   37	   ms).	   	   Fluorescence	   images	   were	   acquired	  using	  filter	  cubes	  (ex	  =	  350	  ±	  25	  nm,	  em	  =	  450	  ±	  25	  nm,	  for	  coumarin	  probes;	  ex	  =	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440	   ±	   25	   nm,	   em	   =	   550	   ±	   25	   nm	   for	   benzofurazan	   probes	   (JAM127,	   JAM138,	  JAM157).	  	  All	  images	  of	  each	  probe	  in	  transporter-­‐transfected	  and	  control	  cells	  were	  adjusted	  to	  the	  same	  brightness	  and	  contrast	  level	  using	  ImageJ	  (National	  Institutes	  of	  Health).	  	  	  	  
Pharmacological	  Inhibition	  of	  Suspected	  MAT	  Substrates	  For	   inhibition	   studies	  of	   suspected	   substrates,	   cells	  were	  plated	  as	   above.	   	  On	   the	  day	  of	  the	  experiment,	  cells	  were	  washed	  as	  described	  and	  pretreated	  with	  900	  µL	  experimental	   medium	   or	   experimental	   medium	   containing	   inhibitor	   (2	   µM	  nomifensine	   for	   DAT	   and	   NET,	   and	   2	   µM	   imipramine	   for	   SERT).	   	   After	   the	  preincubation	   period,	   cells	   were	   treated	   with	   either	   100	   µL	   of	   10X	   probe	   in	  experimental	  medium	  or	  the	  same	  with	  additional	  inhibitor	  2	  µM.	  	  Treatment	  times	  were	  the	  same,	  and	  images	  were	  acquired	  as	  described	  above.	  
	  
Determination	  of	  Kinetic	  Parameters	  for	  FFNs	  	   Initial	  rates	  experiments	  were	  performed	  essentially	  as	  described	  in	  Chapter	  2.	  	  hNET-­‐HEK	  cells	  were	  plated	  onto	  96-­‐well	  fluorescence	  microplates	  (Falcon)	  at	  a	  density	   of	   ~45,000	   cells/well.	   	   Cells	   were	   incubated	   for	   2	   days	   until	   confluent.	  Specific	   fluorescence	   uptake	   was	   found	   to	   be	   linear	   for	   AGH093	   and	   FFN201	   at	  hNET	   for	   at	   least	   12	   minutes,	   and	   specific	   uptake	   at	   each	   concentration	   was	  calculated	   by	   subtracting	   background	   uptake	   in	   wells	   inhibited	   with	   2	   µM	  nomifensine	  from	  uninhibited	  uptake	  values.	  	  Data	  were	  fit	  to	  the	  Michaelis-­‐Menten	  equation	  using	  GraphPad	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Studies	  of	  FFNs	  in	  Acute	  Mouse	  Brain	  Slice	  	   These	  studies	  were	  based	  on	  protocols	  developed	  and	  reported	  recently	  by	  Dr.	   Pamela	   Rodriguez.(45)	   These	   protocols	   will	   be	   discussed	   in	   detail	   in	   future	  reports	   as	  well	   as	   in	   the	  dissertations	  of	  Matthew	  R.	  Dunn	  and	  Paolomi	  Merchant	  (doctoral	  graduate	  students	  in	  the	  Sames	  Laboratory).	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A	  Small	  Fluorescent	  Analog	  of	  the	  Neurotoxin	  MPP+	  is	  a	  
Marker	  for	  Catecholamine	  Neurons	  in	  the	  Brain,	  but	  is	  Not	  
a	  Fluorescent	  False	  Neurotransmitter(1)	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I:	  	  Introduction	  
	  
MPP+,	  Parkinsonism,	  and	  the	  Dopamine	  Transporter	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MPTP	  and	  MPP+	  have	  been	  used	  as	  tools	  to	  generate	  parkinsonism	  in	  animal	  models,(7,	   17)	   and	   radiolabeled	   MPP+	   is	   also	   a	   common	   tool	   used	   in	   the	   study	   of	  monoamine	  and	  cation	  transporters	  (see	  Chapter	  5).	  
	  	  
Figure	   2:	   A	   metabolite	   of	   MPTP	   induces	   parkinsonism	   by	   selectively	   killing	  nigrostriatal	   dopamine	   neurons.	   	   A.)	   Circulating	   MPTP	   is	   lipophilic	   and	   readily	  crosses	   the	   blood	   brain	   barrier	   (red	   line),	   where	   it	   is	   converted	   by	   action	   of	  monoamine	  oxidase	  B	   (MAO-­‐B)	   to	  MPP+	   in	   astroglia.	   	   B.)	  MPP+	   is	   a	   substrate	   for	  high	   affinity	   monoamine	   transporters	   including	   DAT.	   	   Once	   inside	   dopaminergic	  neurons,	  MPP+	  is	  known	  to:	  1	  –	  become	  localized	  to	  mitochondria	  by	  action	  of	  the	  electrochemical	  potential	  across	  the	  mitochondrial	  membrane	  and	  lead	  to	  apoptosis,	  and	   2	   –	   become	   vesicularized	   by	   action	   of	   VMAT2	   (blue	   ovals).	   	   The	   interplay	  between	   these	   two	   competing	   processes	   is	   important	   for	   MPP+	   toxicity	   and	  protection	   therefrom,	   and	   we	   became	   curious	   about	   whether	   VMAT2-­‐dependent	  sequestration	   (situation	   2)	   of	   a	   fluorescent	   MPP+	   analog	   would	   be	   sufficient	   to	  exploit	  for	  imaging	  purposes.	  	  	  
Fluorescent	   Analogs	   of	   MPP+	   Have	   Been	   Used	   to	   Study	   Plasma	   Membrane	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known	  as	  the	  Organic	  Cation	  Transporters	  (OCTs;	  for	  a	  full	  discussion	  see	  Ch5).(20-­‐22)	  ASP+	  has	  been	  used	  as	  a	  fluorescent	  substrate	  to	  study	  and	  image	  OCT	  expression,	  activity,	  and	  pharmacological	  properties	  in	  transfected	  cells	  and	  tissues.(21,	  23,	  24)	  	   In	   a	   groundbreaking	   2003	   report,	   DeFelice	   et	   al	   demonstrated	   ASP+	  substrate	   activity	   at	   plasma	   membrane	   monoamine	   transporters	   DAT,	   NET,	   and	  SERT	   (Figure	   3).(25)	   This	   represented	   the	   first	   conclusive	   report	   of	   a	   fluorescent	  substrate	  for	  any	  of	  the	  high	  affinity	  monoamine	  transporters	  (MATs),	  proving	  that	  these	  MATs	  are	  capable	  of	  accepting	  substrates	  significantly	  larger	  than	  endogenous	  monoamines	  or	  MPP+.	   	   It	  was	   found	   that	  ASP+	   fluoresces	  brightly	  when	  bound	   to	  the	   transporter	   or	   intracellular	   compartments	   including	   mitochondria,	   but	   is	  quenched	   in	  aqueous	  environments	  via	   the	  twisted	   intramolecular	  charge	  transfer	  (TICT)	  mechanism.(26)	   Since	   the	   rate	   constant	  of	   transport	   is	   slow	  and	   since	  ASP+	  has	  a	  moderate	  affinity	  for	  the	  MATs,	  there	  is	  a	  considerable	  steady-­‐state	  population	  of	   the	   compound	   bound	   to	   the	   transporter	   in	   the	   hydrophobic	   transmembrane	  region,	  where	  ASP+	  fluoresces	  brightly.	  	  Because	  of	  this	  property,	  it	  was	  possible	  for	  the	  authors	  to	  spectroscopically	  separate	  ASP+	  binding	  from	  transport,	  and	  to	  study	  the	   substrate	   stoichiometry	   and	   ion	   dependence	   of	   both	   processes.	  (25,	  27)	   	   	   It	  was	  shown	   that	  DAT,	  NET,	   and	   SERT	   can	   bind	   and	   accumulate	  ASP+,	   although	   uptake	  kinetics	   are	   slow	   and	   ASP+	   is	   a	   comparably	   poor	   substrate	   for	   SERT.	   In	   2010,	  Wilson	   reported	   a	   detailed	   study	   consisting	   of	   a	   number	   of	   ASP+	   analogs,	   which	  further	  elucidated	  the	  scope	  of	  pyridinium	  interactions	  and	  transport	  through	  NET,	  and	   found	   a	   relationship	   between	   the	   photophysical	   properties	   of	   transporter-­‐bound	  pyridiniums	  and	  the	  geometry	  of	  binding.(28)	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Because	  of	  the	  slow	  catalytic	  turnover	  (Vmax)	  and	  relatively	  high	  background	  uptake	   of	   these	   styryl	   pyridiniums	   (likely	   related	   to	   their	   high	   lipophilicity),(25,	  27)	  ASP+	  and	  related	  styryl	  pyridiniums	  are	  poor	  candidates	  for	  development	  of	  FFNs.	  	  Despite	  these	  drawbacks,	  however,	  ASP+	  has	  been	  used	  to	  image	  implanted	  glioma	  cells	   in	   brain	   tissue	   because	   of	   its	   favorable	   uptake	   kinetics	   at	   OCT3,	   which	   is	  heavily	  overexpressed	  in	  gliomas.(23)	  	  	  These	  reports	  encouraged	  us	  to	  consider	  how	  smaller,	  less	  lipophilic	  analogs	  of	  MPP+	  would	  behave	  in	  brain	  tissue.	  To	  explore	  the	  possibility	  that	  a	  fluorescent	  MPP+	  analog	  may	  serve	  as	  a	  lead	  for	  FFNs,	  we	  considered	  a	  fluorescent	  analog	  with	  the	   strongly	   electron	   donating	   dimethylamino-­‐group	   in	   the	   4’-­‐position	   of	   a	   biaryl	  pyridinium,	  4-­‐(4-­‐dimethylamino)phenyl-­‐1-­‐methylpyridinium	  (APP+)	  (Figure	  3).	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APP+	  is	  a	  Fluorescent	  Substrate	  for	  DAT,	  NET,	  SERT,	  and	  VMAT	  –	  A	  FFN	  Lead?	  
	   We	  became	  curious	  to	  test	  whether	  a	  smaller	  analog	  of	  MPP+	  would	  serve	  as	  a	  superior	  substrate	  for	  DAT,	  NET,	  SERT,	  and	  VMAT,	  and	  whether	  it	  could	  serve	  as	  a	  lead	   for	   FFNs.	   	  While	  MPP+	   is	   known	   to	   interact	  with	  mitochondria,	   it	   is	   unclear	  whether	  accumulation	  by	  VMAT	  would	  outcompete	  mitochondrial	  binding	  (Figure	  
4).	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II:	  	  Results	  and	  Discussion	  	  
Synthesis	  and	  Photophysical	  Evaluation	  of	  APP+	  
	   The	  structure	  and	  synthesis	  of	  APP+	  iodide	  has	  previously	  been	  reported.(34,	  
41,	   42)	   	  Our	   synthesis	   of	   APP+	   is	   outlined	   in	   Scheme	   1.	   	   APP+	   was	   prepared	   via	   a	  Suzuki	   cross	   coupling	   of	   4-­‐bromopyridine	   with	   4-­‐(dimethylamino)phenylboronic	  acid	  pinnacol	  ester	  to	  afford	  intermediate	  1.	  Alkylation	  with	  iodomethane	  afforded	  APP+	  iodide	  as	  a	  bright	  orange	  powder.	  	  	  
	  
Scheme	  1:	  	  Synthesis	  of	  APP+	  iodide.	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A.	   	   	   	   	   	   B.	  
	  
Figure	  5.	  Relevant	  photophysical	  properties	  of	  APP+.	  A).	  UV-­‐Vis	  spectra	  of	  APP+	  (20	  µM)	  in	  different	  solvents	  illustrating	  the	  blueshift	  of	  the	  absorbance	  maximum	  with	  increasing	   solvent	   polarity,	   characteristic	   of	   pyridiniums	   (λmaxPBS	   =	   416	   nm,	  
λmaxDMSO	  =	  419	  nm,	  λmaxethanol	  =	  424	  nm,	  λmaxCHCl3	  =	  439	  nm).	  (B)	  Emission	  and	  excitation	   profiles	   of	   APP+	   (2	   µM)	   in	   phosphate	   buffered	   saline	   (PBS),	   pH=7.4	  (λexPBS	  =	  417	  nm,	  	  λemPBS	  =	  501	  nm),	  and	  chloroform	  (λexCHCl3	  =	  436	  nm,	  λemCHCl3	  =	  506	  nm),	   illustrating	  the	  strong	  solvent	  effects	  to	  which	  APP+	  is	  subject.	  Spectra	  were	  measured	  at	   the	   corresponding	  emission/excitation	  maxima	   for	  APP+	   in	   the	  respective	   solutions.	   	   Importantly,	   APP+	   is	   approximately	   ten	   times	   more	  fluorescent	  in	  nonpolar	  environments	  than	  in	  aqueous	  buffer.	  
	  This	  fluorescence	  quenching	  is	  due	  to	  the	  well-­‐known	  twisted	  intramolecular	  charge	   transfer	   (TICT)	   mechanism,	   in	   which	   an	   excited	   electron	   decays	   in	   a	  nonradiative	   manner	   to	   a	   triplet	   state.(26,	   33)	   This	   decay	   mechanism	   becomes	  favorable	  in	  polar	  environments	  or	  when	  the	  dihedral	  angle	  between	  the	  two	  arenes	  in	  excited	   states	  of	  biaryl	   systems	  becomes	   large,	   either	  due	   to	  a	   solvent	  effect	  or	  geometric	   restriction.(26,	   33)	   	   The	   resultant	   fluorescence	   quenching	   in	   aqueous	  environments	  is	  important	  for	  interpretation	  of	  results	  later	  in	  this	  chapter.	  
	  
Cell-­‐Based	  Results	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Mitotracker	   Deep	   Red	   (Invitrogen)	   revealed	   a	   high	   degree	   of	  mitochondrial	   label,	  consistent	   with	   previously	   reported	   results.(35)	   	  Both	   hDAT-­‐transfected	   and	   empty	  vector-­‐transfected	  EM4	  cells	  were	  co-­‐exposed	  for	  10	  minutes	  with	  Mitotracker	  Deep	  Red	   (20	   nM)	   and	   APP+	   (2μM).	   	   Each	   probe	   was	   imaged	   separately	   by	   using	   the	  appropriate	   optical	   filters	   with	   no	   cross-­‐channel	   signal	   contamination.	   	   Both	   cell	  types	   were	   similarly	   stained	   by	   the	   Mitotracker	   dye	   (Figure	   6C),	   while	   APP+	  accumulated	   rapidly	   in	   hDAT-­‐transfected	   EM4	   cells.	   The	   empty	   vector-­‐transfected	  EM4	  cells	  afforded	  no	  significant	  uptake	  of	  APP+	  under	  the	  same	  conditions	  (Figure	  
6B).	   	  A	  high	  degree	  of	  colocalization	  of	  APP+	  and	  Mitotracker	   in	  hDAT-­‐transfected	  cells	   (Figure	   6D)	   confirms	   that	   APP+	   labels	  mitochondria	   in	   these	   cells,	  which	   is	  consistent	  with	  a	  previous	  report	  using	  a	  SERT-­‐expressing	  cell	  line,	  and	  is	  ascribed	  to	   its	   permanent	   positive	   charge.	  The	   quenched	   fluorescence	   in	   aqueous	   growth	  media	   is	   advantageous	   for	   cell	   culture	   assays,	   as	   continuous	   measurement	   or	  imaging	   is	   possible	   in	   the	   presence	   of	   APP+	   dye	   with	   no	   need	   for	   washing	   or	  additional	  quenching	  agents.	  	  	  
	  
Figure	   6:	  APP+	  becomes	   localized	   in	  mitochondria	  of	  EM4	  cells	  expressing	  hDAT.	  	  Shown	  are	  epifluorescence	  microscopy	  images	  of	  APP+	  (2μM,	  10	  min	  incubation)	  in	  (A)	   hDAT-­‐transfected	   EM4	   cells,	   and	   (B)	   empty	   vector-­‐transfected	   EM4	   cells.	   	   (C)	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hDAT-­‐transfected	  EM4	  cells	  were	  also	  co-­‐incubated	  with	  Mitotracker	  Deep	  Red	  (20	  nM,	   10	   min).	   (D)	   Overlay	   of	   APP+	   and	   Mitotracker	   images	   shows	   strong	   co-­‐localization,	  indicating	  mitochondrial	  concentration	  of	  APP+.	  	  Scale	  bar	  =	  15	  μm.	  	  	   APP+	  was	   next	   tested	   in	   VMAT2-­‐HEK	   cells	   (described	   in	   Chapter	   2),(16)	   to	  examine	   whether	   substrate	   activity	   at	   VMAT2	   could	   overcome	   mitochondrial	  accumulation,	  and	   if	   accumulation	   in	  VMAT2-­‐expressing	  acidic	   compartments	  was	  strong	   enough	   to	   overcome	   fluorescence	   quenching	   in	   the	   aqueous	   lumen.	   	   In	   a	  series	  of	  experiments	  comparing	  the	  APP+	  staining	  pattern	  to	  Mitotracker	  Deep	  Red	  (control	   for	   mitochondrial	   staining),	   an	   interesting	   result	   was	   observed.	  	  Consistently,	  VMAT2-­‐HEK	  cells	  treated	  with	  APP+	  (2uM,	  60	  min)	  were	  significantly	  less	   bright	   and	   less	   punctate	   than	   null-­‐transfected	   control	   HEK	   cells	   (TetR-­‐HEK)	  (Figure	  7	  A,D).	  	  Note	  that	  a	  longer	  incubation	  time	  is	  required	  for	  ASP+	  to	  enter	  the	  cells	   in	   the	  absence	  of	  MATs.	  TetR-­‐HEK	  cells	   treated	  with	  APP+	  displayed	  a	  highly	  mitochondrial	   staining	   morphology,	   overlaying	   again	   to	   a	   great	   degree	   with	  Mitotracker,	  although	  this	  was	  significantly	  diminished	  in	  VMAT2-­‐HEK	  cells	  (Figure	  
7).	   	   The	   difference	   in	   staining	   does	   not	   likely	   arise	   from	   a	   difference	   in	  mitochondrial	  potential	  between	  each	  cell	  type,	  as	  Mitotracker	  labeled	  VMAT2-­‐HEK	  cells	   similarly	   (Figure	   7	   B,E).	   	  Based	  on	   these	   results	   as	  well	   as	   reports	  of	  VMAT	  rescuing	   cells	   from	  MPP+	   toxicity	   and	   the	   fact	   that	   these	   cells	  were	   cloned	  under	  pressure	   from	   MPP+,	   a	   hypothesis	   was	   developed.	   It	   is	   plausible	   that	   the	  concentration	  of	  cytosolic	  APP+	  is	  low	  when	  there	  is	  not	  a	  high	  affinity	  transporter	  on	   the	   plasma	   membrane	   surface	   (as	   concurrently	   shown),(39)	   and	   this	   low	  concentration	  is	  sequestered	  by	  VMAT2,	  affording	  a	  vesicularized	  concentration	  of	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APP+	  that	  is	  insufficient	  to	  overcome	  fluorescence	  quenching	  in	  the	  aqueous	  lumen.	  	  VMAT2	  binding	  could	  also	  outcompete	   the	  electrochemically-­‐driven	  mitochondrial	  binding.	   	   In	   order	   to	   further	   examine	   this	   hypothesis,	   VMAT2	   inhibition	   studies	  were	  conducted.	  	  
	  
Figure	   7:	   	   The	   APP+	   label	   appears	   to	   be	   reduced	   by	   VMAT2	   in	  HEK	   cells.	   	   A)	   In	  control	   TetR-­‐HEK	   cells,	   APP+	   (2	   μM,	   60	   min)	   consistently	   appears	   bright	   and	  punctate.	   	   B)	   Mitotracker	   (50	   nM,	   10	   min)	   reveals	   the	   spatial	   location	   of	  mitochondria,	  and	  C)	  overlay	  of	   the	  two	  shows	  a	  high	  degree	  of	  colocalization.	   	  D)	  VMAT2-­‐HEK	   cells	   are	   routinely	   less	   bright	   with	   fewer	   puncta.	   	   E)	   Mitotracker	  labeling	   shows	   that	   this	   lower	   apparent	   level	   of	   staining	   is	   independent	   of	  mitochondrial	  potential,	  and	  F)	  overlay	  of	  APP+	  and	  Mitotracker	  signal	   in	  VMAT2-­‐HEK	   cells	   demonstrates	   the	   lower	   overall	  mitochondrial	   labeling	   by	  APP+.	   	  While	  the	  overlay	  is	  obfuscated	  by	  the	  mitotracker	  label,	  it	  is	  apparent	  that	  the	  APP+	  signal	  is	  greatly	  diminished	  compared	  to	  HEK	  control	  cells	  (top	  row).	  	  	   However,	   treatment	  with	   VMAT2-­‐inhibitors	   (2μM	  DTBZ	   or	   1μM	   reserpine)	  revealed	  no	  consistent	  or	  reproducible	  increase	  in	  fluorescence	  of	  the	  cells	  (Figure	  
8).	   	   Several	   explanations	   for	   this	   result	   are	   possible.	   It	   is	   possible	   that	   there	   is	  simply	  not	  enough	  APP+	  crossing	  the	  plasma	  membrane	  through	  passive	  diffusion	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to	  make	  a	  discernable	  difference,	  as	  the	  changes	  in	  fluorescence	  observed	  here	  are	  minor.	   	   It	   is	   also	   likely	   that	   the	   process	   that	   selected	   for	   VMAT2-­‐expressing	  HEK	  cells	   has	   also	   upregulated	   an	   efflux	   transporter	   in	   the	   original	   clone	   or	   the	   cells	  evolved	  some	  similar	  clearance	  mechanism,	  which	  is	  capable	  of	  clearing	  the	  cell	  of	  small	   pyridinium	   compounds.	   	   The	   latter	   explanation	   is	   likely	   as	   inhibition	   of	  VMAT2	  with	  reserpine	  (1μM)	  or	  DTBZ	  (2μM)	  did	  not	  reproducibly	  or	  consistently	  within	   each	   experiment	   lead	   to	   restoration	   of	   mitochondrial	   staining	   by	   APP+.	  	  While	  these	  results	  may	  be	  suggestive	  that	  APP+	  is	  a	  substrate	  for	  VMAT	  and	  that	  its	  fluorescence	  can	  be	  quenched	   in	  aqueous	  compartments,	   they	  are	   inconclusive,	  as	  inhibition	  of	  VMAT2	  does	  not	  restore	  the	  mitochondrial	  label.	  	  
	  
Figure	  8:	  	  The	  effect	  of	  reserpine	  on	  APP+	  labeling	  of	  VMAT2-­‐HEK	  cells.	  	  A)	  APP+	  in	  control	   TetR-­‐HEK	   cells	   (2μM,	   60	   min)	   shows	   mitochondrial	   labeling	   as	   above	  (Figure	   7).	   	   B)	   VMAT2-­‐HEK	   cells	   treated	   under	   the	   same	   conditions	   are	   less	  punctate,	   also	   as	   above.	   	   C)	   Inhibition	   of	   VMAT2	   with	   reserpine	   (1µM)	   does	   not	  restore	  strong	  APP+	  staining	  of	  mitochondria	  in	  VMAT2-­‐HEK	  cells.	  	  	   From	   these	   results,	   it	   was	   still	   unclear	   whether	   action	   of	   a	   high	   affinity	  transporter	   on	   the	   plasma	   membrane	   such	   as	   DAT,	   NET,	   or	   SERT	   could	   provide	  sufficient	  cytosolic	  concentrations	  of	  APP+	  to	  visualize	  a	  vesicular	  label,	  and	  it	  was	  still	  not	  completely	  clear	  whether	  APP+	  was	  a	  VMAT2	  substrate.	  	  Fortunately	  as	  we	  were	  conducting	  these	  experiments,	   it	  was	  reported	  that	  APP+	  was	  a	  substrate	  for	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VMAT2	   (in	   the	   context	   of	   the	   Molecular	   Devices	   Neurotransmitter	   Transporter	  Uptake	   Assay	   Kit).(39)	   Although	   our	   VMAT	   results	   were	   not	   conclusive,	   evidence	  from	   a	   DAT	   and	   VMAT-­‐overexpressing	   system	   revealed	   staining	   of	   both	  mitochondria	   and	   VMAT2-­‐expressing	   compartments,(39)	   so	   we	   decided	   to	   pursue	  preliminary	  labeling	  and	  release	  studies	  in	  acute	  mouse	  brain	  slice	  with	  the	  goal	  of	  describing	  the	  behavior	  of	  APP+	  in	  aminergic	  neurons	  in	  acute	  mouse	  brain	  slices.	  	  
APP+	  is	  a	  Marker	  for	  Catecholamine	  Neurons	  in	  Brain	  Tissue	  
	  
	   Curiosity	   about	   the	   behavior	   of	   APP+	   in	   brain	   tissue	   led	  me	   to	   collaborate	  with	  Matt	   Dunn,	   a	   graduate	   student	   in	   the	   Sames	   Lab	  who	  works	   routinely	   with	  FFNs	  in	  acute	  mouse	  brain	  slice.	  	  Together,	  we	  developed	  a	  number	  of	  experiments	  to	  rigorously	  test	  the	  behavior	  of	  APP+	  in	  catecholaminergic	  innervation	  in	  the	  brain,	  and	  Matt	  performed	  all	  microscopy	  in	  the	  brain.	  	  	  It	   is	   important	   to	  note	   that	   the	   focus	  of	   the	  remainder	  of	   this	  chapter	   is	  on	  catecholaminergic	   neurons	   in	   the	   brain	   (DA-­‐ergic	   and	   NE-­‐ergic)	   because	   of	   the	  availability	  of	   a	  positive	   control	   for	   staining,	   specifically	   green	   fluorescent	  protein	  (GFP)	   expressed	   under	   control	   of	   the	   promoter	   of	   tyrosine	   hydroxylase	   (TH-­‐GFP).(43)	  	  It	  is	  quite	  likely	  that	  APP+	  has	  similar	  behavior	  at	  5HT	  neurons	  in	  the	  brain,	  although	  the	  lack	  of	  an	  adequate	  control	  at	  the	  time	  of	  our	  experiments	  caused	  us	  to	  focus	  on	  catecholaminergic	  innervation.	  Previous	   studies	   investigating	   APP+	   uptake	   by	   cells	   have	   been	   limited	   to	  cultured	   cells	   transfected	   with	   plasma	   membrane	   monoamine	   transporters,(34-­‐36)	  cultured	   cells	   endogenously	   expressing	   SERT,(44)	   primary	   peripheral	   tissue	  expressing	  NET,(38)	  or	  platelets	  and	  lymphocytes.(45)	  We	  were	  motivated	  to	  examine	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the	   behavior	   of	   APP+	   in	   brain	   tissue,	   and	   we	   began	   by	   examining	   labeling	  characteristics	  of	  APP+	  in	  acute	  mouse	  brain	  slices	  containing	  the	  midbrain	  region,	  where	  catecholaminergic	  cell	  bodies	  occur.	  The	  labeling	  selectivity	  of	  cell	  bodies	  was	  determined	  by	  co-­‐localization	  of	  the	  APP+	  and	  GFP	  signals	  in	  brain	  tissue	  obtained	  from	  mice	  expressing	  GFP	  under	  the	  control	  of	  tyrosine	  hydroxylase	  (TH)	  promoter	  (TH-­‐GFP	   mice),(43)	   via	   two-­‐photon	   microscopy	   (Figure	   9).	   For	   dopaminergic	   cell	  bodies,	  we	  examined	  the	  substantia	  nigra	  pars	  compacta	  region	  (SN)	  and	  the	  ventral	  tegmental	   area	   (VTA),	   the	   anatomical	   areas	  where	   the	   neuronal	   cell	   bodies	   of	   the	  nigrostriatal	   and	   mesolimbic	   dopaminergic	   systems,	   respectively,	   reside.	   Acute	  midbrain	   slices	   from	  TH-­‐GFP	   transgenic	  mice	  were	   perfused	   for	   30	  minutes	  with	  oxygenated	   artificial	   cerebral-­‐spinal	   fluid	   (ACSF)	   containing	   500	   nM	   of	   APP+,	  followed	   by	   washing	   for	   10	   min	   with	   oxygenated	   ACSF.	   Staining	   patterns	   and	  colocalization	   were	   determined	   by	   imaging	   individual	   slices	   sequentially	   at	   the	  excitation	  and	  emission	  wavelengths	   for	  APP+	  and	  GFP	  (APP+:	  λex	  =	  800	  nm,	  λem	  =	  435-­‐485	   nm;	   GFP:	   	   λex	   =	   950	   nm,	   λem	   =	   500-­‐550	   nm).	   	   Excitation	   and	   emission	  wavelengths	   were	   chosen	   to	   minimize	   signal	   crosstalk	   between	   APP+	   and	   GFP	  channels.	   	   Labeled	   cell	   bodies	   were	   defined	   as	   areas	   with	   mean	   fluorescence	  intensity	  greater	   than	   two	  standard	  deviations	  above	  background	  signal,	  with	   size	  and	  shape	  consistent	  with	  morphological	  parameters	  of	  dopamine	  neuronal	   soma.	  	  Colocalization	  was	  determined	  by	  assessing	  the	  number	  of	  cell	  bodies	  in	  each	  region	  where	   GFP	   signal	   and	   APP+	   signal	   were	   both	   present	   at	   least	   two	   standard	  deviations	  above	  their	  respective	  backgrounds.	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Every	   cell	   body	   labeled	  by	  APP+	   in	   these	   regions	  was	   found	   to	   contain	   the	  GFP	   signal,	  while	   76%	   of	   TH-­‐GFP	   positive	   cells	   in	   SN/VTA	   contained	   APP+	   signal	  (84/110	   cells,	   n	   =	   6,	  Figure	   9A).	   	   Futher,	   the	  DA	   neuronal	   cell	   body	   labeling	  was	  greatly	  reduced	  by	   treatment	  of	   the	  slice	  with	   the	  DAT	   inhibitor	  nomifensine	  (7%,	  3/43	  cells,	  n	  =	  3,	  Figure	  9B),	  confirming	  that	  APP+	  uptake	  by	  DA	  neuronal	  soma	  is	  DAT	  dependent.	  The	  higher	  magnification	  image	  shows	  a	  heterogeneous	  perinuclear	  staining	   (Figure	   9D)	   similar	   to	   that	   observed	   in	   hDAT-­‐EM4	   cells	   (Figure	   6),	  suggesting	   mitochondrial	   staining.	   These	   results	   indicate	   that	   APP+	   selectively	  labels	  DA	  neuronal	   cell	   bodies	   versus	   other	   neurons	   in	   the	   area,	  which	   appear	   as	  dark	  unstained	  regions	  (Figure	  9A).	  To	  obtain	   the	   level	  of	   soma	   labeling	   specified	  above,	   incubation	  of	   the	   slice	  with	  500	  nM	  APP+	  for	  30	  minutes	  was	  required.	  Under	  these	  conditions,	  a	  high	  level	  of	   punctate	   staining	   was	   observed,	   which	   was	   not	   inhibited	   by	   nomifensine	   in	  SN/VTA	   (Figure	   9A,B),	   and	   was	   also	   present	   in	   brain	   areas	   outside	   of	   SN/VTA	  (Figure	  9E).	  These	  results	   indicate	  that	   the	  majority	  of	   the	  background	  staining	   is	  not	  related	  to	  DA	  neuronal	  structures	  such	  as	  the	  dendrites.	  We	   also	   investigated	   labeling	   of	   noradrenergic	   cell	   bodies	   in	   the	   locus	  coeruleus	  (LC)	  where	  the	  majority	  of	  noradrenergic	  cells	  reside	  (Figure	  9C).	  	  APP+	  selectively	  labeled	  these	  neurons;	  all	  examined	  APP+	  labeled	  cells	  contained	  the	  GFP	  signal	  and	  59%	  of	  TH-­‐GFP	  positive	  cells	  in	  LC	  were	  also	  labeled	  with	  APP+	  (74/126	  GFP	   positive	   cells,	   n	   =	   3).	   We	   found	   that	   for	   analysis	   of	   APP+	   uptake	   by	  noradrenergic	   neurons	   in	   LC,	   young	  mice	   (<30	  d	   postnatal)	  were	   required,	   as	   the	  staining	  was	  dim	  and	   inconsistent	   in	   older	  mice	   (data	   not	   shown).	   This	   finding	   is	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consistent	  with	  reported	  down-­‐regulation	  of	  NET	  protein	  expression	  in	  cell	  bodies	  of	  noradrenergic	  neurons	  in	  the	  LC	  of	  older	  mammals,	  including	  mice.(46,	  47)	  	  As	  in	  the	  SN/VTA	  region,	  APP+	  provides	  a	  high	  level	  of	  punctate	  background	  staining	  in	  LC.	  	  Our	   studies	   demonstrate	   that	   APP+	   labels	   catecholamine	   neurons	   in	   the	  indicated	  brain	  areas	   in	  a	  DAT/NET	  dependent	  manner.	  Despite	   the	   fair	  degree	  of	  unidentified	   punctate	   staining,	   the	   catecholamine	   neuronal	   cell	   bodies	   could	   be	  readily	  identified	  in	  acute	  unfixed	  brain	  slice	  by	  simple	  perfusion	  of	  the	  tissue	  with	  the	  APP+	  dye.	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Figure	   9: APP+	   labels	   catecholaminergic	   neuronal	   cell	   bodies	   in	   acute	   mouse	  midbrain	   slices.	   TH-­‐positive	   cell	   bodies	   (TH-­‐GFP	   in	   green)	   in	   the	   (A)	   DAT-­‐expressing	   ventral	   tegmental	   area	   and	   substantia	   nigra	   (VTA/SN),	   and	   (C)	   NET-­‐expressing	   locus	   coeruleus	   (LC)	   accumulate	   APP+	   (in	   red)	   in	   a	   selective	   manner	  relative	  to	  other	  cell	  bodies	  (black	  holes)	  after	  perfusion	  of	  APP+	  (500	  nM)	   for	  30	  min.	  (B)	  Accumulation	  of	  APP+	  into	  cell	  bodies	  in	  the	  SN/VTA	  can	  be	  substantially	  inhibited	   if	   the	   slice	   is	  pre-­‐treated	  with	  a	  DAT	   inhibitor	   (nomifensine,	  1	  µM;	   scale	  bars	   =	   20	   µm).	   (D)	   A	   closer	   view	   of	   an	   APP+	   labeled	   cell	   body	   from	   SN/VTA	  illustrates	  a	  perinuclear,	  punctate	  staining	  pattern	  similar	  to	  what	  is	  seen	  in	  hDAT-­‐transfected	  EM4	  cells,	  suggesting	  mitochondrial	  staining	  (TH-­‐GFP	  in	  green,	  APP+	  in	  red;	  scale	  bar	  =	  20	  µm).	  (E)	  No	  staining	  of	  cell	  bodies	  was	  observed	  in	  the	  primary	  visual	  cortex	  of	  the	  same	  slice	  (scale	  bar	  =	  20	  µm).	   	  Images	  are	  from	  collaboration	  with	  Matt	  Dunn.	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APP+	  Labels	  Dopaminergic	  Structures	  in	  the	  Dorsal	  Striatum	  
	  
 The	   dorsal	   striatum	   is	   heavily	   innervated	   by	   the	   dopamine	   neurons	  originating	   in	   SN	   (see	   above).	   Among	   other	   functions,	   dopamine	   in	   the	   dorsal	  striatum	   modulates	   excitatory	   inputs	   from	   the	   cortex	   and	   other	   brain	   areas	   and	  plays	   crucial	   roles	   in	   sensory-­‐motor	   coordination	   and	   habit	   formation.(48)	  Coronal	  mouse	  brain	  slices	  comprising	  the	  dorsal	  striatum	  were	  loaded	  with	  APP+	  using	  the	  experimental	  conditions	  described	  above,	  except	  that	  a	  lower	  concentration	  of	  APP+	  (100	  nM)	  for	  only	  15	  min	  was	  sufficient	  to	  provide	  bright	  punctate	  staining	  	  (Figure	  
10A).	  The	  overall	  pattern	  of	  APP+	  staining	  is	  similar	  to	  that	  of	  GFP	  in	  TH-­‐GFP	  mice.	  Quantitative	  comparison	  showed	  a	  good	  degree	  of	  colocalization:	  83.4	  ±	  6.9%	  (mean	  
±	  SD,	  n=3)	  of	  APP+	  puncta	  contained	  the	  GFP	  signal	  (Figure	  10A-­‐C).	  We	  observed	  a	  small	   degree	   of	  APP+	   signal	   contamination	   in	   the	  GFP	   channel,	   enough	   for	   10.1	  ±	  5.7%	  of	  the	  brightest	  APP+	  labeled	  puncta	  to	  be	  picked	  up	  in	  the	  GFP	  channel	  of	  GFP	  negative	   brain	   slices	   (mean	   ±	   SD,	   n	   =	   3).	   To	   provide	   another	   quantitative	  colocalization	  measure	  in	  complete	  absence	  of	  a	  signal	  crosstalk,	  we	  also	  examined	  colocalization	  of	  APP+	  and	  FFN102	  in	  wild	  type	  mice.	   	  As	  discussed	  above,	  FFN102	  is	  to	  date	  the	  most	  selective	  FFN	  probe	  for	  dopamine	  neurons,	  featuring	  strong	  DAT	  dependence	   and	   ~90%	   colocalization	  with	   TH-­‐GFP	   signal	   in	   dorsal	   striatum,	   and	  thus	  may	  serve	  as	  a	  reliable	  reference	  signal.(40)	  We	  found	  that	  74.1	  ±	  6.9	  %	  (mean	  ±	  SD,	  n	  =	  3)	  of	  APP+	  puncta	  were	  FFN102	  positive	   (Figure	  10D-­‐F).	   	   	   	  These	   results	  indicate	   that	  APP+	   labels	   fine	  axonal	  processes	  of	  dopamine	  neurons	   in	   the	  dorsal	  striatum	  with	  selectivity	  >70%	  as	  defined	  by	  colocalization	  to	  two	  reference	  signals.	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Figure	  10:	  APP+	  colocalizes	  with	  dopaminergic	  markers	  in	  the	  dorsal	  striatum.	  (A)	  Signal	   from	  GFP	   expressed	   under	   control	   of	   the	   TH	   promoter.	   	   (B)	   100	   nM	  APP+	  perfusion	   for	   15	   min	   creates	   a	   punctate	   staining	   pattern	   in	   dorsal	   striatal	   acute	  slices.	   	   (C)	   APP+	   colocalizes	   well	   with	   TH-­‐GFP	   (83.4	   ±	   6.9%,	   mean	   ±	   SD,	   n	   =	   3).	  Because	   of	   a	   small	   amount	   of	   crosstalk	   between	   APP+	   and	   GFP	   channels,	   we	  confirmed	   dopaminergic	   labeling	   with	   another	   marker,	   FFN102,	   which	   has	  previously	  been	  shown	  to	  label	  dopaminergic	  terminals	  in	  the	  dorsal	  striatum.	  	  (D)	  FFN102	  staining	  in	  the	  same	  frame.	  	  (E)	  APP+	  staining	  when	  loaded	  under	  the	  same	  conditions	   as	   above	   in	   the	   presence	   of	   FFN102.	   (F)	   Overlay	   of	   the	   two	   channels	  shows	   good	   colocalization	   of	   puncta	   (74.1	  ±	   6.9%,	  mean	  ±	   SD,	   n	   =	   3),	   confirming	  APP+	  as	  a	  marker	  for	  dopaminergic	  innervations	  in	  the	  dorsal	  striatum.	  	  Scale	  bars	  =	  5	  µm.	  	  Images	  are	  from	  collaboration	  with	  Matt	  Dunn.	  	  We	   next	   examined	   whether	   the	   good	   selectivity	   of	   APP+	   for	   DA	   axonal	  processes	  was	  DAT	  dependent.	  Preincubation	  of	   the	  slice	  with	  nomifensine	   (1	  μM,	  15	  min),	   followed	  by	  a	  15	  min	  coincubation	  of	  nomifensine	  (1	  µM)	  and	  APP+	  (100	  nM)	  under	  continuous	  perfusion	   in	  oxygenated	  ACSF	  reduced	  the	  number	  of	  APP+	  labeled	  puncta	  per	  image	  by	  2.3	  fold,	  from	  147.8	  ±	  1.4	  to	  61.4	  ±	  10.0	  (mean	  ±	  SD,	  n	  =	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3,	  Figure	  11C).	  Further,	  the	  staining	  pattern	  of	  the	  dorsal	  striatum	  was	  dramatically	  different	  under	  the	  DAT-­‐inhibition	  conditions	  compared	  to	  that	  of	  control	  slices;	  the	  remaining	   puncta	   were	   more	   heterogeneous	   in	   size	   and	   brightness,	   owing	   to	  formation	   of	   large	   bright	   puncta	   (Figure	   11A,B).	   These	   findings	   suggest	   that	  additional	  transporter	  systems	  are	  present	  in	  the	  dorsal	  striatum	  that	  may	  facilitate	  APP+	  uptake	  when	  DAT	  is	  inhibited.	  	  	  
	  	  
	  
Figure	   11:	   	   APP+	   uptake	   into	   dorsal	   striatum	   is	   inhibited	   with	   the	   DAT	   blocker	  nomifensine.	  	  (A)	  Nomifensine	  significantly	  reduces	  the	  mean	  number	  of	  puncta	  per	  frame	  from	  147.8	  ±	  1.4	  to	  61.4	  ±	  10.0	  (mean	  ±	  SD,	  significance	  determined	  by	  t-­‐test,	  p	   <	   0.001,	   n	   =	   3).	   (B)	   A	   representative	   image	   of	   APP+	   staining	   in	   mouse	   dorsal	  striatum	  (100	  nM,	  15	  min	  perfusion).	  	  (C)	  Pretreatment	  with	  nomifensine	  (1	  µM,	  15	  min)	   followed	  by	  cotreatment	  with	  APP+	  (100	  nM,	  15	  min	  perfusion)	  significantly	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reduces	  the	  number	  of	  stained	  puncta	  while	  changing	  the	  appearance	  of	  remaining	  structures.	  Scale	  bars	  =	  5	  µm.	  	  Images	  are	  from	  collaboration	  with	  Matt	  Dunn. 	   Indeed,	  inhibition	  of	  DAT	  with	  nomifensine	  afforded	  a	  dramatically	  different	  staining	   pattern	   with	   a	   smaller	   number	   of	   puncta	   (2.3	   fold)	   and	   greater	   relative	  proportion	  of	  large	  punctate	  structures	  (>2	  µm).	  Although	  the	  inhibition	  experiment	  supports	   the	   importance	   of	   DAT	   for	   uptake	   of	   APP+	   and	   formation	   of	   the	   fine	  punctate	  staining	  pattern	  (which	  is	  similar	  to	  that	  of	  TH-­‐GFP	  and	  FFN102	  signal),	  it	  also	   suggests	   the	   presence	   of	   other	   transporter	   systems	   capable	   of	   transporting	  APP+	   into	   different	   cellular	   structures.	   Consistent	   with	   this	   hypothesis	   are	   the	  observations	   in	   the	  midbrain	  (SN/VTA	  and	  LC),	  where	   in	  addition	  to	  cell	  bodies	  of	  catecholamine	   neurons	   other	   structures	   were	   labeled	   throughout	   the	   tissue	  surrounding	  the	  neurons.	  The	  staining	  of	  these	  unidentified	  punctate	  structures	  was	  not	  inhibited	  by	  nomifensine	  and	  was	  also	  present	  in	  the	  areas	  that	  do	  not	  contain	  catecholamine	  neurons.	  Relatedly,	  It	  has	  been	  reported	  that	  the	  endocytic	  dye	  FM4-­‐64	   was	   taken	   up	   by	   cortical	   astrocytes	   via	   store-­‐operated	   Ca2+	   entry	   (SOCE)	  channels.(49)	  It	  was	  also	  suggested	  by	  the	  authors	  of	  this	  paper	  that	  the	  background	  staining	  in	  the	  brain	  slice	  (observed	  with	  FM4-­‐64)	  might	  be	  due	  to	  astrocytic	  uptake	  occurring	  via	  these	  SOCE	  channels.	  	  As	  FM4-­‐64	  is	  considerably	  larger	  than	  APP+,	  it	  is	  possible	   that	   APP+	   is	   accumulated	   by	   a	   similar	   process.	   	   The	   organic	   cation	  transporters	   such	   as	   OCT3,	  which	   is	  widely	   expressed	   in	   the	   brain	   and	   shown	   to	  transport	  MPP+,(50,	  51)	  may	   also	   contribute	   to	   the	   extra-­‐catecholaminergic	   staining	  (See	  Chapter	  5	  for	  a	  thorough	  discussion	  of	  APP+	  at	  Uptake2	  transporters).	  Finally,	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APP+	  is	  also	  a	  substrate	  for	  SERT,(34,	  35)	  so	  it	  is	  likely	  that	  serotonergic	  structures	  are	  labeled.	  	  
	  
APP+	  is	  not	  a	  Fluorescent	  False	  Neurotransmitter	  
	  
	   Encouraged	   by	   the	   highly	   catecholaminergic	   label	   afforded	   by	   perfusion	   of	  acute	  mouse	  brain	  slice	  with	  sub-­‐micromolar	  concentrations	  of	  APP+,	  we	  set	  out	  to	  apply	   previously	   developed	   FFN	   releasing	   techniques	   to	   APP+.	   	   If	   APP+	   could	   be	  released,	   through	   exocytosis	   upon	   impulse	   by	   high	   concentrations	   of	   KCl	   or	  with	  direct	  electrical	  stimulation,	  it	  may	  serve	  as	  a	  functional	  “destaining”	  FFN	  specific	  to	  aminergic	  neurons.	  It	   is	  known	  that	  neuronal	  depolarization	  and	  subsequent	  exocytotic	  release	  of	  neurotransmitters	  can	  be	  induced	  in	  vitro	  by	  high	  potassium	  concentrations.	  	  We	  have	   previously	   shown	   that	   FFN102-­‐loaded	   presynaptic	   terminals	   in	   dorsal	  striatum	  were	  completely	  destained	  through	  the	  action	  of	  40	  mM	  KCl.(40)	  With	  APP+,	  however,	   we	   found	   that	   KCl	   only	   partially	   destained	   terminal	   fields	   compared	   to	  ACSF-­‐treated	  control	  (Fig.	  12).	  	  The	  analysis	  was	  accomplished	  by	  measuring	  mean	  fluorescence	  intensity	  of	  a	  field	  of	  background-­‐subtracted	  puncta,	  before	  and	  during	  KCl	   treatment,	   and	   comparing	   the	   results	   to	   those	   obtained	   with	   an	   untreated	  control.	   	   It	   is	   important	   to	   note	   that	   individual	   puncta	   could	   not	   be	   tracked	  throughout	   the	   course	   of	   this	   experiment	   due	   to	   the	   high	   degree	   of	   slice	  deformation	  upon	  KCl	  stimulation.	  We	  found	  that	  a	  mean	  APP+	  signal	  collected	  from	  all	   labeled	  structures	   is	   reduced	  by	  15.3	  ±	  2.5	  %	  after	  8	  minutes	  of	  KCl	   treatment	  (mean	  ±	  SD,	  n	  =	  3;	  (t-­‐test,	  p	  <	  0.05	  for	  t	  =	  1-­‐3	  min,	  p	  <	  0.01	  for	  t	  =	  4-­‐8	  min).	  These	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results	  show	  that	  under	  the	  conditions	  of	  prolonged	  depolarization	  and	  exocytosis,	  APP+	  is	  released	  from	  presynaptic	  terminals	  in	  a	  small	  but	  significant	  manner.	  This	  is	  consistent	  with	  previously	  reported	  release	  of	  MPP+	  under	  similar	  depolarization	  conditions.(52)	  We	  were	  not	   able	   to	   observe	   the	   released	  APP+	   in	   the	   extracellular	  space	   with	   two-­‐photon	   microscopy,	   most	   likely	   due	   to	   quenching	   of	   APP+	  fluorescence	   in	   aqueous	   media	   (Figure	   12).	   	   Due	   to	   the	   high	   degree	   of	   slice	  deformation	   upon	   KCl	   treatment,	   we	  were	   unable	   to	   track	   individual	   puncta	   and	  could	  not	  discern	  whether	  the	  loss	  of	  signal	  was	  due	  to	  a	  loss	  of	  a	  small	  amount	  of	  the	  label	  from	  each	  of	  the	  puncta	  or	  from	  a	  complete	  destaining	  of	  a	  subset	  of	  puncta	  (active	  synaptic	  zones	  vs.	  areas	  dense	  with	  mitochondria).	   	  To	  address	  this,	  we	  set	  out	   to	   pursue	   release	   studies	   using	   a	   milder	   and	   more	   physiologically	   relevant	  direct	  electrical	  stimulation	  of	  the	  dorsal	  striatum.	  
	  
Figure	   12:	   Treatment	   of	   APP+	   loaded	   dopaminergic	   axonal	   structures	   with	   KCl	  leads	  to	  a	  small	  but	  significant	  degree	  of	  destaining.	  (A)	  Dorsal	  striatal	  slices	  were	  loaded	   with	   APP+	   (100	   nM)	   and	   treated	   with	   a	   KCl	   (40	   mM)	   to	   induce	  depolarization	   and	   exocytosis.	   	   Images	   were	   collected	   every	   60	   seconds.	   APP+	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destaining	  was	  greatest	   at	  8	  min	  after	   application	  of	  KCl.	  Release	  was	   statistically	  significant	  after	  1	  min	  of	  KCl	  treatment	  compared	  to	  a	  control	   imaged	  without	  KCl	  (t-­‐test,	   p	   <	   0.05	   from	   t	   =	   1-­‐3	  min,	   p	   <	   0.01	   from	   t	   =	   4-­‐8	  min).	   (B)	  Representative	  image	  of	  APP+	  signal	  at	  t	  =	  0	  min.	  (C)	  Representative	  image	  of	  APP+	  signal	  at	  t	  =	  8	  min.	  	  Scale	  bars	  =	  5	  µm.	  Images	  are	  from	  collaboration	  with	  Matt	  Dunn.	  
	   Local	   electrical	   stimulation	   (application	   of	   electrical	   current)	   via	   a	   bipolar	  electrode	  induces	  neuronal	  depolarization	  and	  exocytosis,	  enables	  the	  control	  over	  the	  frequency	  and	  number	  of	  pulses	  applied	  to	  the	  brain	  region	  of	  interest,	  and	  is	  a	  less	  drastic	  means	  of	  inducing	  exocytotic	  release	  of	  vesicularized	  neurotransmitter	  or	   false	  neurotransmitter.	  Electrical	   stimulation	   leads	   to	   far	   less	   slice	  deformation	  and	   movement	   in	   comparison	   to	   KCl	   perfusion,	   and	   thus	   allows	   for	   measuring	  release	  kinetics	  of	  individual	  puncta.	  	  To	  study	  the	  effects	  of	  electrical	  stimulation	  on	  APP+	   in	   the	   dorsal	   striatum,	   we	   employed	   a	   method	   used	   routinely	   within	   our	  laboratories	   for	   determining	   kinetics	   of	   electrically-­‐stimulated	   FFN	   release,(40)	  which	   involved	   imaging	   z-­‐stacks	   at	   15	   second	   intervals.	   Under	   these	   conditions,	  photobleaching	   was	   a	   concern.	   It	   became	   apparent	   that	   photobleaching	   would	  obscure	  exocytotic	  destaining	  of	  puncta,	  as	  73	  ±	  25%	  of	  APP+	  signal	  was	  lost	  after	  application	   of	   the	   imaging	   sequence	   (controlled	   to	   slices	   imaged	   only	   at	   the	   start	  and	   end	   of	   the	   experiment;	  mean	  ±	   SD).	  We	   thus	   sampled	   a	   greater	   number	   of	   z	  sections	  throughout	  the	  experiment	  while	  exciting	  each	  area	  fewer	  times	  (once	  per	  minute),	  which	  effectively	  eliminated	  APP+	  photobleaching	  and	  allowed	  us	  to	  track	  puncta	   over	   6	   min	   of	   continuous	   electrical	   stimulation.	   This	   duration	   of	   10	   Hz	  stimulation	  was	  sufficient	  to	  observe	  the	  destaining	  of	  FFN102	  from	  DA	  presynaptic	  terminals,	  or	  the	  destaining	  of	  endocytic	  dye	  FM1-­‐43	  from	  excitatory	  inputs	   in	  the	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striatum.(53)	   Under	   these	   conditions,	   there	   was	   no	   significant	   decrease	   in	   the	  number	   of	   APP+	   puncta	   (ANOVA,	   p	   >	   0.05,	   n	   =	   3)	   (Figure	   13A).	   	   Relative	   to	   the	  number	   of	   puncta	   present	   at	   t	   =	   0,	   94.6	  ±	   11.8%	   of	   puncta	  were	   present	   after	   6	  minutes	  in	  control	  unstimulated	  slices,	  and	  86.7	  ±	  9.7%	  of	  puncta	  remained	  after	  6	  min	   of	   10	   Hz	   electrical	   stimulation	   (mean	   ±	   SD,	   n=3).	   	   Similarly,	   there	   was	   no	  statistical	  difference	  in	  puncta	  intensity	  at	  the	  final	  time	  point	  (unstimulated	  control	  intensity	  after	  6	  min	  =	  89.6	  ±	  9.2%;	  10	  Hz	  stimulation	  =	  91.6	  ±	  3.1%;	  mean	  ±	  SD,	  n	  =	  3,	   ANOVA,	   p	   >	   0.05)	   (Fig.	   13B).	   These	   data	   show	   that	   few	   if	   any	   APP+	   puncta	  underwent	  complete	  destaining	  and	  that	  an	  ensemble	  of	  puncta	  (100’s	  per	   image)	  did	   not	   undergo	   significant	   destaining	   under	   conditions	   of	   local	   electrical	  stimulation.	  We	  thus	  conclude	  that	  the	  binding	  of	  APP+	  to	  mitochondria	  and	  other	  cellular	   compartments	   within	   the	   DA	   synaptic	   terminals	   and	   axonal	   processes	  creates	   a	   non-­‐releasable	   fluorescent	   background	   signal	   that	   overwhelms	   the	  releasable	   signal	   and	   thus	   limits	   the	   dynamic	   range	   of	   the	   APP+	   destaining	  measurement.	  These	  results	  indicate	  that	  only	  a	  small	  portion	  of	  the	  fluorescence	  signal	  of	  APP+	  originates	   from	   the	   releasable	   synaptic	   vesicular	  pool,	  while	   the	  majority	   of	  the	  APP+	   signal	   is	   derived	   from	  an	   intracellular	  mixture	  of	   labeled	  non-­‐exocytotic	  compartments	   and	   cellular	   structures	   including	   mitochondria.	   Since	   APP+	   is	  quenched	   in	   aqueous	   environments,	   these	   results	   from	   acute	   mouse	   brain	   slice	  preparations	   indicate	   that	   APP+	   is	   not	   a	   sufficiently	   strong	   VMAT2	   substrate	   to	  become	   entirely	   sequestered	   in	   synaptic	   vesicles.	   	  Our	   findings	   appear	   similar	   to	  those	   obtained	  with	   the	   antihypotensive	   agent	   amezinium	   (4-­‐amino-­‐6-­‐methoxy-­‐1-­‐
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phenyl-­‐pyridazinium	  salt)	  reported	  by	  others.(54)	  This	  pyridinium	  analog	  of	  similar	  size	  and	  shape	  to	  APP+	  was	  taken	  up	  by	  noradrenergic	  terminals	  via	  NET	  in	  the	  rat	  occipital	   cortex	   (which	   receives	   noradrenergic	   inputs	   from	   the	  LC),	   although	  only	  ~1%	   of	   the	   total	   [3H]-­‐amezinium	   tissue	   content	   was	   released	   on	   electrical	  stimulation	   of	   the	   brain	   slice.	   	   These	   results	   indicate	   that	   only	   a	   small	   portion	   of	  amezinium	  is	  taken	  up	  by	  synaptic	  vesicles	  and	  thus	  releasable	  by	  exocytosis.	  	  Our	  data	   indicate	   that	  APP+	   is	  not	   a	  promising	   candidate	   for	  use	   in	  kinetic	  measurements	  of	  individual	  presynaptic	  terminals	  and	  thus	  is	  not	  a	  promising	  lead	  for	  development	  of	  catecholaminergic	  FFNs.	  	  However,	  the	  structural	  and	  behavioral	  similarities	   of	   APP+	   to	   the	   mitochondrial	   potential	   probe	   2-­‐(4-­‐(dimethylamino)styryl)-­‐1-­‐methylpyridiniumiodide	   DASPMI(19)	   may	   facilitate	   the	  selective	  study	  of	  mitochondrial	  function	  of	  catecholamine	  neurons	  in	  brain	  tissue.	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Acute	  Toxicity	  Does	  Not	  Perturb	  DAT	  Activity	  Within	  1	  hour	  	  	   To	   study	   whether	   acute	   toxicity	   has	   a	   significant	   effect	   on	   the	   ability	   of	  dopaminergic	  somata	  in	  the	  SN	  to	  load	  FFN102	  after	  preloading	  with	  APP+.	  	  After	  a	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30	  minute	  loading	  of	  500nM	  APP+	  followed	  by	  a	  15	  minute	  wash	  (45	  minute	  total	  treatment),	   APP+-­‐labeled	   somata	   of	   the	   SN/VTA	  were	   capable	   of	   loading	   FFN102	  under	   previously-­‐reported	   conditions(40)	   with	   imperceptible	   effects	   on	   FFN102	  loading	   (Figure	   14,	   n	   =	   2	   independent	   experiments).	   While	   APP+	   is	   a	   likely	  neurotoxin	  similar	  to	  MPP+,	  this	  result	  suggests	  that	  acute	  toxicity	  is	  insufficient	  to	  perturb	  DAT	   activity.	   	   This	   also	   suggests	   that	  APP+	  may	  have	  utility	   as	   a	   labeling	  control	   for	  catecholamine	  neurons,	  as	   the	  neurons	  are	  still	  competent	  to	  carry	  out	  basic	   functions	   in	   the	  presence	  of	   the	  APP+	   label	  within	  at	   least	   an	  hour	  of	   initial	  treatment.	   	  This	  also	   suggests	   that	   toxicity	   is	  not	  directly	   responsible	   for	   the	  non-­‐releasable	  APP+	  labeling	  characteristics	  observed	  above.	  	  
	  
Figure	   14:	   Application	   of	   APP+	   to	   SN/VTA	   regions	   of	   the	   midbrain	   has	   no	  perceptible	  effect	  on	  subsequent	  FFN102	  labeling.	  	  SN/VTA	  slices	  were	  loaded	  with	  APP+	  (500	  nM,	  30	  min,	  washed	  for	  15	  min,	  and	  treated	  with	  FFN102	  as	  described	  previously.(40)	  No	  changes	   in	   the	  uptake	  of	  FFN102	  were	  noted.	  This	  suggests	   that	  non-­‐TH-­‐GFP	  positive	  staining	  caused	  by	  this	  concentration	  of	  APP+	  in	  the	  midbrain	  is	  not	  likely	  an	  effect	  of	  toxicity	  of	  APP+	  in	  the	  time	  frame	  of	  the	  experiment.	  Scale	  bar	  =	  20	  µm.	  	  Images	  are	  from	  collaboration	  with	  Matt	  Dunn.	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III:	  	  Conclusions	  and	  Outlook	  	   In	   this	   study,	   we	   investigated	   the	   behavior	   of	   APP+,	   a	   small,	   fluorescent	  analog	  of	  MPP+,	  specifically	   for	   the	  purpose	  of	  examining	  pyridiniums	  as	  potential	  FFNs.	   	   Intrigued	   by	   the	   known	   substrate	   activity	   of	   APP+	   at	   plasma	   membrane	  transporters	  DAT,	  NET,	  and	   SERT,	   (and	   later	  VMAT)	  we	  were	   curious	   to	   test	  APP+	  staining	   characteristics	   in	   selected	   areas	   of	   the	   acute	   mouse	   brain	   tissue,	   with	  results	   from	   photophysical	   investigations	   and	   secondary-­‐cell	   based	   systems	  providing	  rationale	  for	  the	  explanation	  of	  APP+	  behavior	  in	  brain	  tissue.	  	  As	  a	  DAT	  and	  NET	  substrate,	  APP+	  labels	  catecholamine	  neuronal	  cell	  bodies	  with	   high	   selectivity	   in	   the	   relevant	   midbrain	   regions,	   namely	   SN/VTA	   and	   LC.	  Although	  the	  dendritic	  processes	  are	  largely	  obscured	  by	  the	  punctate	  staining	  that	  is	   DAT	   or	   NET-­‐independent,	   the	   somata	   of	   catecholamine	   neurons	   can	   readily	   be	  identified.	   Thus,	   APP+	   can	   be	   used	   as	   a	   marker	   of	   catecholamine	   neurons	   in	   the	  absence	  of	   additional	   fluorescent	  markers	   such	  as	   the	  GFP	   signal	   in	  TH-­‐GFP	  mice.	  APP+	  also	  enables	  examination	  of	  the	  DAT	  and	  NET	  function	  in	  these	  neurons	  in	  the	  native	  context	  of	  the	  living	  brain	  tissue.	  Because	  we	  lacked	  a	  reliable	  positive	  control	  for	   serotonergic	   innervation,	   we	  were	   unable	   to	   investigate	   serotonergic	   labeling,	  although	  reported	  substrate	  activity	  of	  APP+	  at	  SERT	  suggests	  that	  it	  would	  behave	  similarly	  in	  regions	  of	  the	  brain	  innervated	  with	  serotonergic	  neurons.	  	  Since	  APP+	  labels	   mitochondria	   inside	   the	   cells,	   it	   may	   therefore	   be	   envisioned	   that	   if	   the	  mitochondrial	   accumulation	   of	   the	   dye	   is	   dependent	   on	   the	   mitochondrial	  membrane	  potential,	  APP+	  may	  serve	  as	  a	  catecholamine-­‐neuron	  selective	  reporter	  of	  mitochondrial	  function.	  
	   161	  
We	  have	   also	   shown	   that	  APP+	   serves	  as	  a	  marker	   of	   dopaminergic	   axonal	  processes	  and	  presynaptic	  terminals	   in	  the	  dorsal	  striatum	  (75-­‐80%	  colocalization	  with	  GFP	   in	  TH-­‐GFP	  mice	   and	   FFN102	   in	  wild	   type	  mice)	   that	   is	   largely	   stable	   to	  exocytotic	   conditions.	   It	   was	   found	   that	   only	   a	   small	   degree	   of	   signal	   destaining	  occurs	  (<15%)	  when	  depolarization	  is	  induced	  by	  KCl	  or	  electrical	  stimulation.	  This	  can	  be	  attributed	   to	   low	  uptake	  of	  APP+	  by	  synaptic	  vesicles	  and/or	  quenching	  of	  the	  fluorescence	  signal	  in	  the	  vesicular	  lumen	  relative	  to	  a	  bright,	  mitochondrial	  or	  protein-­‐bound	  population.	  These	  results	  are	  consistent	  with	  results	  from	  secondary	  cells	   expressing	   VMAT2,	   and	   suggest	   that	   APP+	   is	   not	   readily	   adaptable	   for	  quantitative	   imaging	   of	   exocytosis	   and	   neurotransmitter	   secretion	   under	   these	  conditions,	  and	  thus	  is	  not	  well	  suited	  for	  the	  development	  of	  new	  FFNs.   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   162	  
IV:	  	  Experimental	  	  
	  	  




	   	  	   Unless	   otherwise	   noted,	   all	   chemicals	   were	   purchased	   from	   Sigma-­‐Aldrich	  and	  were	  used	  without	   further	  purification.	   	  When	  necessary,	   solvents	  were	  dried	  by	  passing	  them	  through	  a	  column	  of	  alumina	  under	  argon.	  	  Flash	  chromatography	  was	   performed	   on	   SILICYCLE	   silica	   gel	   (230-­‐400	   mesh).	   	   Nuclear	   Magnetic	  Resonance	   spectra	   were	   recorded	   at	   300K	   on	   Bruker	   300	   or	   400	   MHz	   Fourier	  transform	  NMR	   spectrometers.	   	   Proton	   chemical	   shifts	   are	   expressed	   in	   parts	   per	  million	  (ppm,	  δ	  scale)	  and	  referenced	  to	  residual	  protium	  in	  the	  NMR	  solvent	  (CDCl3,	  δ	   7.26;	   CD3OD,	   δ	   3.30).	   	   Data	   for	   1H	  NMR	   are	   reported	   as	   follows:	   chemical	   shift,	  integration,	  multiplicity	  (s	  =	  singlet,	  d	  =	  doublet,	  t	  =	  triplet,	  m	  =	  multiplet,	  bs	  =	  broad	  singlet),	  and	  coupling	  constant	  in	  Hertz	  (Hz).	  	  Carbon	  chemical	  shifts	  are	  expressed	  in	  parts	  per	  million	  (ppm,	  δ	  scale)	  and	  are	  referenced	  to	  the	  carbon	  resonance	  of	  the	  NMR	  solvent	  (CDCl3,	  δ	  77.0;	  CD3OD,	  δ	  49.0).	  	  Mass	  spectra	  were	  recorded	  on	  a	  JOEL	  LCmate	  (ionization	  mode:	  APCI+).	  	  	  
	  
Preparation	  of	  APP+	  Iodide:	  The	  structure	  and	  synthesis	  of	  APP+	  iodide	  has	  previously	  been	  reported,(34,	  
41,	  42)	  and	   all	   data	   including	   1H	  NMR	   data	   for	   intermediate	  1	   and	   APP+	   Iodide	   are	  consistent	  with	  previous	  reports	  (see	  below).	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Intermediate	  1	  To	   a	   mixture	   of	   4-­‐bromopyridine	   HCl	   (0.21	   g,	   1.03	   mmol),	   4-­‐(dimethylamino)phenylboronic	  acid	  pinacol	  ester	  (169.9	  mg,	  1.09	  mmol),	  and	   cesium	   carbonate	   (0.99	   g,	   3.04	  mmol)	   in	   tetrahydrofuran	   (THF,	   0.5	  mL)	   and	   dimethylformamide	   (DMF,	   1.5	   mL)	   was	   added	   palladium	   (II)	  acetate	  (0.014	  g,	  5	  mol%)	  and	  tricyclohexylphosphine	  tetrafluoroborate	  (0.046	  g,	  10	  mol%).	  	  The	  reaction	  mixture	  was	  refluxed	  overnight,	  after	  which	  time	  the	  reaction	  mixture	  was	  filtered	  through	  a	  celite	  plug	  and	  concentrated.	  	  The	  crude	  product	  was	  purified	   by	   flash	   chromatography	   (silica,	   CH2Cl2:methanol	   =	   99:1	  →	   95:5)	   to	   give	  compound	  1	  as	  a	  tan	  solid	  (31%).	  	  1H	  NMR	  (400	  MHz,	  Chloroform-­‐d):	  δ	  8.56	  (d,	  J	  =	  4.9	  Hz,	  2H),	  7.61	  –	  7.55	  (m,	  2H),	  7.46	  (dd,	  J	  =	  4.7,	  1.5	  Hz,	  2H),	  6.82	  –	  6.76	  (m,	  2H),	  3.02	  (s,	  6H).	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Methanol-­‐d4)	  δ	  8.55	  (d,	  J	  =	  7.1	  Hz,	  2H),	  8.17	  (d,	  J	  =	  7.2	  Hz,	  2H),	  7.94	  (d,	  J	  =	  9.2	  Hz,	  2H),	  6.90	  (d,	  J	  =	  9.2	  Hz,	  2H),	  4.24	  (s,	  3H),	  3.12	  (s,	  6H).	  	  LRMS	  (APCI+,	  M	  –	  CH3):	  Calc’d	  for	  C13H14N2	  198.26	  m/z,	  measured	  199.21	  (MH+)	  	  
	  
B.	  	  Photophysical	  Characterization	  of	  RJK150	  and	  APP	  Iodide	  
General	  Ultraviolet	   absorption	   spectra	   were	   measured	   on	   a	   BioTek	   H1MF	   plate	  reader/spectrophotometer	   operated	   through	   Gen5	   Data	   Collection	   and	   Analysis	  software.	  	  Fluorescence	  measurements	  (emission/excitation)	  were	  carried	  out	  on	  a	  Jobin	  Yvon	  Fluorolog	  3	  fluorescence	  spectrofluorometer.	  	  
Absorption	  
	  UV	  absorption	  spectra	  were	  taken	  by	  adding	  APP+	  (2µL	  of	  10	  mM	  stock	  solution	  in	  DMSO)	  to	  998µL	  of	  PBS	  buffer,	  DMSO,	  ethanol,	  or	  CHCl3	  (final	  probe	  concentration	  =	  20	  µM)	  in	  a	  quartz	  cuvette.	  	  	  	  
Emission/Excitation	  
	  Fluorescence	  Emission/Excitation	  spectra	  were	  taken	  by	  adding	  APP+	  (2µL	  of	  1	  mM	  stock	  solution	  in	  DMSO)	  to	  998µL	  of	  PBS	  buffer	  or	  CHCl3	  (final	  probe	  concentration	  =	  2	  µM)	  in	  a	  quartz	  cuvette.	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D.	  	  Cell	  Culture	  Studies	  
	  
Epifluorescence	  Microscopy	   in	   hDAT-­‐EM4	   and	   EM4	   cells.	   	  An	  EM4	   cell	  line	  stably	  expressing	  hDAT	  (hDAT-­‐EM4)	  and	  an	  empty	  vector-­‐transfected	  EM4	  cell	  line	   to	  serve	  as	  a	  control	  were	  kindly	  provided	  by	  Drs.	   Jonathan	   Javitch	  and	  Mark	  Sonders	   of	   the	   Department	   of	   Psychiatry	   at	   Columbia	   University	   Medical	   Center.	  	  Cells	  were	  grown	  in	  DMEM	  +	  Glutamax	  (Invitrogen)	  with	  10%	  Fetal	  Bovine	  Serum	  (FBS)	   (Atlanta	   Biologicals),	   100	   U/mL	   penicillin	   (Invitrogen),	   and	   100	   µg/mL	  streptomycin	   (Invitrogen).	   	   For	   fluorescence	   microscopy	   experiments,	   cells	   were	  plated	  on	  poly-­‐D-­‐lysine	  (Sigma-­‐Aldrich,	  0.1	  mg/mL)	  coated	  six-­‐well	  plates	  (Falcon)	  at	   a	   density	   of	   100,000	   cells/well	   and	  were	   incubated	  until	   confluence	   (4	   days	   at	  37˚C	   in	   a	   humidified	   atmosphere	   containing	   5%	   CO2).	   	   The	   medium	   was	   then	  removed	  by	  aspiration	  and	  wells	  were	  carefully	  washed	  with	  PBS	  (2	  mL/well).	  	  Cells	  were	   then	   treated	  with	  900µL	  of	   experimental	  medium	  (DMEM	  minus	  phenol	   red	  containing	  25	  mM	  HEPES	  (Invitrogen)	  with	  1%	  FBS	  (Atlanta	  Biologicals))	  for	  3h.	  	  To	  investigate	   intracellular	   localization	   of	   APP+,	   solutions	   of	   APP+	   (20	   µM),	  Mitotracker	   Deep	   Red	   (200	   nM)	   (Invitrogen),	   or	   a	   mixture	   of	   both	   in	   100	   µL	  experimental	  medium	  (all	  prepared	   from	  stock	  solutions	   in	  DMSO)	  were	  added	   to	  wells	   for	   final	   concentrations	   of	   2	   µM	   APP+	   and	   20	   nM	   mitotracker	   in	   mL	   of	  experimental	  medium.	  	  After	  incubating	  at	  37˚C	  for	  10	  minutes,	  images	  were	  taken	  using	   a	   Leica	   DMI	   4000B	   inverted	   epifluorescence	   microscope	   equipped	   with	   a	  Leica	  DFC	  360	  FX	  digital	  camera	  controlled	  through	  Leica	  LAS	  AF	  6000E	  software.	  	  Bright	   field	   and	   fluorescence	   images	   were	   acquired	   sequentially	   (BF	   acquisition	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time	  =	  37	  ms).	   	  Fluorescence	   images	  were	  acquired	  using	   filter	   cubes	   (APP+,	  ex	  =	  440	  ±	  25	  nm,	  em	  =	  550	  ±	  25	  nm,	  500	  ms	  acquisition	  time;	  Mitotracker	  Deep	  Red,	  ex	  =	  580	  ±	  20	  nm,	  em	  =	  660	  ±	  25	  nm,	  500	  msec	  acquisition	  time).	  	  Using	  these	  filters,	  no	   crosstalk	  was	  observed	  between	   fluorophores.	   	  All	   images	  of	   each	   fluorophore	  were	  adjusted	  to	  the	  same	  brightness	  and	  contrast	  level,	  respectively,	  using	  ImageJ	  (National	  Institutes	  of	  Health).	  
	  
Epifluorescence	  Microscopy	  in	  VMAT2-­‐HEK	  and	  TetR-­‐HEK	  cells.	  	   A	   HEK	   cell	   line	   stably	   expressing	   rVMAT2	   (VMAT2-­‐HEK)	   and	   an	   empty	  vector-­‐transfected	   HEK	   cell	   line	   to	   serve	   as	   a	   control	   (TetR-­‐HEK)	   were	   kindly	  provided	   by	   Professor	   Robert	   Edwards	   of	   the	   Department	   of	   Neurology	   at	   the	  University	   of	   California	   San	   Francisco	   (UCSF).	   	   Cells	   were	   grown	   in	   DMEM	   +	  Glutamax	   (Invitrogen)	   with	   10%	   Fetal	   Bovine	   Serum	   (FBS)	   (Atlanta	   Biologicals),	  100	  U/mL	  penicillin	   (Invitrogen),	   and	   100	   µg/mL	   streptomycin	   (Invitrogen).	   	   For	  fluorescence	   microscopy	   experiments,	   cells	   were	   plated	   on	   poly-­‐D-­‐lysine	   (Sigma-­‐Aldrich,	   0.1	   mg/mL)	   coated	   six-­‐well	   plates	   (Falcon)	   at	   a	   density	   of	   100,000	  cells/well	   and	   were	   incubated	   until	   confluence	   (4	   days	   at	   37˚C	   in	   a	   humidified	  atmosphere	  containing	  5%	  CO2).	  	  The	  medium	  was	  then	  removed	  by	  aspiration	  and	  wells	  were	   carefully	  washed	  with	  PBS	   (2	  mL/well).	   	   Cells	  were	   then	   treated	  with	  900µL	  of	  experimental	  medium	  (DMEM	  minus	  phenol	  red	  containing	  25	  mM	  HEPES	  (Invitrogen)	  with	  1%	  FBS	   (Atlanta	  Biologicals))	   for	  1-­‐3h.	   	   Cells	  were	   then	   treated	  with	  2	  µM	  APP+	  for	  50	  minutes	  followed	  by	  addition	  of	  Mitotracker	  Deep	  Red	  for	  a	  final	   concentration	   of	   50nM	   Mitotracker	   Deep	   Red.	   	   Cells	   were	   incubated	   for	   an	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additional	   ten	   minutes	   before	   images	   were	   acquired	   in	   presence	   of	   both	   dyes.	  	  Brightfield	   and	   fluorescence	   images	   were	   acquired	   as	   described	   above,	   with	  sequential	  exposures	  using	  filter	  sets	  optimized	  for	  each	  fluorophore	  (as	  described	  above	   for	   APP+	   and	   Mitotracker	   Deep	   Red).	   	   Controls	   indicated	   that	   crosstalk	  between	  fluorophores	  in	  the	  different	  filter	  sets	  was	  negligible.	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I:	  Introduction	  
	  
The	  Uptake2	  System	  
	   Regulation	   of	   the	   synaptic	  and	   extrasynaptic	   concentrations	  of	  monoamine	  neurotransmitters	  is	  essential	  to	  proper	  function	  of	  the	  central	  nervous	  system,	  and	  perturbations	   of	   this	   homeostasis	   have	   been	   implicated	   in	   a	   number	   of	  neuropsychiatric	   disorders.	   	   While	   the	   transporters	   principally	   responsible	   for	  clearing	   the	  extracellular	  milieu	  of	  monoamine	  neurotransmitters	   are	   the	  Na+	  and	  Cl-­‐	   dependent,	   high	   affinity	   members	   of	   the	   SCL6A	   family	   of	   monoamine	  transporters	   (MATs:	  DAT/NET/SERT,	   collectively	   referred	   to	   here	   as	   the	   Uptake1	  system),	   there	   also	   exists	   a	   secondary	   system	   of	   low	   affinity,	   high	   capacity	  transporters	  known	  as	  the	  Uptake2	  system.	  	  These	  transporters	  include	  the	  Plasma	  Membrane	  Monoamine	  Transporter	   (PMAT)	  and	   the	  Organic	  Cation	  Transporter	  3	  (OCT3),	   both	   of	  which	   are	   expressed	  widely	   in	   the	   brain.(1,	  2)	   	   	  These	   transporters	  have	  garnered	   interest	   recently	  due	   to	   their	   ability	   to	   translocate	  monoamines.	   	  A	  detailed	   study	   comparing	   the	   substrate	   scope	   of	   hOCT3	   and	   hPMAT	  was	   recently	  reported	  by	  the	  Wang	  laboratory	  at	  the	  University	  of	  Washington,	  and	  the	  results	  are	  reproduced	  in	  Table	  1	  (hOCT3)	  and	  Table	  2	  (hPMAT)	  below.	  
Table	  1:	  	  hOCT3	  Substrate	  Efficiencies	  






MPP+ 166+11 15,664 ± 821 94.7 ± 1.1 100% 
TEA 921+161 2,760 ± 92 3.03 ± 0.43 3.2% 
Dopamine 1033+127 22,676 ± 484 22.1 ± 3.2 23% 
Serotonin 988+264 11,562 ± 3,109 11.7 ± 0.2 12% 
Norepinephrine 923+172 30,134 ± 2,674 32.9 ± 1.3 35% 
Epinephrine 458+37 12,760 ± 605 28.0 ± 3.6 30% 
Histamine 641+24 34,604 ± 47 54.0 ± 2.1 57% The	  Michaelis-­‐Menten	  constants	  (Km),	  maximum	  uptake	  rates	  (Vmax),	  and	  specificity	  constants	  (Vmax/Km)	  of	  different	  substrates	  for	  hOCT3,	  as	  well	  as	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the	  percentage	  of	  substrate	  efficiency	  compared	  to	  MPP+.	  (Reproduced	  from	  Duan	  and	  Wang	  2010)	  (3)	  	  
Table	  2:	  hPMAT	  Substrate	  Efficiencies	  






MPP+ 111 ± 3 6,557 ± 942 59.2 ± 10.0 100% 
TEA 8,759 ± 3,175 15,246 ± 3,023 1.79 ± 0.30 3.0% 
Dopamine 406 ± 4 22,402 ± 3,166 55.1 ± 1.3 93% 
Serotonin 283 ± 40 14,194 ± 2,381 50.1 ± 1.4 85% 
Norepinephrine 1,078 ± 107 8,822 ± 1,323 8.16 ± 0.41 14% 
Epinephrine 951 ± 59 7,252 ± 195 7.65 ± 0.68 13% 
Histamine 4,379 ± 679 42,374 ± 4,098 9.72 ± 0.57 16% The	  Michaelis-­‐Menten	  constants	  (Km),	  maximum	  uptake	  rates	  (Vmax),	  and	  specificity	  constants	  (Vmax/Km)	  of	  different	  substrates	  for	  hPMAT,	  as	  well	  as	  the	  percentage	  of	  substrate	  efficiency	  compared	  to	  MPP+.	  (Reproduced	  from	  Duan	  and	  Wang	  2010).(3)	  	  	  	  	  	  
Uptake2	  System	  and	  its	  Relevance	  in	  CNS	  Disease	  There	   is	   emerging	   evidence	   implicating	   low	   affinity,	   high	   capacity	  transporters	   of	   the	   Uptake2	   system	   as	   potential	   contributors	   to	   monoamine	  clearance	   from	   the	   extracellular	   space	   under	   certain	   circumstances.(3-­‐6).	   For	  example,	   it	   has	   been	   found	   that	   expression	   of	   OCT3	   is	   upregulated	  when	   SERT	   is	  knocked	   out,(7)	   and	   that	   this	   upregulation	   has	   a	   compensatory	   effect	   on	   5HT	  clearance	  from	  SERT	  deficient	  mice.(4)	  It	  has	  thus	  been	  suggested	  that	  OCT3	  can	  act	  as	   a	   compensatory	   uptake	   mechanism	   for	   5HT	   when	   SERT	   activity	   is	   reduced.(8)	  	  Additionally,	   mice	   lacking	   OCT3	   have	   less	   anxiety	   than	   wild	   type	   littermates.(9)	  	  Interestingly,	  PMAT	  has	  been	  shown	  to	  transport	  DA	  and	  5HT	  more	  efficiently	  than	  OCT3,	   while	   OCT3	   transports	   norepinephrine	   more	   efficiently.(3)	   In	   fact,	   studies	  using	  a	  brain	  synaptosome	  uptake	  assay	  and	  in	  vitro	  hybrid	  depletion	  analysis	  have	  estimated	  that	  PMAT	  may	  contribute	  up	  to	  20-­‐30%	  of	  total	  brain	  5HT	  uptake	  under	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normal	   conditions.(3,	   10)	   	   Importantly,	   both	   PMAT	   and	   OCT3	   are	   not	   inhibited	   by	  currently	   prescribed	   antidepressants	   such	   as	   the	   selective	   serotonin	   reuptake	  inhibitors	   (SSRIs).(10)	   Thus,	   it	   is	   possible	   that	   OCT	   and	   PMAT	   may	   be	  pharmacologically	   relevant	   in	   a	  number	  of	   neuropsychiatric	   disorders;	   potent	   and	  selective	  inhibitors	  of	  these	  transporters	  may	  constitute	  an	  augmentation	  therapy	  to	  SSRIs	  in	  cases	  of	  drug	  inefficacy.(6)	  
	  
Figure	   1:	   	   A	   possible	   example	   of	   the	   relationship	   between	   high-­‐affinity	  reuptake	   transporters	   (MATs,	   Uptake1	   system)	   and	   low-­‐affinity	   transporters	  (Uptake2	   system),	   shown	   in	   the	   hippocampus.	   	   5HT	   (black	   dots)	   is	   released	   from	  serotonergic	  neurons	  and	  modulates	  the	  activity	  of	  fast	  synapses.	  It	  has	  been	  shown	  that	  transporters	  of	  the	  Uptake2	  system	  (OCT3	  in	  red,	  PMAT	  in	  blue)	  can	  contribute	  to	  the	  clearance	  of	  monoamines	  escaped	  from	  the	  synapse,	  and	  may	  compensate	  for	  diminished	  Uptake1	  activity	  (SERT,	  depicted	  in	  green).	  	  
Uptake2	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cells	   in	   a	   manner	   not	   entirely	   dependent	   on	   VMAT2	   or	   DAT/NET/SERT.	   	   This	  information	   is	   important	  when	   interpreting	  FFN	  results	   from	  the	  brain.	   	   Second,	  a	  FFN	  or	  FFN-­‐like	  Uptake2	  substrate	  could	  prove	  useful	  in	  the	  study	  of	  OCT3	  and/or	  PMAT	  activity	  and	  distribution	   in	  brain	   tissue.	   	  Given	   the	  potential	   involvement	  of	  these	   transporters	   in	   disease	   or	   drug	   treatment	   inefficacy	   as	   discussed	   above,	   a	  selective	   OCT3	   or	   PMAT	   FFN	   (or	   fluorescent	   FFN-­‐like	   substrate)	   could	   be	  advantageous	   to	   the	   study	   of	   these	   transporters	   as	   alternative	   means	   to	   clear	  monoamines	   from	   the	  extracellular	  milieu	  or	   to	   load	  VMAT2-­‐expressing	   cells	  with	  neurotransmitters.	  	  Third,	  a	  well-­‐characterized	  fluorescent	  substrate	  of	  the	  Uptake2	  transporters	  could	  serve	  as	  a	  tool	  for	  the	  pharmacological	  study	  of	  OCT3	  or	  PMAT	  as	  a	   fluorescence-­‐based	   alternative	   to	   radiolabeled	   substrates.	   	  As	   part	   of	   our	   broad	  FFN	  program,	  we	  therefore	  became	  interested	  in	   identifying	  fluorescent	  substrates	  for	  OCT3	  and	  PMAT.	  	  	  A	   fluorescent	   analog	   of	   MPP+,	   4-­‐(4-­‐(dimethylamino)phenyl)-­‐1-­‐methylpyridinium	   (ASP+),	   has	   previously	   been	   identified	   as	   substrate	   of	  Uptake2,	  and	  has	  been	  widely	  used	  to	  study	  OCT3	  expression	  and	  pharmacology.	  (11-­‐13)	  ASP+	  was	   also	   used	   as	   the	   first	   fluorescent	   substrate	   for	   study	   of	   high	   affinity	   plasma	  membrane	   monoamine	   neurotransmitter	   transporters	   DAT,	   NET,	   and	   SERT	   (see	  Chapters	   3	   and	   4).(14)	   	   More	   recently,	   a	   smaller	   pyridinium	   analog,	   APP+,	   was	  developed	   to	   overcome	   a	   number	   of	   drawbacks	   inherent	   to	   ASP+;	   it	   is	   a	   superior	  SERT	   substrate	  by	   comparison	   to	  ASP+,	   and	   it	   displays	   less	  background	  uptake	   in	  cell	  culture.(15,	  16)	   	  Although	  APP+	  has	  been	  suggested	  to	  be	  a	  substrate	  for	  Uptake2	  system,(15)	  characterization	  of	   its	  substrate	  activity	  at	  these	  transporters	  has	  yet	  to	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be	  reported.	  	  As	  part	  of	  a	  broad	  program	  aimed	  at	  imaging	  neurotransmission	  with	  fluorescent	   substrates	   of	   solute	   carriers	   in	   the	  brain,	  we	  became	   interested	   in	   the	  scope	  of	  the	  utility	  of	  this	  compound.(17)	  Since	  APP+	  is	  a	  small	  fluorescent	  analog	  of	  the	   Uptake2	   substrate	   MPP+,	   we	   were	   especially	   curious	   to	   test	   the	   substrate	  activity	  of	  APP+	  in	  cultured	  cells	  stably	  expressing	  hOCT3	  or	  hPMAT.	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II:	  	  Results	  and	  Discussion	  	  
Screening	  of	  FFNs	  and	  Related	  Probes	  as	  Possible	  Substrates	  for	  Uptake2	  	   A	   number	   of	   FFNs	   and	   FFN-­‐like	   fluorescent	   probes	   were	   screened	   for	  substrate	  activity	  at	  hOCT3	  and	  hPMAT	  by	  using	   isogenic	  Flp-­‐HEK	  cells	  developed	  by	   the	  Wang	   lab.(3)	   	  A	   number	   of	   FFNs	   and	   FFN-­‐like	   fluorescent	   compounds	  were	  screened	   for	  hOCT3	  and	  hPMAT-­‐dependent	  accumulation	   in	   transfected	  HEK	  cells	  (Flp-­‐HEK	  transfected	  with	  hOCT3,	  hPMAT,	  or	  a	  pcDNA	  empty	  vector).	  	  The	  screened	  compounds	   were	   primarily	   produced	   within	   the	   Sames	   Lab	   as	   potential	   FFNs	   or	  related	   fluorescent	  probes,	   and	  were	   selected	   for	   this	   study	  based	  on	   a	   variety	   of	  factors:	   low	   lipophilicity,	   acceptable	   photostability	   (as	   determined	   by	   previous	  studies),	  some	  were	  known	  Uptake1	  or	  VMAT2	  substrates	  (previous	  studies),(18-­‐20)	  some	  were	  known	  specifically	  not	  to	  be	  Uptake1	  or	  VMAT2	  substrates,	  and	  others	  were	  included	  based	  on	  similarities	  to	  known	  Uptake2	  substrates.	  	  	  The	   screen	   uncovered	   a	   variety	   of	   different	   behaviors	   of	   the	   various	  compounds,	  and	  representative	  results	  are	  shown	  (Figure	  2,	  Figure	  3).	  	  The	  results	  of	   this	   screen	   have	   been	   compiled	   qualitatively	   and	   are	   indicated	   in	  Table	   3	   (7-­‐hydroxycoumarins),	  Table	   4	   (7-­‐aminocoumarins),	   and	  Table	   5	   (pyridiniums	   and	  other	  motifs).	  	  Each	  compound	  was	  screened	  at	  the	  same	  concentration	  and	  over	  the	  same	  time	  period	  in	  hOCT3-­‐HEK,	  hPMAT-­‐HEK,	  and	  pcDNA-­‐HEK	  (serving	  as	  a	  control	  for	   passive	   diffusion/background	   uptake),	   and	   substrate	   activity	   was	   initially	  determined	   by	   comparing	   transporter-­‐dependent	   accumulation	   of	   the	   compound	  with	   background	   staining	   on	   an	   epifluorescence	   microscope	   with	   excitation	   and	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emission	  wavelengths	  filtered	  appropriately	  for	  each	  fluorophore	  (see	  Figure	  3	  for	  representative	  images).	  	  	  	  
	  	  
Figure	   2.	   	   	   Representative	   images	   of	   some	   FFNs	   and	   FFN-­‐related	   probes	   in	   cells	  transfected	   with	   pcDNA	   (empty	   vector	   control,	   left	   column),	   hOCT3	   (center	  column),	   or	   hPMAT	   (right	   column).	   	   A)	   Representative	   images	   of	   transporter-­‐independent	  uptake,	  in	  this	  case	  NG54.	  	  B)	  AGH093	  is	  a	  substrate	  for	  hOCT3	  and	  for	  hPMAT.	   	   C)	   FFN202	   is	   a	   substrate	   for	   OCT3	   and	   not	   appreciably	   a	   substrate	   for	  PMAT,	   likely	  due	  to	  the	   increased	  steric	  bulk	  of	  the	  6-­‐position	  relative	  to	  AGH093.	  	  All	  treatments	  were	  20µM	  for	  1h.	  AGH	  093	  and	  FFN202	  images	  are	  representative	  images	  of	  3	  independent	  experiments,	  at	  least	  3	  images	  per	  well.	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Table	  3:	  	  7-­‐Hydroxycoumarins	  screened	  for	  Uptake2	  Substrate	  Activitya,b	  
Name Structure hOCT3 hPMAT  Name Structure hOCT3 hPMAT 
Mini101 
 























































X X  
aQualitative comparisons of probe accumulation as a function of Uptake2 
transporter expression.  X = no observable transporter-dependent uptake, * = 
minimal detectable increase in fluorescence compared to background uptake in 
control cells, ** = clear increase in fluorescence, *** = bright probe accumulation 
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hydroxycoumains with any substrate activity at hOCT3 or hPMAT displayed a 
general cytosolic staining pattern as indicated by representative images in Figure 2.  
cAGH093 is cleanly inhibited by D22 at PMAT but is not as consistently bright as 
in hOCT3-HEK cells.  	  
	  
	  
Table	  4:	  	  7-­‐Aminocoumarins	  Screened	  for	  Uptake2	  Substrate	  Activitya	  
 
Name Structure hOCT3 hPMAT  Name Structure hOCT3 hPMAT 
FFN200 
 
X X  G171  X X 
FFN206 
 
X X  G174  X X 
AGH180 
 















X X  G180  X X 
PV7122 
 
X X  
aNo transporter-dependent uptake was observed with any of the 7-aminocoumarins 
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Table	  5:	  	  Pyridiniums	  and	  Other	  Fluorescent	  Probes	  Screened	  for	  Uptake2	  
Substrate	  Activitya	  
 
















aQualitative comparisons of probe accumulation as a function of Uptake2 
transporter expression.  X = no observable transporter-dependent uptake, * = 
minimal detectable increase in fluorescence compared to background uptake in 
control cells, ** = clear increase in fluorescence, *** = bright probe accumulation 
cleanly inhibited by pharmacological agents: a definite substrate. b APP+ appears to 
be accumulated to a very small degree in hPMAT-HEK cells compared to control 
cells, although the amount is inconsequential compared to the bright staining 
afforded in the presence of hOCT3 (see Figure 6 for representative images). 
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There	   are	   a	   number	   of	   important	   negative	   results	   to	   highlight.	   None	   of	   the	   7-­‐aminocoumarins,	  many	  of	  which	  are	  FFNs	  employed	  in	  advanced	  systems,	  appeared	  to	  act	  as	   substrates	   for	  Uptake2	   transporters.	   	  These	  negative	  results	   suggest	   that	  labeling	   results	   in	   advanced	   systems	   are	   not	   likely	   skewed	   by	   Uptake2	   transport	  activity.	  	  	  	  Additionally,	  NG54	  is	  a	  substrate	  for	  DAT,	  NET,	  and	  SERT	  (Chapter	  3)	  and	  VMAT2	   (Chapter	   2),	   but	   shows	   no	   OCT3	   or	   PMAT	   dependent	   uptake.	  	  Correspondingly,	  NG54	  displays	  a	  high	  degree	  of	  colocalization	  with	  TH-­‐GFP	  in	  the	  mouse	   dorsal	   striatum	   (Chapter	   3),	   indicating	   clean	   labeling	   of	   dopaminergic	  neurons.	  
	  	  
Figure	  4:	  	  FFN202	  is	  inhibited	  by	  corticosterone	  at	  hOCT3.	  	  Top	  Panel	  –	  60	  minute	  treatment	  of	  Flp-­‐HEK	  cells	  with	  20µM	  FFN202	  shows	  that	  FFN202	   is	  accumulated	  by	   hOCT3-­‐HEK	   cells	   (center	   column)	   compared	   to	   hPMAT-­‐HEK	   (right	   column)	   or	  pcDNA-­‐HEK	   (left	   column).	   	  Bottom	  Panel	   –	  Treatment	  with	  100µM	  corticosterone	  inhibits	   FFN202	   uptake	   into	   hOCT3-­‐HEK	   cells	   and	   has	   no	   effect	   on	   uptake	   of	  FFN202	  into	  hPMAT-­‐HEK	  or	  pcDNA-­‐HEK	  cells.	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Figure	   5:	   Cellular	   accumulation	   of	  AGH093	  by	  hOCT3	   and	  hPMAT	   is	   inhibited	  by	  corticosterone	   (hOCT3	   inhibitor)	   and	  by	  D22	   (hOCT3	  and	  hPMAT	   inhibitor).	   	   Top	  Panel	   –	   60	   minute	   treatment	   of	   Flp-­‐HEK	   cells	   with	   20	   µM	   AGH093	   shows	  accumulation	  by	  hOCT3-­‐HEK	  (center	  column)	  and	  hPMAT-­‐HEK	  (right	  column)	  cells	  with	   negligible	   uptake	   by	   pcDNA-­‐HEK	   (left	   column).	   	   Bottom	   Panel	   –	   Treatment	  with	  100	  µM	  corticosterone	   inhibits	  AGH093	  uptake	   into	  hOCT3-­‐HEK	  cells	  and	  50	  
µM	  D22	  inhibits	  uptake	  of	  FFN202	  into	  hPMAT-­‐HEK.	  	   Substrate	  activity	  at	  Uptake2	  system	  transporters	  was	  observed	  with	  several	  of	   the	   7-­‐hydroxycoumarins,	   and	   confirmed	   with	   inhibition	   (Figures	   4	   and	   5	   are	  representative).	   From	   these	   results,	   we	   can	   draw	   some	   preliminary	   conclusions	  about	  the	  substrate	  tolerance	  of	  OCT3	  and	  PMAT	  with	  respect	  to	  these	  fluorescent	  probes	   (Figure	   6).	   It	   appears	   that	   hOCT3	   is	  more	   tolerant	   of	   diverse	   ethylamine	  regiochemistry	  (both	  the	  3-­‐	  and	  4-­‐position	  afforded	  substrate	  activity,	  Table	  3),	  the	  length	   of	   alkyl	   group	   linking	   the	   amine	   to	   the	   arene	   (a	   methylamine	   analog	   of	  AGH093,	  compound	  AGH113,	  is	  a	  weak	  substrate	  for	  OCT3	  but	  not	  PMAT,	  Table	  3),	  and	  steric	  bulk	  in	  the	  6-­‐position	  (FFN202	  is	  a	  strong	  OCT3	  substrate	  but	  not	  a	  PMAT	  substrate,	   while	   the	   smaller	   6-­‐fluoro	   substituted	   AGH093	   is	   a	   substrate	   for	   both,	  
Table	  3).	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Figure	   7:	   	   Representative	   image	   of	   FFN202	   staining	   cell	   bodies	   in	   the	   dorsal	  striatum	  of	  an	  acute	  mouse	  brain	  slice	  preparation.	   	  The	  bright	  oval	  structures	  are	  cell	  bodies	  of	  presumably	  astrocytes,	  and	  the	  relatively	  faint	  fine	  punctate	  staining	  are	   dopamine	   presynaptic	   terminals.	   The	   bright,	   elongated	   structures	   are	   blood	  vessels.	   	  Scale	  bar	  =	  20	  µm.	  This	  representative	  image	  was	  obtained	  by	  Matt	  Dunn	  (graduate	   student	   colleague)	   during	   studies	   of	   FFN202	   uptake	   and	   release	   from	  dopaminergic	   presynaptic	   elements	   in	   this	   region	   of	   the	   brain,	   and	   highlights	   the	  importance	  of	  understanding	  secondary	  uptake	  mechanisms	  in	  brain	  tissue.	  	  	  	   This	   screen	   also	   uncovered	   an	   interesting	   result	   concerning	   fluorescent	  pyridiniums,	   which	   may	   satisfy	   the	   third	   goal	   of	   this	   screening	   program.	   	   APP+	  (discussed	  in	  detail	  in	  Chapter	  4)	  was	  found	  to	  be	  an	  excellent	  substrate	  for	  hOCT3	  at	  low	  concentrations	  and	  short	  treatment	  times	  (2µM,	  10	  min).	  	  Preliminary	  results	  suggested	  that	  APP+	  might	  be	  useful	  as	  a	  fluorescent	  substrate	  to	  study	  transporter	  activity	   and	   inhibition;	   it	   was	   characterized	   more	   rigorously	   in	   additional	  experiments	  (see	  below).	  	  
APP+	  is	  an	  Excellent	  Substrate	  for	  hOCT3	  but	  a	  Poor	  Substrate	  for	  hPMAT	  	  In	  the	  initial	  screen	  described	  above,	  it	  was	  found	  that	  incubation	  of	  isogenic	  Flp-­‐HEK	  cells	  stably	  transfected	  with	  an	  empty	  vector	  (pcDNA-­‐HEK),	  human	  PMAT	  (hPMAT-­‐HEK),	   and	   human	   OCT-­‐3	   (hOCT3-­‐HEK),	   with	   APP+	   (2	   μM,	   10	   min)	  uncovered	   an	   interesting	   phenomenon;	   APP+	   is	   accumulated	   rapidly	   by	   action	   of	  hOCT3	  but	  not	  hPMAT,	  with	  minimal	  relative	  background	  uptake	  in	  control	  pcDNA-­‐
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HEK	  cells	  (Figure	  8).	  	  The	  resulting	  intracellular	  fluorescent	  label	  is	  consistent	  with	  reported	  behavior	  of	  APP+,(15,	  17)	  and	  the	  intracellular	  localization	  into	  mitochondria	  affords	  a	  more	  stable	  signal	   than	   that	  of	   the	  FFNs,	  which	   tend	  to	   leak	  or	  wash	  out	  through	  the	  plasma	  membrane	  over	  time	  (data	  not	  shown).	  Uptake	  of	  APP+	  in	  OCT3-­‐HEK	   cells	   can	   be	   inhibited	   by	   the	   OCT3	   inhibitor	   corticosterone	   (100	   μM,	   Figure	  6D).(3)	  These	  images	  suggest	  that	  APP+	  is	  a	  substrate	  for	  OCT3	  and	  is	  well	  suited	  for	  imaging	  applications,	  whereas	   it	   is	  at	  best	  a	  poor	  substrate	  for	  PMAT	  (Figure	  8B).	  Substrate	  activity	  of	  APP+	  at	  OCT3	  is	  not	  surprising,	  considering	  the	  reported	  robust	  transport	   activity	   of	   OCT3	   towards	   the	   structurally	   related	   ASP+	   and	   MPP+.	  	  However,	   the	   relatively	   small	   uptake	   by	   PMAT	   towards	   APP+	   is	   somewhat	  unexpected,	  as	  MPP+	  is	  an	  excellent	  substrate	  for	  PMAT.	  	  These	  data	  would	  suggest	  that	  PMAT	  is	  a	  more	  sterically	  discriminating	  transporter	  than	  OCT3,	  at	  least	  within	  this	   pyridinium	   motif.	   	   On	   the	   basis	   of	   these	   results,	   we	   chose	   to	   pursue	  fluorescence-­‐based	  studies	  of	  the	  behavior	  of	  APP+	  at	  OCT3.	  	  	  
	  
Figure	  8:	  	  APP+	  is	  an	  excellent	  fluorescent	  substrate	  for	  hOCT3	  and	  a	  poor	  substrate	  for	   hPMAT.	   	   (A)	   pcDNA-­‐transfected,	   (B)	   hPMAT-­‐transfected,	   and	   (C)	   hOCT3-­‐	  transfected	  HEK293	  cells	  were	  treated	  with	  2µM	  APP+	  in	  experimental	  medium	  for	  10	  minutes	  before	  imaging.	  	  In	  this	  time,	  uptake	  into	  empty-­‐vector	  transfected	  cells	  and	   hPMAT-­‐transfected	   cells	   is	   negligible	   while	   uptake	   by	   hOCT3	   is	   robust.	   (D)	  hOCT3-­‐dependent	   uptake	   of	   APP+	   over	   the	   same	   time	   period	   was	   confirmed	   by	  
CB A D
	   192	  
inhibition	   with	   corticosterone	   (100	   µm)	   which	   significantly	   reduces	   APP+	  accumulation.	  	  Scale	  bar	  =	  10	  µm.	  	  	  	  
Kinetics	  of	  APP+	  Uptake	  by	  hOCT3	  Examination	   of	   initial	   rates	   of	   fluorescence	   accumulation	   of	   different	  concentrations	   of	   APP+	  was	   employed	   to	   determine	   the	   apparent	   Km	   of	   APP+	   at	  hOCT3,	   in	   collaboration	  with	  Dr.	  Adam	  Henke.	   	   Flp-­‐in	  HEK	   cells	   stably	   expressing	  hOCT3	   were	   grown	   on	   a	   96-­‐well	   microplate	   and	   treated	   with	   concentrations	   of	  APP+	  ranging	  from	  5	  μM	  to	  150	  μM,	  and	  fluorescence	  accumulation	  was	  monitored	  for	   4.5	   minutes	   (see	   Experimental	   Section	   IV).	   	   The	   apparent	   Michaelis	   constant	  (Km)	  of	  APP+	  at	  OCT3	  was	  determined	  to	  be	  26.0	  ±	  4.6	  μM	  (mean	  of	  3	  independent	  experiments	  ±	   SEM;	  Figure	  9A).	   	  This	  result	   is	  consistent	  with	  reported	  values	   for	  ASP+	  at	  OCT2	  (~24-­‐42	  μM),(11)	  and	  surprisingly	  compares	  to	  the	  reported	  apparent	  Km	   of	   APP+	   at	   DAT	   (30	   μM).(16)	   	   The	   hill	   coefficient	   was	   calculated	   to	   be	   ~1.2,	  suggesting	  no	  cooperativity	  in	  transport.	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Figure	  9:	  Quantitative	  analysis	  of	  APP+	  as	  a	  substrate	  for	  hOCT3.	  	  A)	  Apparent	  Km	  of	  APP+	   at	   hOCT3	  was	   determined	   by	   initial	   rates	   experiments	   to	   be	   26.0	   ±	   4.6	   μM	  (mean	  ±	  SEM).	  Shown	  is	  the	  average	  of	  three	  independent	  initial	  rates	  experiments.	  	  Error	  bars	  represent	  SEM.	  	  B)	  Dose	  response	  curves	  of	  some	  select	  OCT3	  inhibitors	  (mean	   of	   two	   independent	   experiments,	   two	   identical	   plates	   each,	   error	   bars	   =	  SEM).	   	   APP+	   uptake	   is	   normalized	   to	   controls:	   uninhibited	   uptake	   =	   100%,	   2mM	  MPP+	   cotreatment	   =	   0%.	   	   EC50	   values	   for	   corticosterone,	   phenoxybenzamine,	   and	  desipramine	  were	  determined	  to	  be	  19.6	  ±	  3.9	  μM,	  9.0	  ±	  1.4	  μM,	  and	  	  40.8	  ±	  4.2	  μM,	  respectively	   (means	   ±	   SEM,	   n	   =	   2).	   	   Ki	   values	   were	   calculated	   using	   the	   Cheng-­‐Prusoff	  equation,	  and	  were	  determined	  to	  be	  16.5	  μM	  for	  corticosterone,	  14.4	  μM	  for	  phenoxybenzamine,	  and	  34.2	  μM	  for	  desipramine.	  C)	   	  Structures	  of	  the	  fluorescent	  hOCT3	  substrate	  APP+	  and	  OCT3	  inhibitors	  corticosterone,	  phenoxybenzamine,	  and	  desipramine.	  
	  
Inhibition	  of	  APP+	  cell	  uptake	  by	  reported	  OCT3	  inhibitors	  In	   order	   to	   determine	   the	   applicability	   of	   APP+	   as	   a	   screening	   agent	   or	  research	  tool	  to	  study	  inhibitor	  interaction	  with	  hOCT3,	  we	  set	  out	  to	  confirm	  the	  Ki	  values	  of	  some	  known	  inhibitors	  of	  hOCT3	  using	  the	  APP+	  cell	  assay.	  Although	  OCT3	  is	   a	   low	   affinity	   transporter	   for	   monoamines,	   the	   Km	   of	   APP+	   for	   OCT3	   was	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determined	  to	  be	  moderately	  low	  (~25	  µM),	  and	  we	  found	  that	  5	  µM	  is	  a	  sufficient	  concentration	  of	  APP+	  to	  furnish	  reproducible	  results	  from	  inhibition	  experiments.	  	  Compounds	   tested	   for	   potency	   of	   APP+	   inhibition	   include	   corticosterone,	  phenoxybenzamine,	  and	  desipramine	  (Figure	  9B).	  	  These	  compounds	  were	  selected	  as	   their	   inhibition	  potencies	  have	  been	  compared	  directly	   in	   the	  same	  study	  using	  hOCT3,	   and	   they	   are	   structurally	   distinct	   from	   one	   another.	   The	   Cheng-­‐Prusoff	  equation	  was	  used	  to	  convert	  measured	  IC50	  values	  to	  Ki	  values	  of	  the	   inhibitors.	   I	  was	   able	   to	   measure	   IC50	   values	   for	   corticosterone,	   phenoxybenzamine,	   and	  desipramine,	  which	  were	  determined	  to	  be	  19.6	  ±	  3.9	  μM,	  9.0	  ±	  1.4	  μM,	  and	  	  40.8	  ±	  4.2	   μM,	   respectively	   (means	   ±	   SEM,	   n	   =	   2).	   	   Ki	   values	   were	   calculated	   using	   the	  Cheng-­‐Prusoff	   equation,	   and	   were	   determined	   to	   be	   16.5	   ±	   3.3	   μM	   for	  corticosterone,	   7.6	   ±	   1.2	   μM	   for	   phenoxybenzamine,	   and	   34.2	   ±	   3.5	   μM	   for	  desipramine.	  	  Our	   measured	   inhibition	   potencies	   of	   compounds	   known	   to	   interact	   with	  OCT3	   compare	   variably	   with	   those	   previously	   reported	   using	   other	   substrates	  including	  [3H]-­‐MPP+.(21)	  	  For	  example,	  while	  the	  Ki	  of	  phenoxybenzamine	  measured	  here	  (7.6	  ±	  1.2	  μM)	  is	  essentially	  the	  same	  as	  measured	  by	  scintillation	  counting	  of	  [3H]-­‐MPP+	   	  (6.13	  ±	  2.04	  μM),(21)	   the	  Ki	  of	  corticosterone	  measured	  with	  APP+	  was	  found	  to	  be	  	  to	  be	  considerably	  higher	  (16.5	  ±	  3.3	  μM)	  than	  that	  found	  by	  [3H]-­‐MPP+	  	  (0.29	  ±	  0.04	  μM).	  (21)	  	  	  The	  considerably	  higher	  value	  for	  corticosterone	  is	  consistent	  with	  inhibition	  potencies	  measured	  using	  the	  related	  pyridinium,	  ASP+,(11)	  and	  may	  suggest	   a	   unique	   substrate-­‐specific	   inhibition	   profile,	   which	   is	   a	   well-­‐known	  phenomenon	   in	   low	   affinity	   transporters	  with	   large	   or	  multiple	   substrate	   and/or	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inhibitor	   binding	   sites.	   	   The	   shifted	   Ki	   for	   corticosterone	   as	   measured	   by	   APP+	  compared	   to	   that	   measured	   with	   radiosubstrate	   assays	   using	   [3H]-­‐MPP+	   is	  somewhat	   problematic,	   and	   demonstrates	   that	   APP+	   may	   miss	   or	   misrepresent	  activities	   or	   inhibition	   potencies	   of	   experimental	   inhibitors	   in	   a	   high-­‐throughput	  (HT)	  setting.	  	  	  
	  
Applicability	  of	  APP+	  for	  High	  Throughput	  Screening	  	   The	  Z’-­‐Factor	  is	  an	  important	  parameter	  used	  to	  describe	  the	  applicability	  of	  a	  particular	  assay	  for	  HT	  applications.	   	  Using	  the	  standard	  method	  for	  determining	  this	  value,(22)	  we	  were	  unable	  to	  reliably	  achieve	  a	  Z’-­‐factor	  for	  an	  APP+-­‐based	  OCT3	  inhibition	  assay	  greater	   than	  Z’	  =	  0.5	  (5	  µM	  APP+,	  100	  µM	  corticosterone	  positive	  control,	   15	   min	   incubation).	   	   Our	   results	   indicated	   a	   positive	   Z’-­‐factor	   but	   were	  highly	   variable	   (Z’	   ~	   0.3),	   suggesting	   that	   this	   compound	   could	   be	   used	   in	   a	   +/-­‐	  assay	   as	   currently	   optimized,	   but	   further	   optimization	   would	   be	   required	   for	  rigorous	  and	  conservative	  high	  throughput	  screening.	   	  One	  additional	  drawback	   is	  that	   substrate-­‐specific	   inhibition	   of	   APP+	   may	   contribute	   to	   missed	   or	  misrepresented	   hits	   in	   a	   HT	   campaign,	   as	   inhibition	   of	   APP+	   may	   not	   relate	  particularly	  closely	  to	  inhibition	  of	  endogenous	  substrates.	  
	  
Potential	  Utility	  of	  APP+	  at	  the	  Uptake2	  System	  Based	   on	   these	   results	   above,	   it	   is	   possible	   that	   APP+	   can	   be	   used	   as	   an	  alternative	  to	  radiolabeled	  substrates	  in	  the	  study	  of	  OCT3,	  although	  there	  are	  some	  concerns	   as	   mentioned	   above.	   	   Since	   APP+	   is	   already	   marketed	   by	   Molecular	  
	   196	  
Devices	  in	  the	  Neurotransmitter	  Transporter	  Uptake	  Assay	  Kit	  developed	  for	  use	  in	  HT	  applications	  for	  DAT,	  NET,	  and	  SERT,(23)	  there	  is	  significant	  precedent	  for	  the	  use	  of	   this	   motif	   as	   a	   fluorescent	   substrate	   of	   plasma	   membrane	   transporters	   as	   a	  screening	   agent	   for	   inhibition	   assays.(16,	  24)	  ASP+	   has	   been	   used	   previously	   in	   the	  pharmacological	   study	   of	   OCT3,(11)	   although	   APP+	   is	   reported	   to	   overcome	  limitations	  of	  ASP+,	  including	  background	  uptake,(15,	  16)	  suggesting	  that	  APP+	  may	  be	  more	  suitable	  for	  the	  study	  of	  OCT3	  as	  well.	  	  Indeed,	  when	  the	  same	  concentrations	  of	   ASP+	   and	   APP+	   are	   compared	   in	   HEK293	   cells,	   ASP+	   background	   uptake	   is	  markedly	  greater,	  presumably	  due	  to	  a	  higher	  rate	  of	  passive	  diffusion	  as	  ASP+	  is	  a	  more	   lipophilic	   pyridinium.(15)	   	   As	   such,	   the	   use	   of	   APP+	   may	   lead	   to	   a	   more	  sensitive	   HT	   assay	   than	   one	   employing	   ASP+.	   Potent	   and	   selective	   inhibitors	  identified	   from	   such	   an	   assay	   could	   serve	   as	   an	   augmentation	   therapy	   to	   SSRI	  treatment	   in	   cases	   of	   treatment	   resistant	   depression,	   or	   after	   SSRI	   inefficacy	  manifests	   from	   long-­‐term	   treatment.	   	   Although	   a	   number	   of	   drugs	   have	   already	  been	  shown	  to	  interact	  with	  OCT3	  and	  PMAT,	  there	  is	  a	  debate	  over	  the	  relevance	  of	  these	   molecules	   in	   eliciting	   the	   phenotypic	   response;(11,	   25)	   a	   more	   selective	   and	  potent	  inhibitor	  would	  be	  needed	  for	  further	  study.	  As	  we	  have	  shown	  in	  brain	  tissue,	  APP+	  labels	  catecholaminergic	  axons	  and	  cell	  bodies	  (Chapter	  4).	  (17)	   	  At	  concentrations	  of	  APP+	  required	  to	  label	  cell	  bodies,	  there	   is	   additional	   staining	   of	   non-­‐catecholaminergic	   structures,	   a	   likely	  consequence	  of	  APP+	  uptake	  by	  OCT3.	  	  As	  APP+	  can	  be	  used	  as	  an	  imaging	  agent	  in	  brain	  tissue,	  it	  may	  prove	  a	  useful	  research	  tool	  when	  investigating	  areas	  innervated	  with	   OCT3-­‐expressing	   neurons	   or	   glia	  with	   corresponding	   sparse	  monoaminergic	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innervations.	   APP+	   may	   also	   facilitate	   fluorescence	   microscopy	   studies	   of	   OCT3	  activity	   and	   upregulation	   in	   specific	   areas	   of	   the	   brain	   of	   Uptake1	   system	   (MAT)	  knockout	  animals.	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III:	  	  Conclusions	  and	  Outlook	  A	  number	  of	  FFNs	  and	  FFN	  related	  fluorescent	  probes,	  including	  all	  advanced	  FFNs	  used	   in	  brain	   tissue	   studies,	  have	  been	  screened	   for	   substrate	  activity	  at	   the	  Uptake2	  transporters	  hOCT3	  and	  hPMAT	  using	  epifluorescence	  microscopy.	   	  These	  transporters	   have	   been	   suggested	   to	   contribute	   significantly	   to	   monoamine	  clearance	  from	  the	  extracellular	  space,	  and	  may	  prove	  to	  be	  viable	  pharmacological	  targets.	   	   As	   such,	   fluorescent	   probes	   may	   be	   useful	   for	   study	   of	   Uptake2	   system	  activity	   in	   tissue	   or	   for	   identification	   and	   characterization	   of	   novel	   Uptake2	  inhibitors.	   	   It	   is	   important	   to	   understand	   the	   behavior	   of	   FFNs	   at	   Uptake2	  transporters	  for	  our	  interpretation	  and	  analysis	  of	  FFN	  results	  in	  complex	  settings	  of	  primary	  tissue	  culture,	  brain	  slice	  preparations,	  or	   in	  vivo	  applications.	   	  Interesting	  trends	  have	  been	  noticed	  with	   FFN	   structure	   and	   substrate	   activity	   at	   hOCT3	   and	  hPMAT,	   most	   notably	   that	   the	   regiochemistry	   of	   the	   ethylamine	   is	   important	   for	  transport,	   as	   well	   as	   the	   sterics	   of	   substituents	   on	   positions	   6	   and	   8,	   with	  substitution	  of	  position	  8	  with	  halogens	  being	  completely	  excluded.	  It	  can	  be	  noted,	  however,	   that	   AGH093	   and	   FFN202	   are	   the	   brightest	   FFNs	   in	   hOCT3-­‐HEK,	   and	  AGH093	   is	   brightest	   of	   all	   in	   hPMAT-­‐HEK,	   each	   relative	   to	   background	   uptake	   in	  empty	   vector-­‐transfected	   control	   cells.	   	   The	   above	   results	   will	   affect	   our	  interpretation	  of	  observed	  behavior	  of	  these	  compounds	  in	  more	  advanced	  systems.	  We	  are	  beginning	  a	  collaboration	  with	  Professor	  Joanne	  Wang	  to	  study	  PMAT	  activity	  in	  the	  hippocampus	  with	  FFNs.	  Many	  of	  the	  compounds	  found	  here	  to	  have	  substrate	   activity	   at	   hOCT3	  and/or	   hPMAT	   are	   known	   to	   be	  VMAT2	   substrates	  as	  well,	  including	  all	  the	  hydroxycoumarins	  with	  Uptake2	  activity.	  A	  lead	  for	  this	  study	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will	  be	  the	  PMAT/VMAT	  substrate	  AGH093	  that,	  in	  the	  presence	  of	  OCT3	  inhibitors	  in	  the	  hippocampus,	  could	  be	  used	  as	  a	  tracer	  of	  SERT-­‐independent	  5HT	  uptake	  and	  release,	  as	  PMAT	  is	  suggested	  to	  be	  expressed	  on	  presynaptic	  serotonergic	  neurons	  and	  AGH093	  is	  not	  a	  substrate	  for	  SERT.(6)	  	  Additionally,	  we	   have	   observed	   the	   interesting	   result	   that	   APP+	   is	   a	   good	  substrate	  for	  hOCT3,	  although	  is	  a	  relatively	  poor	  substrate	  for	  hPMAT	  in	  HEK	  cells	  stably	  expressing	  these	  transporters.	  	  We	  have	  determined	  the	  apparent	  Km	  of	  APP+	  at	  hOCT3,	  and	  I	  compare	  inhibition	  constants	  of	  known	  hOCT3	  inhibitors	  obtained	  with	   APP+	   with	   the	   reported	   values	   obtained	   using	   3H-­‐MPP+.	   With	   further	  optimization,	   APP+	   may	   be	   applicable	   to	   high-­‐throughput	   screening	   for	   OCT3	  inhibitors,	   and	   it	   may	   prove	   useful	   as	   a	   fluorescent	   alternative	   to	   radiolabeled	  substrates	  in	  fundamental	  experiments	  on	  the	  pharmacology	  of	  OCT3.	  	  	  APP+	  is	  likely	  a	  better	  choice	  for	  optimization	  of	  HTS	  experiments	  than	  many	  of	   the	   FFNs,	   as	   APP+	   is	   sequestered	   into	   mitochondria	   and	   chromatin	   where	   it	  fluoresces	  brightly	  and	  remains	  quite	  stable	  as	  an	   intracellular	   label.	   	  FFNs,	  on	  the	  other	  hand,	  exhibit	  general	  cytosolic	  labeling	  which	  is	  less	  stable,	  as	  the	  compound	  can	   leak	   from	   the	   cells	   more	   readily	   via	   passive	   diffusion	   across	   the	   plasma	  membrane	   or	   through	   reverse	   transport	   through	   OCT3	   or	   PMAT.	   	   FFN206,	   for	  example,	   is	   an	   excellent	   HTS	   candidate	   for	   VMAT2	   activity	   and	   provides	   a	   stable	  signal	  for	  at	  least	  an	  hour	  as	  it	  is	  sequestered	  into	  VMAT2-­‐expressing	  organelles	  and	  cannot	   easily	   diffuse	   from	   the	   cell.	   	  While	   FFNs	   are	   not	   likely	   appropriate	   for	   HT	  applications	   for	   Uptake2	   transporters,	   quantitative	   examination	   and	  characterization	  of	  FFNs	  as	  hOCT3	  and	  hPMAT	  substrates	  is	  still	  an	  important	  future	  
	   200	  




































	   201	  
IV:	  	  Experimental	  	  	  
Cell	  culture	  Isogenic	  Flp-­‐in	  HEK	  cells	  stably	  transfected	  with	  either	  hOCT3,	  hPMAT,	  or	  an	  empty	  vector	  (pcDNA)(3)	  were	  maintained	  in	  Dulbecco’s	  Minimal	  Essential	  Medium	  (DMEM)	  with	  Glutamax	   (Invitrogen)	   supplemented	  with	  10%	  Fetal	  Bovine	   Serum	  (FBS,	   Atlantis	   Biologicals),	   150	  µg/mL	   hygromycin-­‐B	   (to	  maintain	   the	   transgene),	  100	   µg/mL	   Penicillin,	   and	   100	   U/mL	   Streptomycin	   (Invitrogen).	   	   Cells	   were	  routinely	   cultured	   in	  10	   cm	  polystyrene	   culture	  plates	   (Falcon),	  were	   subcultured	  before	  reaching	  confluence	  (every	  3-­‐4	  days),	  and	  were	  maintained	   in	  a	  humidified	  atmosphere	  at	  37	  ˚C	  containing	  5%	  CO2.	  	  	  
	  
Uptake	  of	  FFNs	  by	  hOCT3	  and	  hPMAT	  	  	  Flp-­‐in	  HEK	  cells	  expressing	  either	  hOCT3,	  hPMAT,	  or	  an	  empty	  vector	  were	  subcultured	   into	  6-­‐well	  polystyrene	  plates	   (Falcon)	   coated	  with	  poly-­‐D-­‐lysine	  at	   a	  density	   of	  ~200,000	   cells/well	   ,	   or	   into	  12-­‐well	   plates	  with	   the	   same	   coating	   at	   a	  density	   of	  ~100,000	   cells/well	   and	  were	   allowed	   to	   grow	   for	   3	   days	   in	   complete	  medium.	   	   Prior	   to	   the	   experiment,	   wells	   were	   aspirated	   and	   washed	   with	   2	   mL	  DPBS,	   and	   were	   subsequently	   refilled	   with	   900	   µL	   clear	   experimental	   medium	  (DMEM	  without	  phenol	  red,	  25	  mM	  HEPES,	  1%	  FBS).	   	  Cells	  were	   incubated	  for	  60	  min	  at	  37˚C.	   	  For	   inhibition	  experiments,	   cells	  were	  preincubated	   for	  60	  min	  with	  corticosterone	   (100	   µM)	   or	   D22	   (50	   µM)	   in	   experimental	   medium.	   	   Uptake	   was	  initiated	  by	  adding	  100	  µL	  of	  a	  200	  µM	  solution	  of	  FFN	   in	  clear	  medium	  (or	  clear	  medium	  +	   corticosterone	  100	  µM	  or	  D22	  50	  µM	   for	   inhibition	   studies)	   for	   a	   final	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concentration	  of	  20	  µM	  probe	  in	  each	  well.	   	  Cells	  were	  incubated	  for	  60	  min,	  after	  which	   time	  experimental	  medium	  containing	   the	  probe	  was	   aspirated,	  wells	  were	  washed	  with	  1	  mL	  DPBS,	  and	  were	  refilled	  with	  1	  mL	  warm	  experimental	  medium.	  	  Images	  were	   taken	   using	   a	   Leica	   DMI4000B	   inverted	   epifluorescence	  microscope	  using	  a	  filter	  cube	  for	  corresponding	  to	  the	  excitation/emission	  wavelengths	  of	  the	  respective	   probe.	   	   Images	   of	   each	   probe	   were	   adjusted	   to	   the	   same	   levels	   of	  brightness	  and	  contrast	  using	  ImageJ	  (NIH).	  	  
	  
Imaging	  APP+	  uptake	  in	  HEK	  cells	  APP+	   iodide	   was	   prepared	   as	   described	   previously(17)	   (Chapter	   4	   of	   this	  work).	   For	  microscopy	   studies	  of	  APP+	  uptake,	   cells	  were	   subcultured	   into	  6-­‐well	  polystyrene	  plates	  (Falcon)	  coated	  with	  poly-­‐D-­‐lysine	  (Sigma-­‐Aldrich),	  at	  a	  density	  of	  ~200,000	  cells/well	  and	  were	  allowed	  to	  grow	  for	  3	  days	  to	  confluence.	  	  Prior	  to	  the	   experiment,	   wells	   were	   aspirated	   and	   washed	   with	   DPBS	   (2	   mL),	   and	   were	  subsequently	   refilled	   with	   900	   µL	   experimental	   medium	   consisting	   of	   DMEM	  without	   phenol	   red,	   supplemented	   with	   HEPES	   (25	   mM),	   glutamine	   (2	   mM),	   1%	  FBS,	  100	  µg/mL	  penicillin,	  and	  100	  U/mL	  streptomycin.	  Cells	  were	  incubated	  for	  60	  min.	   	  Uptake	  was	  initiated	  by	  adding	  100	  µL	  of	  a	  20	  µM	  solution	  of	  APP+	  iodide	  in	  clear	  medium	  for	  a	   final	  concentration	  of	  2	  µM	  in	  each	  well.	   	  Fluorescence	   images	  were	   taken	   after	   10	   minutes	   of	   uptake	   in	   the	   presence	   of	   the	   probe	   (filter	   cube	  parameters:	  ex	  =	  440	  ±	  25	  nm,	  em	  =	  550	  ±	  25	  nm,	  250	  msec	  acquisition	  time).	   	  All	  microscopy	   was	   conducted	   on	   a	   Leica	   DMI	   4000B	   inverted	   epifluorescence	  microscope	  connected	  to	  a	  Leica	  DFC	  FX	  360	  camera	  controlled	  through	  Leica	  LAS	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AF	  6000E	  software.	   	  All	  images	  were	  adjusted	  to	  the	  same	  levels	  of	  brightness	  and	  contrast	  using	  ImageJ	  (NIH).	  	  
	  
Determination	  of	  Apparent	  Km	  of	  APP+	  at	  hOCT3	  	  	  hOCT3-­‐HEK	   cells	   were	   plated	   onto	   white,	   clear	   bottom	   96-­‐well	   plates	  (Falcon)	   pre-­‐coated	   with	   poly-­‐D-­‐lysine	   (Sigma	   Aldrich)	   at	   a	   density	   of	   ~50,000	  cells/well	  and	  were	  incubated	  for	  24	  hours	  in	  complete	  growth	  medium.	  	  Before	  the	  experiment,	  complete	  medium	  was	  aspirated,	  wells	  were	  washed	  with	  200	  μL	  PBS,	  and	   treated	   with	   experimental	   medium	   (100	   μL)	   or	   experimental	   medium	  containing	   the	   OCT3	   inhibitor	   corticosterone	   (100	   μM)	   for	   30	   minutes.	   	   2x	  concentrated	  solutions	  of	  APP+	  in	  experimental	  medium	  (100	  μL)	  or	  experimental	  medium	  containing	  corticosterone	  were	  added	  to	  the	  plate	  for	  final	  concentrations	  indicated.	   	  Fluorescence	  accumulation	  was	  measured	  (λex	  =	  450	  nm,	  λem	  =	  516	  nm)	  every	   1.5	   minutes	   for	   4.5	   minutes	   using	   a	   BioTek	   H1MF	   plate	   reader	   controlled	  through	  Gen5	  software.	   	  Background	  uptake	  for	  each	  concentration	  was	  defined	  as	  uptake	   of	   APP+	   in	   inhibited	   wells,	   and	   was	   subtracted	   from	   each	   corresponding	  uninhibited	   value.	   	   Rates	   of	   APP+	   uptake	   were	   determined	   from	   the	   slope	   of	   the	  resulting	  linear	  uptake	  curves,	  and	  were	  plotted	  as	  a	  function	  of	  APP+	  concentration.	  	  Data	  were	  analyzed	  using	  GraphPad	  Prism	  5.	  	  The	  Km	  value	  was	  calculated	  using	  the	  Michaelis-­‐Menten	   nonlinear	   regression	   analysis.	   	   The	   Hill	   coefficient	   was	  determined	   using	   a	   sigmoidal	   dose	   response	   fit	   with	   variable	   slope	   constrained	  through	  0.	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Dose-­‐Response	   Studies	   of	   Inhibitors	   using	   APP+	   as	   a	   Fluorescent	   OCT3	  
Substrate	  	  	  hOCT3-­‐HEK	  cells	  were	  cultured	   into	  96-­‐well	  plates	  as	  described	  above.	   	  On	  the	  day	  of	   the	  experiment,	   complete	  medium	  was	  removed	  and	  replaced	  with	  100	  
µL	   serum-­‐free	   experimental	   medium	   containing	   vehicle	   control	   or	   experimental	  compounds	  at	  2x	  the	  final	  concentrations.	  	  Cells	  were	  pre-­‐incubated	  for	  15	  minutes	  before	   addition	   of	   100	   μL	   of	   serum-­‐free	   experimental	   medium	   containing	   10	   μM	  APP+,	   for	   a	   final	   in-­‐well	   concentration	   of	   5	   μM	   APP+	   and	   a	   1x	   concentration	   of	  experimental	  compounds	  as	  reported.	  	  Uptake	  was	  conducted	  for	  20	  minutes	  before	  medium	  was	  removed,	  wells	  were	  quickly	  washed	  with	  200	  μL	  PBS,	  and	  finally	  filled	  with	   PBS	   (120	   μL,	   pH	   =	   7.4).	   	   Fluorescence	   accumulation	   was	   measured	   using	   a	  BioTek	  H1MF	   plate	   reader	   at	   the	   same	   excitation	   and	   emission	  maxima	   as	   above.	  	  EC50	  values	   from	   each	   experiment	  were	   determined	   using	   GraphPad	   Prism	   5,	   and	  corresponding	  Ki	  values	  were	  calculated	  using	  the	  Cheng-­‐Prusoff	  equation.	  	  	  
	  
Determination	  of	  Z’-­‐Factor	  of	  APP+	  at	  OCT3	  	  Cells	   were	   cultured	   into	   96-­‐well	   plates	   as	   above.	   	   On	   the	   day	   of	   the	  experiment,	   two	  96-­‐well	  plates	  were	  washed	  with	  PBS	  as	  above	  and	  filled	  with	  90	  μL	   serum-­‐free	   experimental	   medium	   per	   well,	   containing	   either	   a	   DMSO	   vehicle	  control	   (0.11%)	  or	  corticosterone	   in	  DMSO	  (111	  μM).	   	  Half	  of	   the	  plate	   (48	  wells)	  was	  treated	  with	  the	  vehicle	  control	  while	  half	  was	  treated	  with	  corticosterone.	  	  The	  plates	  were	  preincubated	  for	  15	  minutes	  at	  37˚C	  before	  addition	  of	  APP+	  (50	  μM,	  10	  μL/well)	   for	   a	   final	   concentration	   of	   5	   μM	   APP+	   in	   each	   well	   containing	   either	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vehicle	   control	   or	   corticosterone	   (100	   μM).	   	   Plates	   were	   incubated	   for	   20	  min	   at	  37˚C,	   after	  which	   time	  wells	  were	  washed	  with	  200	  μL	  PBS	   and	   finally	   filled	  with	  120	   μL	   PBS.	   	   Fluorescence	   accumulation	   was	   immediately	   measured	   on	   a	   plate	  reader	  as	  described	  above.	   	   Z’-­‐factor	  was	   calculated	   from	   the	  means	  and	   standard	  deviations	  of	  each	  control	  data	  set	  as	  described	  previously.	  (22)	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“In	  the	  adult	  centers,	  the	  nerve	  paths	  are	  something	  fixed,	  ended,	  and	  immutable.	  	  
Everything	  must	  die,	  nothing	  may	  be	  regenerated.	  	  It	  is	  for	  the	  science	  of	  the	  future	  to	  
change,	  if	  possible,	  this	  harsh	  decree.”	  
	  





Neuroplasticity	  and	  Chemical	  Neuroscience	  
	   	  
	   When	  Ramón	  y	  Cajal	   famously	  elucidated	   the	  discrete	  nature	  of	  neurons	   in	  the	   brain,	   it	   was	   widely	   assumed	   that	   neural	   tissue	   was	   static,	   fundamentally	  incapable	   of	   changing	   after	   reaching	   maturity.	   	   It	   is	   now	   well	   understood	   that	  neuroplasticity,	  the	  ability	  of	  the	  brain	  to	  change	  its	  structure	  and	  signaling	  network	  organization	   in	   response	   to	   environmental	   conditions,	   is	   critically	   important	   for	  learning	  and	  behavior,	  as	  well	  as	  the	  development	  and	  treatment	  of	  disease.(3)	  Given	  the	  dynamic	  nature	  of	  the	  brain’s	  structure	  and	  organization,	  as	  well	  as	  the	  extreme	  complexity	   of	   its	   connections,	   it	   has	   not	   yet	   been	   possible	   to	   fully	   elucidate	   and	  characterize	  the	  phenotypes	  that	  underlie	  specific	  functions	  in	  healthy	  brain	  tissue.	  	  It	   is	   presently	   not	   possible	   to	   fully	   characterize	   the	   causal	   relationships	   between	  brain	  structure	  changes	  and	  disease.	  	  	  Recently,	   the	   Sames	   Group	   has	   become	   interested	   in	   the	   development	   of	  small	  molecules	   capable	   of	  modulating	   brain	   function	   in	   order	   to	   compensate	   for	  genotypic	   or	   phenotypic	   deficiencies	   characteristic	   of	   disease.	   	   Our	   interest	   in	  imaging	  monoaminergic	  neurons,	  particularly	  dopaminergic	  neurons,(4,	  5)	  	  motivated	  us	   to	   consider	   novel	   pharmacological	   mechanisms	   to	   restore	   the	   health	   of	  dopaminergic	   neurons	   that	   have	   been	   damaged	   by	   neurodegenerative	   disease	   or	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substance	  abuse,	  or	   to	   fundamentally	  alter	   the	   structure	  of	  dopaminergic	  neurons	  that	  are	  malformed	  in	  a	  number	  of	  other	  pathologies.	  	  It	  is	  well	  known	  that	  growth	  factors,	   including	   neurotrophic	   factors,	   are	   responsible	   for	   the	   development	   of	  neurons	   and	   the	   maintenance	   of	   their	   physiology	   and	   health,	   and	   have	   been	  demonstrated	   to	   have	   reparative	   and	   restorative	   properties	   in	   the	   case	   of	  neurodegenerative	   disease.(6)	   Unfortunately,	   these	   signaling	   proteins	   are	   not	   drug	  candidates,	   as	   they	   are	   unstable	   in	   the	   blood	   and	   do	   not	   readily	   cross	   the	   blood	  brain	  barrier	  (BBB).(7,	  8)	  If	  a	  drug	  could	  be	  developed	  with	  the	  capability	  of	  inducing	  a	  mature	  brain	   to	  produce	  neurotrophic	   factors	  or	   to	  modulate	  or	  potentiate	  how	  the	   brain	   responds	   to	   the	   low	   levels	   of	   endogenously	   released	   and	   active	   growth	  factors,	   it	   could	   serve	   as	   a	   useful	   therapy	   for	   neurodegenerative	   disease.	   	   This	  chapter	   details	   some	   preliminary	   work	   toward	   this	   goal,	   describing	   experiments	  that	  served	  as	  a	  springboard	  for	  a	  program	  of	  RTK-­‐modulating	  isoquinuclidines.	  
	  
Glial	  Derived	  Neurotrophic	  Factor	  (GDNF)	  and	  its	  Cognate	  Receptor,	  Ret	  
	   	  
	   During	   the	   early	   stages	   of	   development,	   growth	   factors	   including	  neurotrophins	  and	  neurotrophic	  factors	  are	  widely	  expressed	  in	  the	  brain,	  and	  are	  essential	   to	   the	  development	  and	  differentiation	  of	  neurons	   in	   the	  central	  nervous	  system	  (CNS).(9)	  Upon	  reaching	  maturity,	  this	  expression	  is	  significantly	  attenuated.	  	  Glial-­‐Derived	  Neurotrophic	   Factor	   (GDNF)	   is	   one	   specific	   neurotrophic	   factor	   that	  has	  been	  shown	  to	  be	  critical	  for	  neural	  development,(10)	  particularly	  in	  the	  context	  of	  dopaminergic	  neurons.(11)	  	  GDNF	  has	  been	  shown	  to	  signal	   through	  the	  receptor	  tyrosine	  kinase	  Ret	  (rearranged	  during	  transfection,	  Figure	  1).(12)	   	  




Figure	  1:	  	  A	  representation	  of	  GDNF-­‐induced	  Ret	  signaling.	  	  Ret	  (rearranged	  during	  transfection)	   is	   the	   receptor	   tyrosine	   kinase	   for	   which	   GDNF	   is	   a	   ligand.	   	   In	   a	  complex	   equilibrium	   not	   fully	   characterized,	   GDNF	   binds	   with	   a	   membrane-­‐anchored	   co-­‐receptor	   GFRα1,	   which	   recruits	   two	   subunits	   of	   Ret.	   	   The	   resulting	  close	  spatial	  orientation	  of	  the	  cytosolic	  catalytic	  domain	  of	  the	  Ret	  subunits	  causes	  an	  autocatalytic	  phosphorylation	  of	  the	  kinase	  domain	  and	  subsequent	  activation	  of	  the	  indicated	  signaling	  cascades.	  Adapted	  from	  Dr.	  Teresa	  L.	  Jacques.(13)	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oncogene,	   as	   gain	   of	   function	   mutations	   leading	   to	   constitutive	   kinase	   activation	  have	  been	   shown	   to	   cause	   certain	   forms	  of	   cancer.(21)	  Despite	   the	   classification	  of	  Ret	  as	  an	  oncogene,	  Ret/GDNF	  represents	  an	  interesting	  pharmacological	  target	  for	  recovery	   of	   dopamine	   neurons	   damaged	   (or	   plastically	   modulated)	   by	   drug	   and	  alcohol	   abuse,(22,	   23)	   CNS	   trauma,(8,	   9,	   17)	   or	   neurodegeneration.(19)	   	   Ret	   is	   also	   a	  potentially	  promising	  target	  for	  inducing	  plasticity	  in	  pathologies	  causally	  related	  to	  dopaminergic	  dysfunction.	  	  
Ibogaine	  
	   We	  became	  interested	  in	  GDNF	  through	  a	  collaborator,	  Professor	  Dorit	  Ron,	  (UCSF)	  who	  has	   found	  that	   the	  natural	  product	   Ibogaine	  (Figure	  2)	  as	  well	  as	   the	  related	  noribogaine,	  mediates	  GDNF	  release	  in	  the	  midbrain	  of	  rats.(24,	  25)	  	  Professor	  Ron	  has	  demonstrated	  that	  the	  beneficial	  effects	  of	  ibogaine	  are	  related	  to	  its	  ability	  to	  induce	  production	  of	  GDNF,	  at	  which	  point	  autocrine	  or	  paracrine	  signaling	  with	  the	  released	  GDNF	  establishes	  a	  positive	   regulatory	   loop,	   leading	   to	   the	   long-­‐term	  phenotypic	  changes	  associated	  with	  neuronal	  repair.(24,	  26)	  	  Ibogaine	   is	   a	   naturally	   occurring	   alkaloid	   found	   in	   the	   west-­‐African	   plant	  
Tabernanthe	   iboga	   and	   has	   been	   used	   for	   centuries	   in	   traditional	   ceremonies.	  	  Ibogaine	   has	   complex	   pharmacology,	   interacting	   with	   the	   N-­‐methyl-­‐D-­‐aspartate	  receptor	   (NMDAR),	   nicotinic	   acetylcholine	   receptors,	   adrenergic	   receptors,	   the	   κ-­‐opioid	  receptor	  (KOR),	  serotonin	  receptors	  (specifically	  5HT2	  and	  5HT3)	  as	  well	  as	  the	  monoamine	  transporters	  and	  the	  enigmatic	  sigma	  receptors	  σ1R	  and	  σ2R.(27,	  28)	  	  It	   has	   been	   shown	   that	   ibogaine	   has	   anti-­‐addictive	   effects	   in	   rigorous	   animal	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studies,(29)	  and	  anecdotal	  reports	  in	  humans.	   	  The	  complex	  pharmacological	  profile	  of	   ibogaine	   is	   responsible	   for	   hallucinatory	   effects	   as	   well	   as	   ataxia,	   ventricular	  tachycardia,	  and	  nausea.(28,	  30)	  Ibogaine	  is	  currently	  a	  Schedule	  I	  drug	  in	  the	  US.	   	  As	  such,	  there	  would	  be	  benefit	  in	  finding	  a	  compound	  to	  act	  similarly,	  with	  respect	  to	  ibogaine’s	   beneficial	   effects	   on	   dopamine	   neurons,	   without	   such	   promiscuous	  pharmacology.	  	  Our	  group	  hypothesized	  that	  from	  a	  small	  library	  of	  ibogaine-­‐related	  structures,	   specifically	   arylethyl-­‐isoquinuclidines,	   it	   would	   be	   possible	   to	   identify	  compounds	  with	  similar	  GDNF-­‐inducing	  effects.	  
	  
Generation	  and	  Initial	  Biological	  Characterization	  of	  a	  Library	  of	  N-­‐arylethyl	  
Isoquinuclidines	  	  
	   	  	   A	  library	  of	  isoquinuclidine	  compounds	  related	  to	  ibogaine	  was	  synthesized	  by	  Dr.	  Xiaoguang	  Li.	  The	  goal	  was	  to	  examine	  the	  ability	  of	  each	  compound	  to	  induce	  expression	  and	  release	  of	  neurotrophic	  growth	  factors	  or	  otherwise	  induce	  similarly	  neurotrophic	   responses	   as	   ibogaine	   with	   fewer	   deleterious	   side	   effects,	   such	   as	  hallucinatory	  symptoms,	  cardiac	  symptoms,	  etc.	  (Figures	  2,3).	  
	  
Figure	  2:	  	  Ibogaine,	  and	  the	  general	  scheme	  of	  analogs	  tested	  herein.	  	  Structural	  variation	  in	  the	  library	  was	  included	  at	  positions	  R1	  and	  R2,	  the	  length	  of	  linker	  was	  varied,	  as	  was	  the	  hybridization	  state	  of	  the	  C5-­‐C6	  bond	  (see	  preliminarily-­‐screened	  structures	  in	  Figure3).	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Measurement	   of	   growth	   factor	   release	   into	   culture	   medium	   by	   enzyme-­‐linked	  immunosorbent	  assay	  (ELISA)	  is	  widely	  used	  to	  test	  growth	  factor	  secretion	  by	  various	  conditions.	   	  To	  establish	  an	  assay,	  Dr.	  Shu	  Li	  screened	  a	  number	  of	  cell	  lines	   reported	   to	   release	   GDNF	   using	   the	   corresponding	   positive	   control	   inducers	  for	  each	  cell	   line,	  and	  detected	  GDNF	  release	  by	  a	  commercial	  ELISA	  kit	   (Promega	  Emax	   GDNF	   Immunoassay	   System).	   It	   was	   found	   that	   SH-­‐SY5Y,	   Neuro2A,	   SK-­‐N-­‐AS,	  and	   primary	   human	   cortical	   astrocytes	   each	   produced	   GDNF	   levels	   below	   the	  detection	   limit	   of	   the	   kit	   after	   48-­‐hour	   treatment	   with	   the	   respective	   positive	  controls.	  	  It	  was	  also	  found	  that	  C6	  cells	  provided	  a	  detectable	  background	  release	  of	  GDNF,	  and	  several	  experimental	  isoquinuclidines	  released	  GDNF	  under	  preliminary	  screening	  conditions	  (Figure	  3).	  C6	  cells,	  originally	  transformed	  from	  a	  rat	  glioma	  tumor,(31)	  were	  ultimately	  chosen	   for	   wider	   study	   based	   on	   this	   preliminary	   optimization	   as	   well	   as	   the	  numerous	  reports	  documenting	  GDNF	  release	  from	  C6.	  	  In	  fact,	  several	  compounds	  have	  been	  identified	  as	  GDNF	  releasers	  in	  C6	  cells,	  including	  riluzole,	  amitriptyline,	  and	  antipsychotics;	  receptor	  tyrosine	  kinases	  have	  been	  implicated	  either	  as	  direct	  or	  transactivated	  targets	  for	  signaling	  mechanisms	  related	  to	  GDNF	  release	  induced	  by	  many	   of	   these	   compounds.(32-­‐36)	   	  C6	   cells	   proved	   to	   be	   an	   excellent	   system	   for	  screening	  compounds	  for	  capacity	  to	  release	  GDNF,	  as	  active	  forms	  of	  a	  number	  of	  RTKs	  are	  expressed.	  Numerous	  potential	  targets	  funnel	  through	  MEK	  to	  activate	  the	  promoter	   for	   GDNF,	   cAMP	   response-­‐element	   binding	   protein	   (CREB),	   ultimately	  resulting	   in	   upregulation	   of	   GDNF	   transcription,	   translation,	   and	   subsequent	  release.	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II:	  	  Results	  and	  Discussion	  	  
Conventional	  ELISA	  is	  a	  More	  Sensitive	  Method	  for	  Detecting	  GDNF	  Release	  
	  	   The	  release	  of	  GDNF	  from	  C6	  cells	  was	  initially	  screened	  by	  Dr.	  Shu	  Li	  using	  an	  in-­‐situ	  ELISA	  protocol,	  due	  to	  reported	  high	  detection	  sensitivity	  of	  this	  method	  (Figure	  3).	  GDNF	  release	  for	  each	  compound	  was	  calculated	  as	  a	  ratio	  of	  the	  amount	  of	   GDNF	   released	   by	   experimental	   compounds	   to	   the	   amount	   released	   by	   vehicle	  control	   (DMSO	  0.1%	   v/v),	   and	   expressed	   as	   “fold/control.”	   In-­‐situ	   ELISA	   involves	  culturing	  a	  monolayer	  of	  cells	  on	  an	  ELISA	  detection	  plate	  that	  has	  been	  pre-­‐coated	  with	   a	   monoclonal	   capture	   antibody.	   	   Once	   GDNF	   is	   released	   into	   the	   culture	  medium	   from	   cells,	   it	   is	   theoretically	   captured	   by	   the	   monoclonal	   antibody.	   	   To	  terminate	   the	   experiment,	   treatment	   medium	   is	   removed	   and	   cells	   are	  disaggregated/dissociated	  from	  the	  plate	  by	  action	  of	  detergent	  and	  gentile	  rocking.	  As	   seen	   in	  Figure	   3	   above,	   the	   best	   GDNF	   releasers	   as	   detected	   by	   in-­‐situ	   ELISA	  were	  found	  to	  release	  ~2-­‐3	  fold/control.	  	  	  In	   order	   to	   develop	   a	   more	   robust	   assay	   for	   GDNF	   release,	   I	   decided	   to	  optimize	  a	  conventional	  ELISA.	  	  It	  was	  initially	  thought	  that	  the	  GDNF	  released	  into	  conditioned	  media,	  when	  not	  captured	  by	  a	  monoclonal	  antibody	  as	  in	  in-­‐situ	  ELISA,	  autocrine	   signaling	  would	   amplify	   signal	   initiated	   by	   inducing	   compounds.	   It	  was	  observed	  by	  treating	  C6	  cells	  with	  XL-­‐008,	  a	  strong	  inducer	  of	  GDNF	  as	  determined	  using	  in-­‐situ	  ELISA,	  that	  release	  of	  GDNF	  can	  be	  as	  high	  as	  ~	  40	  fold/control	  (Figure	  
4,	   see	  note	  about	  phenotypic	   instability	  above).	   	  Conversely,	   it	   is	  possible	   that	   the	  increased	   sensitivity	   afforded	   by	   conventional	   ELISA	   relates	   to	   the	   method	   of	  detection.	  	  For	  the	  less	  sensitive	  in-­‐situ	  ELISA,	  the	  fact	  that	  cells	  are	  growing	  on	  the	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monoclonal	  antibody-­‐treated	  surface	  or	  the	  detergent	  based	  wash	  could	  contribute	  to	  decreased	  sensitivity	  of	  GDNF	  detection.	  	  	  	   While	  in-­‐situ	  ELISA	  is	  thought	  to	  be	  a	  more	  sensitive	  detection	  method	  in	  for	  some	   applications,	   conventional	   ELISA	   offers	   a	   number	   of	   advantages	   for	   our	  experiments.	   	   First,	   it	   allows	   multiple	   measurements	   of	   conditioned	   media	   from	  each	  replicate	  well,	  as	  the	  treatment	  wells	  are	  not	  limited	  to	  small,	  96-­‐well	  format.	  	  For	   example,	   I	   chose	   to	   pursue	   a	   12-­‐well	   format,	   with	   each	   treatment	   in	   at	   least	  duplicate	  per	  experiment,	  each	  read	  in	  triplicate	  with	  the	  GDNF	  ELISA	  kit.	  	  Further,	  the	   increased	  number	  of	   cells	   in	   each	  of	   these	   larger	  wells	   facilitates	   the	   study	  of	  intracellular	   processes	   via	   western	   blot	   or	   other	   ELISA-­‐based	   experiments	  conducted	   on	   cellular	   lysates	   collected	   immediately	   after	   the	   conditioned	   media	  were	  removed	  at	  the	  termination	  of	  the	  experiment.	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means	  ±	  SEM	  of	  5	  independent	  experiments.	  	  GDNF	  release	  by	  XL-­‐008	  was	  found	  to	  be	  statistically	  significant	  by	  ANOVA	  followed	  by	  Tukey’s	  post	  test	  (***	  p	  <	  0.001).	  	  	  
	  
Dose-­‐Responsive	  GDNF	  Release	  and	  Toxicity	  by	  Isoquinuclidines	  
	   In	   order	   to	   confirm	   pharmacological	   induction	   of	   GDNF	   release	   by	   the	  experimental	  compounds,	  dose-­‐dependence	  was	  studied.	  	  C6	  cells	  were	  treated	  with	  a	   varying	   concentration	   of	   compound	   over	   48	   h,	   and	   GDNF	   release	   into	   the	  conditioned	  media	  was	  measured.	   	   Indeed,	   GDNF	   release	   by	   two	   isoquinuclidines	  studies	   in	   depth,	   XL-­‐008	   and	   XL-­‐026	   (for	   structures	   see	   Figure	   3)	   reproducibly	  displayed	  a	  dose-­‐dependent	  relationship	  (Figure	   5).	   	  These	  particular	  compounds	  were	  chosen	  based	  on	  release	  properties	   in	  preliminary	  experiments	  using	   in-­‐situ	  ELISA,	   as	   well	   as	   the	   reproducibly	   high	   amounts	   of	   GDNF	   detected	   from	   our	  preliminary	  conventional	  ELISA	  results	  with	  XL-­‐008.	  	  The	  potency	  (EC50)	  for	  XL-­‐008	  was	  determined	  to	  be	  2.5	  ±	  0.2	  µM	  (mean	  ±	  SEM,	  n	  =	  4	  independent	  experiments),	  and	  XL-­‐026	  was	  found	  to	  be	  22.4	  ±	  6.6	  µM	  (n	  =	  3	  independent	  experiments)	  	  (Figure	  
5	  A,C).	  	  	  Toxicity	  can	  be	  approximated	  by	  measuring	  release	  of	  lactate	  dehydrogenase	  (LDH)	   into	   the	   culture	   medium,	   as	   LDH	   is	   known	   to	   leak	   through	   perforated	  membranes	   upon	   cell	   death.	   	   When	   toxicity	   was	   determined	   for	   the	   same	  experiments	  above	  by	  LDH	  release	  into	  the	  medium	  relative	  to	  intracellular	  LDH	  in	  untreated	   control	   cells,	   it	   became	   evident	   that	   a	   dose-­‐dependent	   relationship	  existed,	  as	  well	  (Figure	  5	  B,D).	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(ANOVA	   of	   biological	   replicates	   within	   experiment	   followed	   by	   Tukey’s	   post-­‐hoc	  analysis,	   p	   <	   0.01,	   3	   representative	   examples).	   	   This	   interesting	   result,	   as	  well	   as	  morphological	  analysis	  of	  the	  cells	  under	  these	  conditions	  (Figure	  6),	  led	  us	  to	  the	  hypothesis	   that	   XL-­‐008	   may	   be	   altering	   the	   phenotype	   of	   C6	   cells,	   which	   are	  notoriously	   phenotypically	   unstable.	   	   C6	   cells	   are	   known	   to	   differentiate	   under	  stress	  or	  when	  treated	  with	  cAMP	  or	  certain	  small	  molecules,(39,	  40)	  characteristically	  producing	   more	   glial	   fibrillary	   acidic	   protein	   (GFAP),	   and	   behaving	   more	   like	   an	  astrocyte	   than	   a	   tumor.	   	   It	   is	   known	   that	   under	   these	   conditions,	   C6	   cells	   display	  spindly	  morphology	  (as	  in	  Figure	  6C).	  	  	  
	  
Figure	  6:	  	  XL-­‐008	  induces	  morphological	  changes	  in	  C6	  cells	  in	  a	  dose-­‐dependent	  manner.	  	  A)	  DMSO	  vehicle	  control	  (0.1%	  v/v)	  treatment	  leaves	  cells	  with	  typical	  fibroblastic	  morphology.	  	  B)	  XL-­‐008	  (10	  µM)	  begins	  to	  have	  a	  noticeable	  effect	  of	  cell	  size	  and	  shape,	  as	  cells	  become	  considerably	  more	  rounded.	  	  C)	  XL-­‐008	  (40	  µM)	  consistently	  induces	  spindle-­‐like	  morphology	  (highlighted	  by	  arrow)	  from	  considerably	  more	  lymphoblastic	  cells.	  All	  images	  are	  representative	  of	  typical	  experiments,	  400X	  magnification.	  	  	   While	   it	   is	   possible	   that	   toxicity	   of	   XL-­‐008	   is	   truly	   lower	   at	   50	   µM	  concentrations	  due	  to	  some	  phenotypic	  shift,	  the	  appearance	  of	  the	  morphology	  of	  the	   cells	   suggested	   that	   toxicity	   was	   indeed	   occurring	   (cells	   appeared	   round	   and	  lymphoblastic	  with	  spindle-­‐like	  processes).	  	  Because	  the	  LDH	  determination	  is	  made	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in	   the	   presence	   of	   all	   components	   of	   the	   48-­‐hour	   conditioned	   medium	   including	  remaining	   experimental	   compound	   and	   metabolites,	   it	   was	   thought	   that	   the	  compound	  might	  be	  inhibiting	  enzymatic	  activity	  of	  the	  LDH	  present	  in	  conditioned	  media.	   	  Titration	  of	  constant	  amounts	  of	  LDH	  from	  cellular	   lysate	  and	  colorimetric	  reagent	   with	   increasing	   concentrations	   of	   XL-­‐008	   resulted	   in	   no	   decrease	   in	  apparent	   LDH	   activity	   at	   even	   the	   highest	   concentrations	   of	   XL-­‐008	   in	   two	  independent	  experiments	   (Figure	   7).	   	   Consistent	  measurements	  of	   approximately	  20%	  LDH	  activity	  (as	  expected)	  suggests	  that	  XL-­‐008	  is	  not	  inhibiting	  LDH	  activity,	  although	  it	  is	  not	  possible	  to	  rule	  out	  LDH	  inhibition	  by	  metabolites.	  
	  
Figure	  7:	  	  No	  significant	  inhibition	  of	  LDH	  activity	  by	  XL-­‐008	  from	  1-­‐50	  µM	  in	  a	  5:1-­‐diluted	  lysate	  (20%	  LDH	  activity	  expected).	  	  Representative	  of	  two	  independent	  experiments.	  
	  
	  
GDNF	  Release	  by	  XL-­‐008	  and	  XL-­‐026	  is	  Not	  Simply	  Caused	  by	  a	  Leak	  of	  
Cytosolic	  or	  Stored	  GDNF	  into	  the	  Conditioned	  Medium	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the	   released	   GDNF	   was	   true	   induction	   of	   protein	   synthesis	   as	   a	   consequence	   of	  induced	   protein	   synthesis,	   or	   if	   the	   compounds	  were	   simply	   releasing	   previously	  translated	  GDNF	  as	  a	   function	  of	   toxicity-­‐related	  membrane	  permeabilization.	   	  We	  treated	   C6	   cells	   with	   cycloheximide,	   a	   small	   molecule	   inhibitor	   of	   translation	  initiation	   and	   translational	   elongation	   at	   the	   ribosome.(41)	   As	   cycloheximide	   is	  known	   to	  potently	   inhibit	  protein	  synthesis,	   it	   is	  a	  useful	  pharmacological	   tool	   for	  probing	  the	  dependence	  of	  protein	  synthesis	  on	  GDNF	  release.	  	  In	  fact,	  it	  was	  found	  that	  1ug/mL	  cycloheximide	  reproducibly	  inhibited	  GDNF	  synthesis	  as	  caused	  by	  XL-­‐008	  (Figure	  8,	  representative	  of	  2	  experiments)	  and	  XL-­‐026	  (2	  experiments	  by	  Dr.	  Teresa	  Jacques).(13)	  Cycloheximide	  did	  not	  have	  an	  appreciable	  effect	  on	  background	  GDNF	  release.	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significance	  compared	  to	  XL-­‐008,	  determined	  by	  ANOVA	  followed	  by	  Tukey’s	  post-­‐test.	  	   In	  order	   to	  conclusively	  show	  that	  GDNF	   is	  being	  synthesized	   in	  C6	  cells	   in	  response	  to	  the	  experimental	  isoquinuclidines,	  the	  total	  GDNF	  in	  experimental	  wells	  was	  measured	  after	  48-­‐hour	  treatments.	   	  Previously,	  only	  released	  GDNF	  had	  been	  measured	   in	   conditioned	   media,	   leaving	   the	   possibility	   that	   cells	   were	   simply	  leaking	  GDNF	  as	  a	  function	  of	  toxicity,	  similar	  to	  LDH.	  	  To	  accomplish	  this	  analysis,	  after	   the	   48	   hour	   treatment	   period,	   conditioned	  media	   were	   collected	   and	   GDNF	  was	  measured	  as	  before;	  the	  cell	  monolayers	  were	  lysed	  using	  conditions	  optimized	  for	  detection	  of	  GDNF	  from	  lysate	  using	  the	  same	  ELISA	  kit.	  	  If	  the	  compounds	  were	  simply	  inducing	  the	  cells	  to	  leak	  GDNF,	  it	  would	  be	  expected	  that	  the	  total	  GDNF	  in	  the	   system	   would	   be	   unchanged	   as	   measured	   by	   this	   method.	   	   It	   was	   noticed,	  however,	  that	  there	  is	  a	  consistent	  increase	  in	  total	  GDNF	  in	  both	  the	  extracellular	  and	   intracellular	   samples	   (sums	   are	   presented	   in	   Figure	   9,	   representative	   of	   2	  independent	  experiments	  for	  both	  XL-­‐008	  and	  XL-­‐026).	  	  	  These	   experiments	  used	  higher	   concentrations	   of	   isoquinuclidines	   in	   order	  to	  observe	   the	  effects	  of	  massive	   toxicity	  on	  GDNF	  and	  LDH	  as	  detected	  using	   the	  GDNF	  and	  LDH	  kits,	  respectively,	  from	  Promega.	  	  Analysis	  of	  higher	  concentrations	  of	  XL-­‐008	  acting	  on	  C6	  cells	  reveals	  that	  the	  strange	  “bell”	  shaped	  LDH	  activity	  curve	  remains	  with	  a	  local	  minimum	  around	  50	  µM,	  and	  LDH	  activity	  emerges	  to	  a	  global	  maximum	  thereafter	  as	  a	  function	  of	  culture	  death.	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Figure	  9:	   	  GDNF	  is	  synthesized,	  and	  not	  simply	  leaked	  into	  the	  conditioned	  media,	  by	   action	   of	   isoquinuclidines	   XL-­‐008	   and	   XL-­‐026.	   	   For	   these	   experiments,	  intracellular	   and	  extracellular	  GDNF	  were	   collected,	  measured	  using	   an	  optimized	  protocol	  for	  detection	  of	  intracellular	  GDNF,	  and	  summed.	  	  A)	  Dose	  response	  of	  total	  GDNF	   induced	   in	   C6	   cells	   by	   XL-­‐008.	   	   The	   lower	   GDNF	   values	   at	   higher	  concentrations	   of	   XL-­‐008	   are	   a	   direct	   result	   of	   massive	   toxicity	   (intended	   in	   this	  experiment).	   	   B)	   Dose	   response	   of	   relative	   extracellular	   LDH	   (toxicity)	   shows	   the	  same	  local	  minimum	  at	  50	  µM,	  above	  which	  toxicity	  increases.	  	  Note:	  	  this	  detection	  was	   saturated,	   so	   the	   %	   LDH	   activity	   is	   an	   inflated	   representation	   of	   toxicity	   at	  lower	   values.	   	   C)	   Similar	   dose-­‐dependent	   release	   for	   XL-­‐026.	   	   D)	   Corresponding	  toxicity	  for	  XL-­‐026.	  	  All	  figures	  are	  from	  representative	  experiments,	  2	  independent	  experiments.	   	  Error	  bars	   represent	  SEM	  of	  biological	   replicates	   (n	  =	  2)	  within	   the	  representative	   experiment.	   	   Red	   arrows	   are	   included	   in	   XL-­‐008	   experiments	   to	  highlight	  the	  divergence	  observed	  between	  GDNF	  (total)	  and	  LDH	  release	  at	  50	  µM	  XL-­‐008.	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GDNF	  release	  is	  inhibited	  by	  the	  protein	  synthesis	  inhibitor	  cycloheximide	  and	  total	  GDNF	  increases	  as	  a	  function	  of	  increasing	  isoquinuclidine	  concentration.	  	  	  
	  
Release	  of	  GDNF	  by	  XL-­‐008	  is	  MAPK/ERK	  Dependent	  
	  	   GDNF	  is	  known	  to	  be	  expressed	  under	  control	  of	  the	  promoter	  CREB,	  which	  is	  activated	  by	  the	  signaling	  kinases	  ERK	  1/2.	  	  ERK	  1/2	  are	  in	  turn	  activated	  by	  the	  kinase	  MEK,	  which	  specifically	  phosphorylates	  ERK.	  	  MEK/ERK	  signaling	  represents	  the	   convergence	   of	   a	   number	   of	   direct	   and	   transactivation-­‐related	   signaling	  mechanisms.(42)	   In	   order	   to	   preliminarily	   investigate	   the	   mechanism	   of	   GDNF	  release	  and	  the	  effects	  of	   intracellular	  signaling,	  C6	  cells	  were	  treated	  with	  XL-­‐008	  (10	  µM,	  48	  h)	   in	   the	  presence	  of	   the	  MEK	   inhibitors	  PD98059	  and	  U0126	  (30	  µM	  and	  10	  µM,	  respectively,	  with	  an	  additional	  30	  minute	  pre-­‐treatment).	   	  The	  result	  was	   a	   <	   90%	   inhibition	   of	   GDNF	   release	   by	   XL-­‐008	   (Figure	   10,	   mean	   of	   3	  independent	  experiments).	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0.01	  indicates	  statistical	  significance	  for	  each	  inhibitor-­‐treated	  condition	  compared	  to	   XL-­‐008,	   determined	   by	   ANOVA	   followed	   by	   Tukey’s	   post-­‐hoc	   analysis,	   n	   =	   3	  independent	   experiments).	   	   XL-­‐008	   release	   was	   significant	   compared	   to	   vehicle	  control	  during	  the	  same	  experiments	  (#	  p	  <	  0.01,	  ANOVA	  followed	  by	  Tukey’s	  post-­‐hoc	  analysis).	  
	  
	  
Effect	  of	  RTK	  Inhibitors	  on	  GDNF	  Release	  
	   Since	  ERK1/2	   signaling	  was	   found	   to	  be	   responsible	   for	  XL-­‐008-­‐dependent	  GDNF	   release,	   the	   upstream	   receptor	   tyrosine	   kinases	   (RTKs)	   were	  pharmacologically	  evaluated	  for	  their	  potential	  role	  in	  GDNF	  release	  by	  XL-­‐008.	  	  It	  is	  known	  that	  C6	  cells	  release	  GDNF	  in	  response	  to	  fibroblast	  growth	  factor	  (FGF)	  and	  platelet-­‐derived	   growth	   factor	   (PDGF)	   through	   direct	   signaling	   with	   the	   cognate	  RTKs.(13,	   37)	   In	   an	   experiment	   to	   compare	   the	   effects	   of	   RTK	   inhibitors	   on	   FGFb-­‐dependent	   and	   XL-­‐008-­‐dependent	   GDNF	   release,	   cells	   were	   pre-­‐treated	   for	   30	  minutes	   with	   the	   indicated	   RTK	   inhibitors	   (Figure	   11),	   followed	   by	   a	   48	   hour	  cotreatment	  with	  inhibitor	  and	  releaser	  (FGFb	  or	  XL-­‐008,	  or	  DMSO	  vehicle	  control).	  	  GDNF	   release	   by	   the	   growth	   factor	   FGFb	   is	   completely	   inhibited	   by	   PD173074,	   a	  reported	  FGFR-­‐selective	  inhibitor	  (Figure	  11).	  As	  concurrently	  found	  by	  Dr.	  Teresa	  Jacques	  in	  the	  same	  system,	  inhibition	  of	  PDGF-­‐dependent	  GDNF	  release	  by	  KRN633	  and	  SU-­‐5416,(13)	   reported	  PDGFR/VEGFR	   inhibitors,(43,	  44)	   validates	   that	   these	  RTK	  inhibitors	  suppress	  GDNF-­‐release	  caused	  by	  direct	  activation	  of	  the	  corresponding	  growth	  factor	  receptors	  (FGFR	  and	  PDGFR)	  in	  our	  C6	  system.	   	  Partial	   inhibition	  of	  FGF	   by	   the	   PDGFR/VEGFR	   inhibitors	   (KRN633,	   SU-­‐5416)	   was	   ascribed	   to	   likely	  inhibitor	  cross	  reactivity.	  	  These	  RTK	  inhibitors	  are	  all	  known	  to	  compete	  with	  ATP	  at	   the	   intracellular	  kinase	  domain	  of	   the	  RTKs,	  which	  has	  a	  notoriously	  conserved	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sequence	  across	  families	  of	  RTKs.	  	  Related	  to	  this	  is	  the	  dearth	  of	  truly	  selective	  RTK	  inhibitors.(45)	  	  	  As	  VEGFR	  and	  PDGFR	  inhibitors	  KRN633	  and	  SU-­‐5416	  were	  found	  to	  inhibit	  GDNF	  release	  by	  XL-­‐008	  greater	   than	  90%,	  but	   the	  FGFR	   inhibitor	  PD173074	  was	  found	  to	  inhibit	  GDNF	  release	  by	  approximately	  60%	  (Figure	  11,	  representative	  of	  3	  independent	  experiments	  together	  with	  Dr.	  Teresa	  Jacques),	   it	  was	  hypothesized	  that	   either	   VEGFR	   or	   PDGFR	   could	   be	   involved	   in	   GDNF	   release	   by	   our	  isoquinuclidines.	  As	  discussed	  above,	  these	  inhibitors	  are	  not	  entirely	  selective,	  and	  it	  was	  thought	  that	  incomplete	  inhibition	  of	  XL-­‐008	  by	  FGFR	  inhibitors	  was	  simply	  due	  to	  inhibitor	  cross-­‐reactivity	  with	  the	  responsible	  RTK,	  analogous	  to	  the	  partial	  inhibition	  of	  FGF	  by	  KRN633	  and	  SU5416	  (VEGFR/PDGFR	  inhibitors).	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Figure	  11:	  	  RTK	  inhibitors	  reduce	  release	  of	  GDNF	  by	  XL-­‐008.	  	  A)	  Inhibition	  of	  XL-­‐008-­‐	   and	   FGFb-­‐dependent	   GDNF	   release	   by	   RTK	   inhibitors	   reveals	   differences	   in	  inhibition	   profiles.	   SU-­‐5416	   and	   KRN633	   are	   VEGFR/PDGFR	   selective	   inhibitors,	  and	  inhibit	  XL-­‐008	  nearly	  completely,	  while	  only	  inhibiting	  FGFb-­‐dependent	  release	  by	   approximately	   50%.	   	   PD-­‐173074	   is	   a	   FGFR	   inhibitor,	   and	   inhibited	   FGFb-­‐dependent	   release	   completely,	  while	  only	  partially	   inhibiting	  XL-­‐008.	   	  Genistein,	   a	  pan	   tyrosine	   kinase	   inhibitor,	   abolished	   release	   by	   both	   the	   growth	   factor	   and	  isoquinuclidine.	   	   Error	   bars	   represent	   SEM	   of	   intra-­‐assay	   means	   of	   duplicate	  treatment	   wells	   in	   a	   representative	   experiment,	   repeated	   three	   times	   in	  collaboration	  with	  Dr.	  Teresa	   Jacques.	   	  B)	   	  Quantfication	  of	   inhibition	  percentages	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from	   the	   indicated	   experiment	   and	   C)	   structures	   of	   utilized	   RTK	   inhibitors	   are	  shown.	  	   Based	   on	   these	   inhibition	   experiments,	   it	   was	   thought	   that	   an	   RTK	   was	  involved	  in	  upstream	  signaling	  in	  the	  MAPK/ERK	  pathway.	  	  In	  an	  attempt	  to	  isolate	  the	   RTK	   responsible	   for	   signaling	   (and	   possibly	   the	   target	   of	   isoquinuclidine	  activity),	  Dr.	   Teresa	   Jacques	   investigated	   the	  potencies	   of	   exemplar	   FGFR,	   PDGFR,	  VEGFR,	   and	   EGFR	   inhibitors.	   	   From	   comparison	   of	  measured	   inhibition	   potencies	  (IC50s)	   to	   literature	   values,	   we	   proposed	   that	   PDGFR	   was	   likely	   involved	   in	  upstream	  signaling	  of	  GDNF	  release	  by	  XL-­‐008.	  This	  hypothesis	  was	  supported	  by	  the	  observation	  that	  PDGF	  is	  capable	  of	  inducing	  GDNF	  in	  C6	  cells.(13,	  37)	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mechanisms,	   as	   GDNF	   release	   was	   found	   to	   be	   inhibited	   by	   MEK1/2	   and	   RTK	  inhibitors	  (above).	  
	  
	  In	   order	   to	   determine	   the	   pharmacological	   target	   for	   these	   compounds,	  numerous	  studies	  were	  conducted	  by	  Dr.	  Teresa	  Jacques.	  Detailed	  pharmacological	  inhibition	   data	   implicate	   RTK	   involvement.(13)	   At	   this	   time,	   we	   can	   not	   rule	   out	  direct	  activation	  of	  a	  GPCR	  or	  transactivation	  of	  an	  RTK	  by	  action	  of	  a	  GPCR	  (Figure	  
12A),	  direct	  activation	  of	  an	  RTK	  (Figure	   12B),	  or	  any	  other	  means	  of	  directly	  or	  indirectly	   modulating	   RTK	   activity,	   such	   as	   through	   interactions	   with	   the	   σ-­‐receptors.	  	  It	  is	  known	  that	  stress-­‐related	  processes	  can	  induce	  GDNF	  in	  C6	  cells	  via	  RTK/MAPK	  signaling.	  	  Endoplasmic	  reticulum	  (ER)	  stress	  and	  lysosomal	  stress	  from	  alkalinization	   by	   vATPase	   inhibitors	   are	   among	   the	   processes	   shown	   to	   induce	  GDNF	   release	   from	   C6	   cells	   (Figure	   12C).	   (46,	  47)	   	   Gene	   silencing	   experiments	   are	  currently	  underway	  in	  the	  Sames	  lab,	  with	  the	  goal	  of	  understanding	  which	  RTK	  (or	  RTKs)	  are	   involved	   in	   isoquinuclidine	   induction	  of	  GDNF	  release.	   	  While	   the	  exact	  molecular	   target	   remains	   elusive,	   it	   has	   been	   found	   that	   XL-­‐026	   and	   XL-­‐008	   can	  modulate	  FGFb-­‐dependent	  signaling	  and	  GDNF	  release	  (see	  below).	  	  
N-­‐Arylethyl	  Isoquinuclidines	  Potentiate	  GDNF	  release	  by	  FGFb	  
	   In	   order	   to	   examine	   the	   effect	   of	   FGFb	   on	   isoquinuclidine-­‐induced	   GDNF	  release,	   C6	   cells	   were	   treated	   for	   48	   hours	   with	   either	   FGFb,	   isoquinuclidine	   of	  varying	   concentration,	   or	   a	   cocktail	   of	   FGFb	   with	   the	   isoquinuclidine	   of	   varying	  concentration.	  	  It	  was	  found	  that	  under	  most	  conditions,	  the	  release	  of	  GDNF	  caused	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by	   a	   cocktail	   of	   FGF	   and	   isoquinuclidine	   was	   a	   greater	   than	   additive	   release	  compared	  to	  isoquinuclidine	  or	  FGFb	  alone	  (Figure	  13).	  	  As	  XL-­‐008	  is	  approaching	  Emax-­‐apparent	  at	  10	  µM,	  it	  may	  be	  true	  that	  cells	  are	  physically	  incapable	  of	  producing	  more	  GDNF	  in	  these	  conditions.	   	  Thus,	   the	  effect	  of	  FGFb	  treatment	   in	  conjunction	  with	  10	  µM	  XL-­‐008	  is	  minimal	  compared	  to	  the	  effect	  on	  10	  µM	  XL-­‐026,	  which	  at	  10	  
µM	  is	  below	  the	  EC50.	  	  More	  than	  additive	  effects	  are	  noticed	  with	  treatment	  of	  FGFb	  with	   lower	   concentrations	   of	   XL-­‐008	   as	  well	   as	  with	   all	   concentrations	   of	   XL-­‐026	  below	  10	  µM.	  	  This	  implies	  that	  the	  compound	  is	  either	  potentiating	  FGFb	  signaling,	  or	   vice-­‐versa.	   	   A	   full	   quantitative	   study	   to	   confirm	   these	   results	   is	   underway	   in	  Sames	   group,	   using	   optimized	   24h	   treatment	   conditions	   to	   largely	   remove	  contributions	  of	  toxicity.	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  It	  has	  been	  demonstrated	  that	  riluzole	  induces	  GDNF	  release	  from	  C6	  cells	  in	  a	   FGFR-­‐dependent	   manner,(36)	   	   and	   it	   is	   also	   known	   that	   signaling	   pathways	  including	  GPCR-­‐related	  signaling	  converge	  with	  and	  modulate	  the	  activity	  of	  FGFb	  in	  C6	  cells.(48)	   	  FGFR2	  is	  currently	  considered	  an	  attractive	  pharmacological	  target,	  as	  FGF	  signaling	  dysregulation	  has	  been	  implicated	  in	  major	  depression,(49)	  and	  mood	  disorders,(50)	  and	  FGF2	  cannulation	  directly	  into	  brain	  tissue	  of	  rats	  has	  been	  shown	  to	  have	  antidepressant	  effects.(51)	  Thus,	  XL-­‐008	  and	  related	  isoquinuclidines	  warrant	  further	   study,	   as	   potentiation	   or	   amplification	   of	   FGFR	   signaling	   in	   the	   brain,	  whether	  direct	  or	  indirect,	  could	  play	  important	  roles	  in	  neuroprotection,	  treatment	  of	  depression	  or	  mood	  disorders,	  or	  recovery	  from	  traumatic	  brain	   injury	  through	  potentiating	  RTK	  signaling	  from	  endogenous	  levels	  of	  FGF.	  
	  
N-­‐Arylethyl	  isoquinuclidines	  induce	  GDNF	  in	  C6	  cells:	  Additions	  to	  the	  Library	  
of	  Compounds(1)	  
	  	   In	   search	   of	   a	   more	   potent	   GDNF	   releaser,	   and	   in	   order	   to	   explore	   the	  structure	   activity	   relationships	   present	   in	   the	   process	   underlying	  GDNF	   release,	   a	  number	  of	  new	  N-­‐Arylethyl	   isoquinuclidines	  were	  synthesized	  by	  Andrew	  Kruegel	  and	  Dr.	  Souvik	  Rakshit	  and	  screened	  by	  myself	  for	  GDNF	  induction	  in	  C6	  cells.	  	  This	  screen	   was	   accomplished	   using	   the	   12-­‐well	   format	   conventional	   ELISA	   from	  experiments	  above,	  with	  all	  compounds	  treated	  at	  10	  µM	  in	  biological	  replicates	  (n	  =	   2	  wells	   per	   experiment).	   	  Many	   of	   these	   compounds	  were	   screened	   at	   1	  µM	  as	  well,	  with	  the	  hope	  of	  identifying	  a	  compound	  as	  active	  or	  nearly	  as	  active	  at	  1	  µM	  as	  at	  10	  µM,	  thus	  displaying	  sub-­‐micromolar	  activity.	  	  Unfortunately,	  none	  of	  the	  tested	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compounds	   released	   more	   GDNF	   than	   XL-­‐008	   at	   1	   µM	   (data	   not	   shown).	   	   GDNF	  release	   into	   conditioned	   medium	   was	   determined	   for	   each	   compound	   as	   above.	  	  Each	  compound	  claimed	  to	  release	  statistically	  significant	  GDNF	  at	  10	  µM	  did	  so	  in	  each	   of	   three	   independent	   experiments,	   as	   determined	   from	  means	   of	   intraassay	  replicates	  compared	  to	  DMSO	  vehicle	  control	  (0.1%	  v/v).	   	  Results	  are	  summarized	  below	   in	   Tables	   1,	   2,	   and	   3	   (adapted	   from	   reference	   1).	   	   Negative	   results	   are	  summarized	   in	  Figure	   15,	   showing	   compounds	   releasing	   statistically	   insignificant	  amounts	  of	  GDNF	  compared	  to	  the	  DMSO	  control.	  	  Toxicity	  for	  each	  compound	  was	  found	  to	  be	  below	  20%,	  as	  determined	  by	  LDH	  release.	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aAll results represent fold-increase of GDNF release by C6 glioma cells treated with 
the indicated compound for 48 hours, normalized to the vehicle control (conventional 
ELISA, see experimental section).  bResults are from a representative experiment and 
were determined to be statistically significant (ANOVA) compared to the vehicle 


































































Table 2:  7-endo-Seriesa,b
Name Structure GDNF Increase ±  SEM(fold/vehicle control)
aAll results represent fold-increase of GDNF release by C6 glioma cells treated with the 
indicated compound for 48 hours, normalized to the vehicle control (conventional ELISA, 
see experimental section).  bResults are presented from a representative experiment and 
were determined to be statistically significant (ANOVA) compared to the vehicle control.  
All compounds induced a statistically significant increase of GDNF in each of 3 
independent experiments unless otherwise indicated. cSORA-I-103 was tested twice and 



















	   239	  











Table 3:  Related Isoquinuclidinesa,b




aAll results represent fold-increase of GDNF release by C6 glioma cells treated with 
the indicated compound for 48 hours, normalized to the vehicle control (conventional 
ELISA, see experimental section).  bResults are from a representative experiment and 
were determined to be statistically significant (ANOVA) compared to the vehicle 








H 13.56 ± 1.41
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(data	  not	  shown).	  	  Related,	  various	  hydroxyl,	  acetate,	  or	  ether	  substituents	  on	  the	  7-­‐position	  were	  found	  to	  be	  inactive	  at	  10	  µM.	  	  	  	  
	  	  










































Isoquinuclidines Found Not to Release Significant Amounts of GDNF at 10 µM:
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III:	  	  Conclusions	  and	  Outlook	  
	  
	   From	   these	   studies,	   it	   was	   found	   that	   several	   isoquinuclidine-­‐based	  compounds	   are	   capable	   of	   releasing	   GDNF	   from	   C6	   glioma	   cells,	   a	   widely-­‐used	  model	   for	   astroglia	   in	   the	  brain.	   	   Select	   compounds	   identified	   from	  a	   screen	  were	  chosen	   for	   further	   evaluation.	   	   Dose-­‐dependent	   release	   of	   GDNF	   was	   confirmed,	  GDNF	   synthesis	   was	   found	   to	   be	   induced	   by	   action	   of	   the	   compounds,	   and	   the	  beneficial	   MEK/ERK	   signaling	   cascade	   was	   determined	   to	   be	   involved	   in	   the	  observed	   GDNF	   synthesis	   and	   release.	   	   Inhibition	   of	   RTKs	  with	   a	   small	   library	   of	  RTK	  inhibitors	  implicated	  the	  involvement	  of	  these	  beneficial	  signaling	  receptors.	  	  It	  was	  also	  found	  that	  XL-­‐008	  positively	  modulates	  the	  effect	  of	  FGFb	  with	  respect	  to	  GDNF	  synthesis	  and	  release.	  	  	  With	   Dr.	   Teresa	   Jacques,	   a	   number	   of	   potential	   direct-­‐	   and	   transactivation	  mechanisms	  were	  investigated,	  and	  it	  appears	  clear	  from	  pharmacological	  data	  that	  RTKs	  are	  involved	  somewhere	  in	  the	  signaling	  sequence.	  	  While	  the	  GDNF-­‐induction	  of	  FGFb	  is	  amplified	  and	  potentiated	  by	  action	  of	  XL-­‐008,	  we	  cannot	  conclude	  that	  FGFR2	  is	  the	  direct	  molecular	  target	  of	  these	  compounds.	  	  FGFR2	  may	  indeed	  be	  the	  target	   of	   a	   transactivation	   mechanism	   from	   other	   tyrosine	   kinases,	   GPCRs,	  metalloproteases,	  or	  become	  modulated	  by	  adapter	  proteins.	  	  	  With	  Madalee	  Gassaway,	  these	  experiments	  have	  been	  developed	  into	  a	  96-­‐well	   format	   for	  more	   efficient	   screening	   of	   increased	   numbers	   of	   conditions.	   	   By	  shortening	   the	   isoquinuclidine	   treatment	   time	   to	   24	   h,	   Madalee	   has	   optimized	  conditions	   to	   largely	   eliminate	   toxicity	   while	   retaining	   statistically	   significant	  release	  of	  GDNF	  within	  each	  experiment.	  	  Using	  this	  platform,	  it	  has	  been	  confirmed	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IV:	  	  Experimental	  
	  
General	  Cell	  Culture	  
	  
	   C6	  cells	  from	  two	  separate	  lots	  were	  purchased	  from	  American	  Type	  Culture	  Collection	   (ATCC,	   Manassas,	   VA)	   at	   passage	   37,	   and	   displayed	   slightly	   different	  behavior	   as	   discussed	   above.	   	   Cells	   from	   lot	   #58987834	   were	   used	   between	  passages	   44-­‐49.	   	   Cells	   from	   lot	   #	   59673008	  were	   used	   between	   passages	   41-­‐44.	  	  Cultures	  were	  grown	  on	  10	  cm	  polystyrene	  culture	  plates	  (Falcon),	  were	  maintained	  at	  37˚C	   in	  a	  humidified	  atmosphere	  containing	  5%	  CO2,	  and	  were	  subcultured	  at	  a	  1:10	   ratio	   approximately	   every	   three	   days	   upon	   reaching	   confluence.	   	   Complete	  growth	   medium	   consisted	   of	   DMEM	   (high	   glucose	   with	   GlutaMAX,	   Life	  Technologies)	  supplemented	  with	  5%	  fetal	  bovine	  serum	  (FBS,	  Atlanta	  Biologicals),	  100	  U/mL	  penicillin,	  and	  100	  μg/mL	  streptomycin	  (Life	  Technologies).	  	  	  
	  
GDNF	  Release	  Assay:	  GDNF	  Conventional	  ELISA	  in	  C6	  glioma	  cells	  Conventional	   ELISAs	  were	   used	   to	   determine	   compound-­‐induced	   increases	  of	  GDNF	  concentration	   in	  conditioned	  media	  of	  C6	  glioma	  cells,	  and	  have	  afforded	  increased	  sensitivity	  compared	  to	  in-­‐situ	  ELISA	  in	  our	  hands.	  Cells	  were	  incubated	  at	   37oC	   in	   a	   humidified	   atmosphere	   containing	   5%	   CO2.	   	   GDNF	   release	   was	  measured	  for	  each	  compound	  in	  3	  independent	  experiments.	  	  Briefly,	  C6	  cells	  were	  seeded	  into	  sterile	  12-­‐well	  culture	  plates	  (Falcon)	  at	  a	  density	  of	  300,000	  cells	  per	  well	   and	   were	   recovered	   for	   24h	   in	   1mL	   complete	   growth	   medium	   (94%	   high	  glucose	  DMEM,	  5%	  FBS,	  1%	  penicillin/streptomycin).	  Wells	  were	  then	  washed	  with	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1mL	  sterile	  DPBS	  and	  were	  incubated	  for	  an	  additional	  24h	  with	  0.5mL	  low-­‐serum	  medium	  (98.5%	  high	  glucose	  DMEM,	  0.5%	  FBS,	  1%	  penicillin/streptomycin).	  On	  the	  following	  day,	  experimental	  compounds	  or	  DMSO	  vehicle	  control	  were	  added	  each	  to	   duplicate	   wells	   in	   an	   additional	   0.5mL	   of	   low-­‐serum	   medium.	   	   The	   final	  concentration	  of	  each	  compound	  was	  10	  µM	  in	  1mL	  low-­‐serum	  medium	  containing	  0.1%	  DMSO.	   	   Plates	  were	   incubated	  with	   compounds	   and	   vehicle	   control	   for	   48h.	  	  Conditioned	  media	  were	   then	   collected	   from	   each	  well,	   and	   GDNF	   concentrations	  were	   measured	   in	   triplicate	   on	   96-­‐well	   ELISA	   plates	   using	   the	   GDNF	   Emax	  Immunoassay	  System	  from	  Promega	  (Madison,	  WI)	  according	  to	  the	  manufacturer’s	  instructions.	   	   A	   BioTek	  H1MF	  plate	   reader	   (Burlington,	   VT)	  was	   used	   to	  measure	  absorbance	   from	   the	   resulting	   colorimetric	   reaction.	   Total	   GDNF	   release	   for	   each	  compound	  was	  calculated	  from	  the	  standard	  curve	  using	  Microsoft	  Excel.	   	  Data	  are	  normalized	  to	  the	  vehicle	  control	  and	  are	  thus	  presented	  as	   fold	   increase	  of	  GDNF	  concentration	  in	  experimental	  wells	  over	  that	  of	  the	  vehicle	  control.	  	  Data	  presented	  here	  are	  interassay	  means	  from	  the	  indicated	  number	  of	  independent	  experiments	  ±	  interassay	  standard	  error	  of	  the	  mean	  (SEM)	  calculated	  from	  means	  of	  independent	  experiments.	  Statistical	  significance	  was	  determined	  by	  ANOVA	  followed	  by	  Tukey’s	  post-­‐hoc	  analysis	  using	  GraphPad	  Prism.	  
	  
Inhibition	  of	  GDNF	  synthesis	  and	  release	  with	  small-­‐molecules	  C6	   cells	   were	   subcultured	   into	   12-­‐well	   plates	   at	   a	   density	   of	   ~300,000	  cells/well,	   and	  were	   allowed	   to	   recover	   in	   complete	  medium	   for	  24	  hours.	   	  Wells	  were	   washed	   once	   with	   PBS	   and	   treated	   as	   above	   with	   low	   serum,	   high	   glucose	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experimental	  medium	   for	   23.5	   hours.	   	   30	  minutes	   prior	   to	   initiation	   of	   treatment	  with	   experimental	   compounds,	   inhibitors	   were	   added	   for	   the	   indicated	   final	  concentrations.	   	   Treatment	   was	   initiated	   by	   adding	   solutions	   of	   experimental	  compounds	  or	  experimental	  compounds	  +	  inhibitors	  to	  wells.	  Final	  conditions	  were	  10μM	   experimental	   compounds	   or	   10μM	   experimental	   compounds	   +	   indicated	  concentration	  of	  inhibitors.	  	  DMSO	  (0.2%)	  served	  as	  a	  vehicle	  control.	  Final	  volumes	  were	  1	  mL	  per	  well,	  and	  each	  respective	  condition	  was	  run	  in	  duplicate.	  	  Plates	  were	  incubated	   for	  48h	  at	  37˚C,	  5%	  CO2.	   	   	  After	  48h,	  conditioned	  experimental	  medium	  was	   removed	   from	   wells	   and	   frozen	   o/n	   at	   -­‐80˚C.	   	   GDNF	   in	   each	   sample	   was	  measured	  in	  triplicate	  on	  a	  96-­‐well	  ELISA	  plate	  as	  described	  above	  (Promega).	  	  For	  MEK	   inhibition	   experiments,	   data	   presented	   here	   are	   interassay	   means	   from	   the	  indicated	   number	   of	   independent	   experiments	   ±	   interassay	   standard	   error	   of	   the	  mean	   (SEM)	   calculated	   from	   means	   of	   independent	   experiments.	   Statistical	  significance	   for	  was	   determined	  by	  ANOVA	   followed	  by	  Tukey’s	   post-­‐hoc	   analysis	  using	  GraphPad	  Prism.	   	  Tested	   for	  significance	  were	  both	  GDNF	  release	  caused	  by	  the	   experimental	   isoquinuclidine	   compared	   to	   vehicle	   control,	   and	   the	   effect	   of	  inhibitors	  compared	  to	  uninhibited	  release.	   	  For	  cycloheximide	  and	  RTK	  inhibition	  experiments,	   data	   are	   presented	   for	   a	   representative	   experiment,	   and	  means	   and	  standard	  errors	  are	  determined	  from	  intraassay	  biological	  replicates.	  	  
Determination	  of	  Total	  GDNF	  Experiments	  were	  conducted	  as	  above	   in	  12-­‐well	  plates.	   	  GDNF	  and	  LDH	  in	  each	  sample	  were	  measured	  in	  triplicate	  on	  96-­‐well	  plates.	   	  Extracellular	  GDNF	  or	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LDH	   were	   measured	   in	   undiluted	   conditioned	   media	   as	   before	   using	   Promega’s	  GDNF	   ELISA	   or	   the	   Cytotox96	   LDH	   kit,	   respectively.	   	   Intracellular	   GDNF	   was	  collected	  by	  lysing	  cells	  in	  200	  µL	  of	  a	  custom,	  lysis	  buffer	  (see	  below),	  and	  diluting	  the	   resulting	   lysates	   10X	   before	   detection,	   to	   minimize	   the	   concentration	   of	  detergent	  present	  during	  antibody/antigen	  association	  (ELISA	  capture).	  In	   order	   to	   optimize	   lysis	   conditions	   for	   GDNF	   detection,	   4	   different	  conditions	  were	   tested	   for	   their	   compatibility	   with	   Promega’s	   GDNF	   assay.	   	   Cells	  from	   an	   independent	   48-­‐hour	   treatment	   with	   complete	   medium	   (unused	  monolayers	   of	   basal	   treatment)	   were	   lysed	   with	   each	   condition	   and	   were	   then	  assayed	  both	  neat	  and	  diluted	  1:2.	   	  Final	   in-­‐well	  concentrations	  of	  detergent	  were	  compared	  between	  lysis	  buffers	  containing	  1%,	  0.5%,	  0.1%,	  and	  0.05%	  Triton-­‐X	  100	  in	   tris	   buffered	   saline	   (TBS),	   each	   with	   and	  without	   a	   protease	   inhibitor	   cocktail	  (P8340,	   Sigma-­‐Aldrich)	   and	   phosphatase	   inhibitor	   cocktail	   2	   (P5726,	   Sigma-­‐Aldrich).	  Additionally,	  the	  same	  conditions	  were	  tested	  for	  the	  ability	  to	  accurately	  detect	  a	  known	  concentration	  of	  GDNF	  (500	  pg/mL).	   	   It	  was	  determined	  that	   lysis	  conditions	  containing	  protease	  and	  phosphatase	  inhibitors,	  with	  dilution	  conditions	  resulting	   in	   0.05%	   Triton-­‐X	   100	   in	   the	   GDNF	   ELISA	   buffer	   were	   optimal	   for	  detection	  of	  GDNF	  and	  LDH	  from	  the	  lysate.	  
	  
Cytotoxicity	  Counter	  Assay	  A	  counter	  assay	  was	  also	  run	  using	  the	  same	  conditioned	  medium.	  	  Triplicate	  measurements	  of	  each	  sample	  were	  made	  using	  Promega’s	  Cytotox	  96	  LDH	  assay	  kit	  according	  to	  the	  manufacturer’s	  instructions.	   	  Untreated	  cells	  were	  lysed	  using	  the	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lysis	   buffer	   included	   in	   the	   kit,	   and	   a	   standard	   curve	   was	   generated	   from	   the	  intracellular	   lysate	   to	   approximate	   the	   percentage	   of	   total	   LDH	   released	   as	   a	  function	  of	  toxicity	  in	  experimental	  conditioned	  media.	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